<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06479028-20021112-M00001.NB SYSTEM "US06479028-20021112-M00001.NB" NDATA NB>
<!ENTITY US06479028-20021112-M00001.TIF SYSTEM "US06479028-20021112-M00001.TIF" NDATA TIF>
<!ENTITY US06479028-20021112-D00001.TIF SYSTEM "US06479028-20021112-D00001.TIF" NDATA TIF>
<!ENTITY US06479028-20021112-D00002.TIF SYSTEM "US06479028-20021112-D00002.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06479028</PDAT></DNUM></B110>
<B130><PDAT>B1</PDAT></B130>
<B140><DATE><PDAT>20021112</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>09541814</PDAT></DNUM></B210>
<B211US><PDAT>09</PDAT></B211US>
<B220><DATE><PDAT>20000403</PDAT></DATE></B220>
</B200>
<B500>
<B510>
<B511><PDAT>C01B 3100</PDAT></B511>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>423414</PDAT></B521>
<B522><PDAT>4234471</PDAT></B522>
<B522><PDAT>4234472</PDAT></B522>
<B522><PDAT>252502</PDAT></B522>
<B522><PDAT>252503</PDAT></B522>
</B520>
<B540><STEXT><PDAT>Rapid synthesis of carbon nanotubes and carbon encapsulated metal nanoparticles by a displacement reaction</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5110768</PDAT></DNUM>
<DATE><PDAT>19920500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Kaner et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>501  1</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5456986</PDAT></DNUM>
<DATE><PDAT>19951000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Majetich et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>428403</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5457343</PDAT></DNUM>
<DATE><PDAT>19951000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Ajayan et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>257734</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5472749</PDAT></DNUM>
<DATE><PDAT>19951200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Dravid et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>427580</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5474591</PDAT></DNUM>
<DATE><PDAT>19951200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Wells et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT> 75351</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5578543</PDAT></DNUM>
<DATE><PDAT>19961100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Tennent et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>502180</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5589152</PDAT></DNUM>
<DATE><PDAT>19961200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Tennent et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>4234472</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5641466</PDAT></DNUM>
<DATE><PDAT>19970600</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Ebbesen et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>4234472</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5707916</PDAT></DNUM>
<DATE><PDAT>19980100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Snyder et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>502180</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5716708</PDAT></DNUM>
<DATE><PDAT>19980200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Lagow</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>428408</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5747161</PDAT></DNUM>
<DATE><PDAT>19980500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Iijima</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>428367</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5780101</PDAT></DNUM>
<DATE><PDAT>19980700</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Nolan et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>427216</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5783263</PDAT></DNUM>
<DATE><PDAT>19980700</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Majetich et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>427580</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5814370</PDAT></DNUM>
<DATE><PDAT>19980900</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Martino et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>42721335</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5834057</PDAT></DNUM>
<DATE><PDAT>19981100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Edelstein et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>427212</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5850064</PDAT></DNUM>
<DATE><PDAT>19981200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Goldstein</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>2041574</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5851417</PDAT></DNUM>
<DATE><PDAT>19981200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Hung</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>252 6255</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5869626</PDAT></DNUM>
<DATE><PDAT>19990200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Yamamoto et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>534 10</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6183714</PDAT></DNUM>
<DATE><PDAT>20010200</PDAT></DATE>
<KIND><PDAT>B1</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Smalley et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>4234473</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B562><NCIT><STEXT><PDAT>Gillan, E.G., et al., Chem. of Mater., vol. 8:333-343 (1996) ; No. 2 Feb. 1996. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Wiley, J.B., et al., Science, Vol. 255:1093-1097 (1992) Feb. 28, 1992.</PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
</B560>
<B570>
<B577><PDAT>17</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>4234472</PDAT></B582>
<B582><PDAT>423448</PDAT></B582>
<B582><PDAT>4234471</PDAT></B582>
<B582><PDAT>423414</PDAT></B582>
<B582><PDAT>428 341</PDAT></B582>
<B582><PDAT>4282991</PDAT></B582>
<B582><PDAT>428398</PDAT></B582>
<B582><PDAT>428408</PDAT></B582>
<B582><PDAT>428903</PDAT></B582>
<B582><PDAT>252502</PDAT></B582>
<B582><PDAT>252503</PDAT></B582>
</B580>
<B590><B595><PDAT>2</PDAT></B595><B596><PDAT>4</PDAT></B596></B590>
</B500>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Richard B.</PDAT></FNM><SNM><STEXT><PDAT>Kaner</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Santa Monica</PDAT></CITY>
<STATE><PDAT>CA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Jennifer L.</PDAT></FNM><SNM><STEXT><PDAT>O&apos;Loughlin</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Portland</PDAT></CITY>
<STATE><PDAT>OR</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Ching-Hwa</PDAT></FNM><SNM><STEXT><PDAT>Kiang</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Los Angelos</PDAT></CITY>
<STATE><PDAT>CA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Charles H.</PDAT></FNM><SNM><STEXT><PDAT>Wallace</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Portland</PDAT></CITY>
<STATE><PDAT>OR</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>The Regents of the University of California</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>Oakland</PDAT></CITY><STATE><PDAT>CA</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Fulbright &amp; Jaworski L.L.P.</PDAT></STEXT></ONM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>Stanley S.</PDAT></FNM><SNM><STEXT><PDAT>Silverman</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B747>
<PARTY-US>
<NAM><FNM><PDAT>Timothy C.</PDAT></FNM><SNM><STEXT><PDAT>Vanoy</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B747>
<B748US><PDAT>1754</PDAT></B748US>
</B745>
</B700>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>Carbon material having at least a partially curved structure, such as a nanotube, produced by a displacement reaction in which a carbon halide, e.g. C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, is reacted with a metal compound, e.g., lithium acetylide in the presence of a catalyst, e.g., CoCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>. Some applications of the nanotubes of the present invention are use in magnetic data storage media, or use as conductors or semiconductors.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<GOVINT>
<BTEXT>
<H LVL="1"><STEXT><PDAT>STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT</PDAT></STEXT></H>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>This invention was made with Government support under Grant No. 9704964, awarded by the National Science Foundation. The Government has certain rights in this invention.</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BACKGROUND OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>1. Field of the Invention</PDAT></PTEXT></PARA>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>The invention relates generally to displacement reactions for synthesis of carbon nanotubes and metal encapsulated within a carbon lattice structure.</PDAT></PTEXT></PARA>
<PARA ID="P-00005" LVL="0"><PTEXT><PDAT>2. Description of Related Art</PDAT></PTEXT></PARA>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>Pure carbon has many allotropes, such as: diamond; graphite; fullerenes; and nanotubes, each being stable in different temperature and pressure ranges. Fullerenes are a family of closed caged molecules formed entirely of carbon in the sp</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>-hybridized state and constitute a third form of carbon after diamond and graphite. These spherical, cavity containing molecules and their allotropes have been found to possess remarkable properties, and the most stable one known as buckminsterfullerene or C</PDAT><HIL><SB><PDAT>60 </PDAT></SB></HIL><PDAT>has been widely investigated.</PDAT></PTEXT></PARA>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>In 1991 Sumio Iijima synthesized, through the use of an arc discharge method, new carbon structures in the form of needle-like tubes or rolled-up graphite sheets with multiple concentric cylindrical shells of hexagonally bonded carbon atoms. These extended fullerene tube structures have been called carbon nanotubes, more specifically multi-walled nanotubes (MWNTs), having a thickness of several carbon atom layers and typical outside diameters from a few to several tens of nanometers. A variation of the arc discharge method, using two graphite rods of different diameters, has also been reported to produce MWNTs. &lsqb;Ebbeson, T. W., et al., Nature, Vol. 358:220-222 (1992)&rsqb;. MWNTs can also be synthesized by catalytic decomposition of hydrocarbons on metal surfaces. &lsqb;Rodriguez, N. M., et al., Langmuir, Vol., 11:3862-3866 (1995)&rsqb;.</PDAT></PTEXT></PARA>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>In 1993 it was discovered that the use of transition metal catalysts during arc discharge produced single walled nanotubes (SWNTs) &lsqb;Bethune, D. S., et al., Nature, Vol. 363:605-607 (1993), Iijima, S., et al., Nature, Vol. 363:603-605 (1993)&rsqb;. Kiang, C-H. et al., described the synthesis of SWNTs with a metal catalyst &lsqb;Kiang, C.-H., et al., J. Phys. Chem. Solids, Vol. 57:35-39 (1995); Kiang, C.-H., et al., J. Phys. Chem., Vol. 98: 6612-6618 (1994); Kiang, C.-H., et al., Carbon, Vol. 33:903-914 (1995); Kiang, C.-H., et al., Chem. Phys. Left., Vol. 259:41-47 (1996)&rsqb;.</PDAT></PTEXT></PARA>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>SWNTs have been generated by arc-evaporation in the presence of a cobalt catalyst &lsqb;Bethune, D. S., et al., Nature, Vol. 363:605-607 (1993) and Ijima, S., et al., Nature, Vol. 363:603-605 (1993)&rsqb;. A recent modification of this arc-evaporation method has been reported to enable SWNT synthesis in larger yields &lsqb;Journet, C., et al., Nature, Vol. 388:756-758 (1997)&rsqb;. SWNTs are also produced by laser-vaporization of a graphite, cobalt, and nickel mixture at 1200&deg; C. &lsqb;Guo, T., et al., Chem. Phys. Lett., Vol. 243:49-54 (1995)&rsqb;. This method was optimized to reportedly give 70% yield &lsqb;Thess, A., et al., Science, Vol. 273:483-487 (1996)&rsqb;. More recently, SWNTs were synthesized by the Thess et al., method without the assistance of oven heating &lsqb;Maser, W. K., et al., Chem. Phys. Left., Vol. 292:587-593 (1998)&rsqb;. SWNTs are also produced by thinning of MWNTs using CO</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>by pyrolysis of the hydrocarbon &lsqb;Cheng, H. M., et al., Appl. Phys. Left., Vol. 72:3282-3284&rsqb;, and by chemical vapor deposition &lsqb;Hafner, J. H., et al., Chemical Physics Letters, Vol. 296:195-202 (1998)&rsqb;.</PDAT></PTEXT></PARA>
<PARA ID="P-00010" LVL="0"><PTEXT><PDAT>It has been reported that hydrogen gas can condense inside SWNTs &lsqb;Dillon, A. C., et al., &ldquo;Storage of hydrogen in single-walled carbon nanotubes&rdquo;, Nature, Vol. 386:377-379 (1997)&rsqb;, and that elongated crystallites of Ru were encapsulated in SWNTs &lsqb;Sloan, J., et al., The opening and filling of single walled carbon nanotubes (SWNTs), Chem. Commun., Vol. 3: 347-348 (1998)&rsqb;. Metal nanoparticles have been reported to be encapsulated in graphite layers by a modified arc evaporation method &lsqb;Jiao, J., et al., Journal of Applied Physics, Vol. 80:103-108 (1996)&rsqb;. Nanoparticles suitable for magnetic recording media, synthesized via the arc-evaporation method, have been described in U.S. Pat. No. 5,456,986 to Majetich, et al., and U.S. Pat. No. 5,783,263 to Dravid, et al. U.S. Pat. No. 5,780,101 to Nolan, et al., described a method for producing encapsulated nanoparticles and carbon nanotubes using catalytic dis-proportionation of carbon monoxide.</PDAT></PTEXT></PARA>
<PARA ID="P-00011" LVL="0"><PTEXT><PDAT>Nanotubes are superstrong and lightweight and can act as either a conductor or a semiconductor depending on the inner diameter and chirality of the hexagonal carbon lattice along the length of the nanotube. See, Dekker, C., &ldquo;Carbon Nanotubes as Molecular Quantum Wires&rdquo;, Physics Today, Vol. 52:22-28 (1999), Ebbeson, T. W., &ldquo;Carbon Nanotubes&rdquo;, Physics Today, Vol. 49:26-32 (June 1996). Based on their size and weight, nanotubes have novel electrical, optical, magnetic, and thermal properties. See, Han, S., et al., Science, Vol. 277:1287 (1997); Vietze, U., et al., &ldquo;Zeolite-Dye Microlasers&rdquo;, Phys. Rev. Lett., Vol. 81:4628-4631 (1998); Service, R. F., Science, Vol. 281:940-942 (1998); and Heremans, J., et al., &ldquo;Magnetoresistance of bismuth nanowire arrays: A possible transition from one-dimensional to three-dimensional localization,&rdquo; Phys. Rev. B 58: R10091 (1998).</PDAT></PTEXT></PARA>
<PARA ID="P-00012" LVL="0"><PTEXT><PDAT>Some of the many potential applications of nanotubes include: molecular electronics &lsqb;Tans, S. J., et al., &ldquo;Room-temperature transistor based on a single carbon nanotube&rdquo;, Nature, Vol. 393: 49-52 (1998)&rsqb;, hydrogen storage media &lsqb;Dillon, A. C., et al., &ldquo;Storage of hydrogen in single-walled carbon nanotubes&rdquo;, Nature, Vol. 386: 377-379 (1997)&rsqb;, and scanning probe microscope tips &lsqb;Wong, S. S., et at., &ldquo;Covalently functionalized nanotubes as nanometer-sized probes in chemistry and biology,&rdquo; Nature, Vol. 394: 52-55 (1998)&rsqb;. Nanotubes can be created with acidic functionality or with basic or hydrophobic functionality, or with biomolecules at the open tip ends. Macro-applications include lightweight, strong wires, batteries, fuel cells, or bulletproof vests. Biological applications include an open-ended nanotube that could inject a few molecules into a specific region of a cell to carry out molecular surgery on nucleic acids &lsqb;Yakobson, B., et al., &ldquo;Fullerene Nanotubes: C</PDAT><HIL><SB><PDAT>1,000000 </PDAT></SB></HIL><PDAT>and Beyond,&rdquo; American Scientist, Vol. 85:324-337 (1997)&rsqb;. These applications are but a few of the applications requiring strong, small diameter nanotubes. Also, Co, Fe, and Ni are magnetic metals and are of interest as magnetic data storage media.</PDAT></PTEXT></PARA>
<PARA ID="P-00013" LVL="0"><PTEXT><PDAT>Solid-state metathesis (SSM) reactions have been reported to be a rapid route to many solid-state materials including chalcogenides, nitrides, borides, phosphides and intermetallics &lsqb;Gillan, E. G., et al., Chem. of Mater., Vol. 8:333-343 (1996); U.S. Pat. No. 5,110,768 to Kaner, et al.; and Wiley, J. B., et al., Science, Vol. 255:1093-1097 (1992)&rsqb;. A solution phase process for the synthesis of Group III-V semiconductor nanocrystals has also been reported &lsqb;U.S. Pat. No. 5,474,591 to Wells, et al.&rsqb;.</PDAT></PTEXT></PARA>
<PARA ID="P-00014" LVL="0"><PTEXT><PDAT>It has been reported that MWNTs, grown in the vapor phase, are being produced on the kilogram scale daily, but little is known about the possibility to further scale-up this method. There is no comparable method for the bulk synthesis of SWNTs &lsqb;Service, R. G., supra.&rsqb; or of metal encapsulated within a carbon lattice structure. Furthermore, despite the development of SWNT production, the current cost of purified SWNTs is prohibitive, in the range of $1000 per gram.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>BRIEF SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00015" LVL="0"><PTEXT><PDAT>The present invention overcomes drawbacks of the foregoing methods to rapidly prepare carbon material, having at least a partially curved structure, and/or encapsulated metal within a carbon structure. By partially curved structure is meant having a non-flat carbon based structure, such as found in nanotubes. An advantage of the present invention is an increase in yield as the reaction is scaled up.</PDAT></PTEXT></PARA>
<PARA ID="P-00016" LVL="0"><PTEXT><PDAT>The invention comprises a displacement reaction, preferably a double displacement (solid-state metathesis (SSM)) reaction in which a carbon compound, such as a hydrocarbon, halogenated hydrocarbon, or halogenated carbon compound and a metal compound are metathetically reacted in the presence of a catalyst, using heat to initiate the reaction, which is otherwise exothermic, to provide a highly efficient, inexpensive and readily scalable route to MWNTs, SWNTs, and metal encapsulated within a carbon lattice structure.</PDAT></PTEXT></PARA>
<PARA ID="P-00017" LVL="0"><PTEXT><PDAT>In particular the carbon compound preferably has the formula R</PDAT><HIL><SB><PDAT>n</PDAT></SB></HIL><PDAT>X</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>z</PDAT></SB></HIL><PDAT>, wherein R is carbon, n is a number from 1 to a million or more, preferably 1 to 1000, preferably still 1 to 100; X is selected from the halide group consisting of fluorine, chlorine, bromine, and iodine, y is 0 to a million or more; H is hydrogen, z is 0 to a million or more and the ratio of y to z represents the degree of halogenation of the hydrocarbon; the metal compound is represented by M</PDAT><HIL><SB><PDAT>x&prime;</PDAT></SB></HIL><PDAT>R</PDAT><HIL><SB><PDAT>y&prime;</PDAT></SB></HIL><PDAT> wherein M is any of the Group 1, 2, or 13 metal ions capable of forming a salt; R is carbon, x&prime; is any integer, preferably a number from 1 to 3, y&prime; is a number from 0 to a million or more, preferably 0-3, preferably still, x&prime;&equals;y&prime;&equals;2. Preferably the metal compound is lithium acetylide. he catalyst is preferably a transition metal catalyst, such as CoCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, NiCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, or FeCl</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>or an organometallic metal. Heat to initiate the exothermic reaction can be provided from any conventional source, for example, a heated wire.</PDAT></PTEXT></PARA>
<PARA ID="P-00018" LVL="0"><PTEXT><PDAT>The displacement reaction of the present invention uses inexpensive precursors, requires less preparation, and less expensive equipment than existing methods. The reaction also produces nanoparticles comparable in size to those synthesized by modified arc evaporation. Thermodynamic reaction parameters such as maximum reaction temperature and exothermicity can be altered by changing reactants, (for example, from halogenated carbon compounds to halogenated hydrocarbons or pure hydrocarbons) reaction size, or the addition of inert salts, or combinations thereof. These parameters, in conjunction with the type of catalyst and gas atmosphere used, enables the optimization of nanotube yield. Also, the nanotube yield increases with increasing reaction size.</PDAT></PTEXT></PARA>
<PARA ID="P-00019" LVL="0"><PTEXT><PDAT>These and other features, aspects, and advantages of the present invention will become better understood with regard to the following detailed description, appended claims, and accompanying drawings.</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DRWDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BRIEF DESCRIPTION OF THE DRAWINGS</PDAT></STEXT></H>
<PARA ID="P-00020" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT> is a powder X-ray diffraction pattern of the reaction between C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>6 </PDAT></SB></HIL><PDAT>and Li</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>with the addition of 5 mole % CoCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>; and</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIGS. 2</PDAT></FGREF><HIL><ITALIC><PDAT>a-c </PDAT></ITALIC></HIL><PDAT>are transmission electron microscopy (TEM) images of the reaction between C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>6 </PDAT></SB></HIL><PDAT>and Li</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>with the addition of 5 mole % CoCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, where single-walled (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><HIL><ITALIC><PDAT>a</PDAT></ITALIC></HIL><PDAT>), multi-walled (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><HIL><ITALIC><PDAT>b</PDAT></ITALIC></HIL><PDAT>), and cobalt nanoparticles encapsulated in graphite layers (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><HIL><ITALIC><PDAT>c</PDAT></ITALIC></HIL><PDAT>), were produced.</PDAT></PTEXT></PARA>
</BTEXT>
</DRWDESC>
<DETDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>DETAILED DESCRIPTION OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00022" LVL="0"><PTEXT><PDAT>The present invention relates to a method for the high yield synthesis of carbon nanotubes and metal encapsulated within a carbon lattice structure. The reaction is a rapid, self-propagating, double-displacement or metathesis reaction involving a carbon compound, such as a halogenated carbon compound, a halogenated hydrocarbon or a hydrocarbon, with a metal or metal carbon compound in the presence of a catalyst. The reaction is performed at an ambient temperature with stoichiometric amounts of well-mixed reactant powders in a stainless steel reaction vessel. The reaction is initiated by an ignition source such as a resistively heated nichrome wire (T&ap;1100 K), after which the reaction becomes self-propagating and produces the desired material along with salt by-products (e.g. LiCl, NaCl).</PDAT></PTEXT></PARA>
<PARA ID="P-00023" LVL="0"><PTEXT><PDAT>In general, the displacement or metathesis reaction is highly exothermic due to the formation of very stable salt by-products. The heated wire initiates the chemical reaction, which then becomes self-propagating. Although the exothermic reaction is conveniently initiated by the heated wire, other heating methods can be used: external methods, such as direct heating of the walls of the container with heating tape, flames, or lasers; or internal methods, such as the use of microwave energy or friction such as ball milling. Although the reaction took place in a steel reaction vessel, other containers can be used such as glass ampoules. The reaction container could be open as well as closed. The salt by-products are easily removed by washing with water or alcohol allowing for the isolation of the desired product, carbon nanotubes and/or graphite encapsulated metal. The method can be described by reference to the following: </PDAT>
<CWU>
<MATH-US ID="MATH-US-00001">
<MATHEMATICA ID="MATHEMATICA-00001" ALT="mathematica file" FILE="US06479028-20021112-M00001.NB"/>
<MATHML>
<math>
<mtable>
  <mtr>
    <mtd>
      <mrow>
        <mrow>
          <msub>
            <mi>R</mi>
            <mi>n</mi>
          </msub>
          <mo>&it;</mo>
          <msub>
            <mi>X</mi>
            <mi>y</mi>
          </msub>
          <mo>&it;</mo>
          <msub>
            <mi>H</mi>
            <mi>z</mi>
          </msub>
        </mrow>
        <mo>+</mo>
        <mrow>
          <msub>
            <mi>M</mi>
            <msup>
              <mi>x</mi>
              <mi>&prime;</mi>
            </msup>
          </msub>
          <mo>&it;</mo>
          <mrow>
            <msub>
              <mi>R</mi>
              <msup>
                <mi>y</mi>
                <mi>&prime;</mi>
              </msup>
            </msub>
            <mo>&DoubleLongRightArrow;</mo>
            <mrow>
              <mo>(</mo>
              <mrow>
                <mi>n</mi>
                <mo>+</mo>
                <mrow>
                  <msup>
                    <mi>y</mi>
                    <mi>&prime;</mi>
                  </msup>
                  <mo>&af;</mo>
                  <mrow>
                    <mo>(</mo>
                    <mfrac>
                      <mi>y</mi>
                      <mn>2</mn>
                    </mfrac>
                    <mo>)</mo>
                  </mrow>
                </mrow>
              </mrow>
              <mo>)</mo>
            </mrow>
          </mrow>
          <mo>&it;</mo>
          <mi>R</mi>
        </mrow>
        <mo>+</mo>
        <mrow>
          <mfrac>
            <mi>y</mi>
            <mi>m</mi>
          </mfrac>
          <mo>&it;</mo>
          <mi>M</mi>
          <mo>&it;</mo>
          <mstyle>
            <mtext>&emsp;</mtext>
          </mstyle>
          <mo>&it;</mo>
          <msub>
            <mi>X</mi>
            <mi>m</mi>
          </msub>
        </mrow>
        <mo>+</mo>
        <mrow>
          <mfrac>
            <mi>z</mi>
            <mn>2</mn>
          </mfrac>
          <mo>&it;</mo>
          <msub>
            <mi>H</mi>
            <mn>2</mn>
          </msub>
        </mrow>
      </mrow>
    </mtd>
    <mtd>
      <mrow>
        <mo>(</mo>
        <mn>1</mn>
        <mo>)</mo>
      </mrow>
    </mtd>
  </mtr>
</mtable>
</math>
</MATHML>
<EMI ID="EMI-M00001" ALT="embedded image" FILE="US06479028-20021112-M00001.TIF"/>
</MATH-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00024" LVL="7"><PTEXT><PDAT>wherein</PDAT></PTEXT></PARA>
<PARA ID="P-00025" LVL="2"><PTEXT><PDAT>R is carbon, n is a number from 1 to a million or more, preferably 1 to 1000, preferably still 1 to 100; X is selected from the halide group consisting of fluorine, chlorine, bromine, and iodine, y is 0 to a million or more; H is hydrogen, z is a number from 0 to a million or more; M</PDAT><HIL><SB><PDAT>x&prime;</PDAT></SB></HIL><PDAT>R</PDAT><HIL><SB><PDAT>y&prime;</PDAT></SB></HIL><PDAT>is a metal compound capable of forming a salt, M is any of the Group 1, 2, or 13 metal ion capable of forming a salt; x&prime; is a number from 1 to a million or more, preferably 1 to 3; y&prime; is a number from 0 to a million or more, preferably 0 to 3, most preferably x&prime;&equals;y&prime;&equals;2; and m is a number from 1 to a million or more, preferably 1 or 2. Preferably the carbon compound is hexachloroethane and the metal compound is lithium acetylide.</PDAT></PTEXT></PARA>
<PARA ID="P-00026" LVL="0"><PTEXT><PDAT>All reactants used were anhydrous. The reactions were performed in an inert atmosphere of helium, although other gases could be used. An inert atmosphere is not necessary, but a dry atmosphere will keep water from reacting with and decomposing the precursors. The following examples were performed in a helium filled drybox, in which the steel reaction container was located.</PDAT></PTEXT></PARA>
<PARA ID="P-00027" LVL="0"><PTEXT><PDAT>The addition of the transition metal catalyst CoCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>to the reaction mixture leads to the production of MWNTs, SWNTs, and Co metal encapsulated in graphite. The addition of other transition metal catalysts such as: NiCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>or FeCl</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>to the reaction mixture leads to the production of MWNTs and Ni or Fe metal, respectively encapsulated in a carbon lattice structure. No SWNTs were seen in samples that did not have the CoCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>catalyst in the starting reactant mixture. Any free cobalt, nickel, or iron formed in this reaction can be removed by washing in a strong concentrated acid, for example sulfuric, nitric, or hydrochloric acid. Without the addition of the catalyst, the reaction results only in crystalline, layered graphite. By decreasing the amount of CoCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>added, for example from 5 mole percent to 2 mole percent, the yield of SWNTs decreases significantly while the yield of MWNTs and graphite encapsulated Co metal remained fairly constant. The ideal amount of CoCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>catalyst for producing SWNTs is 5 mole percent. Overall nanotube yield (both SWNTs and MWNTs) increases with increasing reaction size.</PDAT></PTEXT></PARA>
<PARA ID="P-00028" LVL="0"><PTEXT><PDAT>The yield of Co, Ni, or Fe metal encapsulated in graphite can be increased by increasing the amount of CoCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, NiCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, or FeCl</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>catalyst from 5 mole % to 10 mole %. Analysis of the products by TEM indicates that at this catalyst concentration, metal nanoparticles encapsulated in graphite are greatly favored over nanotubes. In addition, any unfavorable by-products, such as free graphite or free metal can be removed by washing in a strong, concentrated acid such as concentrated sulfuric, nitric or hydrochloric acid. Surprisingly, the nanoparticles of Co, Ni, or Fe encapsulated in the carbon lattice structure were unaffected by the acid, indicating that they are totally encapsulated, as seen in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><HIL><ITALIC><PDAT>c</PDAT></ITALIC></HIL><PDAT>. Open sheets of graphite and free metal, however, are readily dissolved. Furthermore, the carbon encapsulated cobalt, nickel or iron nanoparticles are stable for extended periods of time (at least 2 weeks and likely indefinitely) in concentrated nitric acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="0"><PTEXT><PDAT>The use of different reactants or the addition of inert salt additives such as NaCl or LiCl, can alter the reaction temperature and exothermicity of each reaction. The maximum reaction temperature of the reaction of Example 1 is calculated to be in excess of 2000&deg; C., which is several hundred degrees higher than the normal reaction temperature used previously to produce SWNTs &lsqb;Guo, T., et al., supra&rsqb;. The driving force in solid-state metathesis reactions is the formation of the very stable salt by-product. The more moles of salt produced in a reaction, the more exothermic a given reaction. By increasing the moles of carbon produced per mole of salt, the reaction exothermicity decreases thereby lowering the maximum reaction temperature as calculated assuming complete reaction at adiabatic conditions.</PDAT></PTEXT></PARA>
<PARA ID="P-00030" LVL="0"><PTEXT><PDAT>For example, if the number of carbons, n, is increased from 1 to 100 in the following reaction:</PDAT></PTEXT></PARA>
<PARA ID="P-00031" LVL="0"><PTEXT><F><PTEXT><PDAT>C</PDAT><HIL><SB><PDAT>n</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2n&plus;2</PDAT></SB></HIL><PDAT>&plus;(</PDAT><HIL><ITALIC><PDAT>n</PDAT></ITALIC></HIL><PDAT>&plus;1)Li</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&rarr;(3</PDAT><HIL><ITALIC><PDAT>n</PDAT></ITALIC></HIL><PDAT>&plus;2)C&plus;2(</PDAT><HIL><ITALIC><PDAT>n</PDAT></ITALIC></HIL><PDAT>&plus;1)LiCl</PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00032" LVL="7"><PTEXT><PDAT>less LiCl salt is produced with respect to moles of carbon and the maximum temperature can be lowered by 60&deg; C. (from 2029 to 1969&deg; C.). By increasing the number of carbons, n to 1000, the effect on the maximum reaction temperature diminishes and the maximum reaction temperature drops by only an additional 1&deg; C. Thus, increasing the length of the carbon chain in the halogenated carbon compound decreases the maximum reaction temperature.</PDAT></PTEXT></PARA>
<PARA ID="P-00033" LVL="0"><PTEXT><PDAT>A more dramatic effect on the maximum reaction temperature is achieved by using a halogenated hydrocarbon, C</PDAT><HIL><SB><PDAT>n</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>. If the number of carbons, n, is held constant (n&equals;1000):</PDAT></PTEXT></PARA>
<PARA ID="P-00034" LVL="0"><PTEXT><F><PTEXT><PDAT>C</PDAT><HIL><SB><PDAT>n</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>&plus;(</PDAT><HIL><ITALIC><PDAT>x</PDAT></ITALIC></HIL><PDAT>/2)Li</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&rarr;(</PDAT><HIL><ITALIC><PDAT>n&plus;x</PDAT></ITALIC></HIL><PDAT>)C&plus;</PDAT><HIL><ITALIC><PDAT>x</PDAT></ITALIC></HIL><PDAT>LiCl&plus;(</PDAT><HIL><ITALIC><PDAT>y</PDAT></ITALIC></HIL><PDAT>/2)H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00035" LVL="7"><PTEXT><PDAT>and the ratio of y to x is increased from 0 to 6, the maximum reaction temperature is predicted to drop by 925&deg; C. (from 1968 to 1043&deg; C.). These temperatures are well within the temperature range in which SWNTs are synthesized. Similar effects are seen with carbon fluorides, C</PDAT><HIL><SB><PDAT>n</PDAT></SB></HIL><PDAT>F</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>y </PDAT></SB></HIL><PDAT>in the following reaction with lithium acetylide:</PDAT></PTEXT></PARA>
<PARA ID="P-00036" LVL="0"><PTEXT><F><PTEXT><PDAT>C</PDAT><HIL><SB><PDAT>n</PDAT></SB></HIL><PDAT>F</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>&plus;(</PDAT><HIL><ITALIC><PDAT>x</PDAT></ITALIC></HIL><PDAT>/2)Li</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&rarr;(</PDAT><HIL><ITALIC><PDAT>n&plus;x</PDAT></ITALIC></HIL><PDAT>)C&plus;</PDAT><HIL><ITALIC><PDAT>x</PDAT></ITALIC></HIL><PDAT>LiF&plus;(</PDAT><HIL><ITALIC><PDAT>y</PDAT></ITALIC></HIL><PDAT>/2)H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00037" LVL="7"><PTEXT><PDAT>If the number of carbons, n is held constant (n&equals;1000) and the ratio of y to x is increased from 0 to 6, the reaction temperature drops by 384&deg; C. (from 1584 to 1200&deg; C.). The lower temperatures are again well within the temperature range in which SWNTs are synthesized.</PDAT></PTEXT></PARA>
<PARA ID="P-00038" LVL="0"><PTEXT><PDAT>Long-chain halogenated hydrocarbons, such as the polymers, polyvinylchloride and polyvinylidene chloride are promising precursors in solid state metathesis reactions. By lowering the maximum reaction temperature and exothermicity, the yield of MWNTs to SWNTs to other by-products can be altered and optimized. The ability to alter these parameters makes the displacement reaction, preferably the double displacement reaction a useful method for synthesizing carbon materials.</PDAT></PTEXT></PARA>
<PARA ID="P-00039" LVL="0"><PTEXT><PDAT>In order to synthesize carbon nanotubes, both single-walled and multi-walled, as well as carbon encapsulated metal, a variety of carbon producing reactions were used. Both SSM reactions (also known as double displacement reactions) and single displacement reactions were used.</PDAT></PTEXT></PARA>
<PARA ID="P-00040" LVL="0"><PTEXT><PDAT>In the following examples, X-ray diffraction and TEM studies were carried out to characterize the synthesized samples.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 1</PDAT></STEXT></H>
<PARA ID="P-00041" LVL="0"><PTEXT><PDAT>In this example 0.0078 moles of lithium acetylide (Li</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>) was reacted with 0.0026 moles of hexachloroethane (C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>) in the presence of 0.0011 moles (5 Mole % based on C) of CoCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>catalyst as given in equation (2).</PDAT></PTEXT></PARA>
<PARA ID="P-00042" LVL="0"><PTEXT><F><PTEXT><PDAT>C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>&plus;3Li</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&rarr;8C&plus;6LiCl&emsp;&emsp;(2)</PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00043" LVL="7"><PTEXT><PDAT>All reactants were mixed simultaneously and completely, using an agate mortar and pestle, until the individual reactants were no longer visible. The mixing time was approximately 5 minutes. The reactants were placed in a steel container and placed in contact with a nichrome wire. Current was passed through the wire for approximately a few seconds, causing the wire to be resistively heated. The heat from the wire initiated the reaction, which was otherwise exothermic. The reaction went to completion in less than 1 second. Products were washed in deionized water to remove any salt by-products and dried in air.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>RESULTS</PDAT></STEXT></H>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>The powder X-ray diffraction pattern of the products of reaction (2) with the CoCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>catalyst indicated the formation of polycrystalline graphite, as seen by the peak at 26 degrees two theta in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>, and cubic cobalt metal. This peak is representative of the interplanar spacing of carbon-carbon layers. The most crystalline graphite was found in this example. Upon further investigation by TEM, many nanophase materials were found. These nanophase materials comprised MWNTs, SWNTs, as well as cobalt nanoparticles encapsulated within graphitic shells. Nanotubes (both SWNTs and MWNTs) comprised between approximately 10% to 20% by volume, of the total yield of product. The remainder of the sample yield was metal nanoparticles encapsulated with a carbon lattice structure. The greatest number of SWNTs were synthesized using 5 Mole % CoCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>catalyst, as seen in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><HIL><ITALIC><PDAT>b. </PDAT></ITALIC></HIL></PTEXT></PARA>
<PARA ID="P-00045" LVL="0"><PTEXT><PDAT>As seen in the TEM image of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><HIL><ITALIC><PDAT>a</PDAT></ITALIC></HIL><PDAT>, some of the MWNTs extended up to 50 nm or more in length and possessed a bamboo-like structure. The distance between the layers in the MWNTs was 0.34 nm (3.4 &angst;), as expected for carbon-carbon layers. The SWNTs, as seen in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><HIL><ITALIC><PDAT>b</PDAT></ITALIC></HIL><PDAT>, appeared to grow from a graphite and amorphous carbon mix and were about 2.9 nm in diameter and approximately 10 nm in length. Cobalt nanoparticles were also found to be encapsulated in layers of a carbon lattice structure, as seen in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><HIL><ITALIC><PDAT>c</PDAT></ITALIC></HIL><PDAT>. These nanoparticles were found to be stable with respect to oxidation by air or concentrated nitric acid, indicating the that graphitic shells were closed.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 2</PDAT></STEXT></H>
<PARA ID="P-00046" LVL="0"><PTEXT><PDAT>The procedures of Example 1 were followed by substituting 2 Mole % CoCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>for the 5 Mole % CoCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>RESULTS</PDAT></STEXT></H>
<PARA ID="P-00047" LVL="0"><PTEXT><PDAT>The powder X-ray diffraction pattern of the products of reaction (2) with 2 Mole % CoCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>catalyst indicated the formation of polycrystalline graphite and cubic cobalt metal. Upon further investigation by TEM, many nanophase materials were found. These nanophase materials comprised MWNTs, SWNTs, as well as cobalt nanoparticles encapsulated within layers of a carbon lattice structure. The yield of SWNTs decreased significantly and the yield of MWNTs and Co nanoparticles encapsulated in graphitic shells remained fairly constant.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 3</PDAT></STEXT></H>
<PARA ID="P-00048" LVL="0"><PTEXT><PDAT>The procedures of Example 1 were followed by substituting 4 Mole % CoCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>for the 5 Mole % CoCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>and the reaction scale was decreased to {fraction (1/10)}th the original size.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>RESULTS</PDAT></STEXT></H>
<PARA ID="P-00049" LVL="0"><PTEXT><PDAT>TEM indicated that the overall nanotube yield decreases significantly. Thus, nanotube yield is dependent on reaction size such that the yield of nanotubes increases with increasing reaction size.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 4</PDAT></STEXT></H>
<PARA ID="P-00050" LVL="0"><PTEXT><PDAT>The procedures of Example 1 were followed by substituting 10 Mole % CoCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>for the 5 Mole % CoCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>RESULTS</PDAT></STEXT></H>
<PARA ID="P-00051" LVL="0"><PTEXT><PDAT>The powder X-ray diffraction pattern of the products of reaction (2) with 10 Mole % CoCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>catalyst indicated the formation of polycrystalline graphite and cubic cobalt metal. Upon further investigation by TEM, nanophase materials were found to comprise MWNTs and cobalt nanoparticles encapsulated within layers of a carbon lattice structure.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 5</PDAT></STEXT></H>
<PARA ID="P-00052" LVL="0"><PTEXT><PDAT>The procedures of Example 1 were followed by substituting an approximately equal molar amount of 5 mole % NiCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>for the 5 mole % CoCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>RESULTS</PDAT></STEXT></H>
<PARA ID="P-00053" LVL="0"><PTEXT><PDAT>TEM studies indicated that the products consisted of MWNTs and Ni nanoparticles encapsulated in graphitic shells. The Ni nanoparticles were similar to the Co nanoparticles formed when the CoCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>was used. They were spherical in shape and encapsulated completely in graphitic shells.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 6</PDAT></STEXT></H>
<PARA ID="P-00054" LVL="0"><PTEXT><PDAT>The procedures of Example 5 were followed by substituting 10 mole % NiCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>for the 5 mole % NiCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>RESULTS</PDAT></STEXT></H>
<PARA ID="P-00055" LVL="0"><PTEXT><PDAT>TEM indicated that by increasing the percentage of NiCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>catalyst from 5 to 10%, the yield of Ni nanoparticles encapsulated in graphitic shells increased. The yield of nanotubes remained fairly constant.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 7</PDAT></STEXT></H>
<PARA ID="P-00056" LVL="0"><PTEXT><PDAT>The procedures of Example 1 were followed by substituting 2 mole % of FeCl</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>for 5 mole % CoCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>RESULTS</PDAT></STEXT></H>
<PARA ID="P-00057" LVL="0"><PTEXT><PDAT>TEM studies indicated that the products consisted of MWNTs and Fe nanoparticles encapsulated in graphitic shells. The Fe nanoparticles were spherical in shape and encapsulated completely in graphitic shells. They were similarly resistant to oxidation by air and strong acid, indicating complete encapsulation.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 8</PDAT></STEXT></H>
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>The procedures for Example 1 were followed by substituting 10 mole % FeCl</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>for 2 mole % FeCl</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>as Example 7.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>RESULTS</PDAT></STEXT></H>
<PARA ID="P-00059" LVL="0"><PTEXT><PDAT>TEM indicated that by increasing the percentage of FeCl</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>catalyst from 5 to 10%, the yield of Fe nanoparticles encapsulated in graphitic shells increased. The yield of nanotubes remained fairly constant.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 9</PDAT></STEXT></H>
<PARA ID="P-00060" LVL="0"><PTEXT><PDAT>The procedure of Example 1 was followed with the exception that no catalyst was used.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>RESULTS</PDAT></STEXT></H>
<PARA ID="P-00061" LVL="0"><PTEXT><PDAT>TEM and X-ray diffraction studies indicated that the product was graphite only.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 10</PDAT></STEXT></H>
<PARA ID="P-00062" LVL="0"><PTEXT><PDAT>The procedure of Example 1 was followed by substituting polytetrafluoroethylene for the halogenated carbon compound, hexachloroethane.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>RESULTS</PDAT></STEXT></H>
<PARA ID="P-00063" LVL="0"><PTEXT><PDAT>TEM indicated the synthesis of MWNTs, SWNTs, and Co nanoparticles encapsulated in a graphitic shell.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 11</PDAT></STEXT></H>
<PARA ID="P-00064" LVL="0"><PTEXT><PDAT>The procedure of Example 1 was followed by substituting a copolymer of polyvinylidene chloride and polyvinylchloride for the halogenated carbon compound, hexachloroethane.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>RESULTS</PDAT></STEXT></H>
<PARA ID="P-00065" LVL="0"><PTEXT><PDAT>TEM indicated the synthesis of MWNTs, SWNTs, and Co nanoparticles encapsulated in a graphitic shell.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 12</PDAT></STEXT></H>
<PARA ID="P-00066" LVL="0"><PTEXT><PDAT>The procedure of Example 1 was followed by substituting a copolymer of polyvinylidene chloride and polyvinylchloride for the halogenated carbon compound, hexachloroethane and substituting 10 mole % FeCl</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>for the 5 mole % CoCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>RESULTS</PDAT></STEXT></H>
<PARA ID="P-00067" LVL="0"><PTEXT><PDAT>TEM indicated the synthesis of MWNTs, SWNTs, and Fe nanoparticles encapsulated in a graphitic shell. All of the Fe nanoparticles appeared to be completely encapsulated in graphitic shells when this halogenated hydrocarbon was used in lieu of hexachloroethane.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 13</PDAT></STEXT></H>
<PARA ID="P-00068" LVL="0"><PTEXT><PDAT>In this example 0.0052 moles of magnesium was reacted with 0.0026 moles of carbon tetrabromide (CBr</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>) in the presence of 0.0011 moles (10 atomic percent) of CoCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>catalyst as given in equation (3). 0.5 moles of N(CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>Br was added to the reaction mixture, as an inert salt additive to control the reaction temperature.</PDAT></PTEXT></PARA>
<PARA ID="P-00069" LVL="0"><PTEXT><F><PTEXT><PDAT>CBr</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>&plus;2Mg&rarr;C&plus;2MgBr</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&emsp;&emsp;(3)</PDAT></PTEXT></F></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>RESULTS</PDAT></STEXT></H>
<PARA ID="P-00070" LVL="0"><PTEXT><PDAT>TEM results indicated the product was MWNTs and Co nanoparticles encapsulated in graphitic shells.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 14</PDAT></STEXT></H>
<PARA ID="P-00071" LVL="0"><PTEXT><PDAT>The procedures of Example 1 were followed by substituting an halogenated hydrocarbon, hydrocarbon, or halogenated carbon compound for the halogenated hydrocarbon, hexachloroethane, by substituting a metal or metal carbon compound for lithium acetylide, or a combination thereof.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 15</PDAT></STEXT></H>
<PARA ID="P-00072" LVL="0"><PTEXT><PDAT>The procedures in Example 1 were followed by reacting lithium acetylide (Li</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>) with carbon tetrabromide (CBr</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>) as given in equation (4):</PDAT></PTEXT></PARA>
<PARA ID="P-00073" LVL="0"><PTEXT><F><PTEXT><PDAT>CBr</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>&plus;2Li</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&rarr;5C&plus;4LiBr&emsp;&emsp;(4)</PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00074" LVL="7"><PTEXT><PDAT>The calculated maximum reaction temperature was 1745&deg; C.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 16</PDAT></STEXT></H>
<PARA ID="P-00075" LVL="0"><PTEXT><PDAT>The procedures in Example 1 were followed by reacting hexachloroethane (C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>) with magnesium as given in equation (5):</PDAT></PTEXT></PARA>
<PARA ID="P-00076" LVL="0"><PTEXT><F><PTEXT><PDAT>C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>C</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>&plus;3Mg&rarr;2C&plus;3MgCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&emsp;&emsp;(5).</PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00077" LVL="7"><PTEXT><PDAT>The calculated maximum reaction temperature was 4111&deg; C.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 17</PDAT></STEXT></H>
<PARA ID="P-00078" LVL="0"><PTEXT><PDAT>The procedures in Example 1 can be followed by substituting a polymer carbon halide, such as polyvinylidene chloride, polyvinyl chloride, or polytetrafluoroethylene, for the carbon halide hexachloroethane.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 18</PDAT></STEXT></H>
<PARA ID="P-00079" LVL="0"><PTEXT><PDAT>The procedures of Examples 1 to 9 can be followed with the addition of an inert salt additive, such as NaCl or LiCl, to lower the reaction temperature.</PDAT></PTEXT></PARA>
<PARA ID="P-00080" LVL="0"><PTEXT><PDAT>The following references are incorporated herein by reference: Ebbeson, T. W., et al., Nature, Vol. 358:220-222 (1992); Rodriguez, N. M., et al., Langmuir, Vol., 11:3862-3866 (1995); Bethune, D. S., et al., Nature, Vol. 363:605-607 (1993); Iijima, S., et al., Nature, Vol. 363: 603-605 (1993); Kiang, C.-H., et al., J. Phys. Chem. Solids, Vol. 57:35-39 (1995); Kiang, C.-H., et al., J. Phys. Chem., Vol. 98: 6612-6618 (1994); Kiang, C.-H., et al., Carbon, Vol. 33: 903-914 (1995); Kiang, C.-H., et al., Chem. Phys. Left., Vol. 259:41-47 (1996); Journet, C., et al., Nature, Vol. 388:756-758 (1997); Guo, T., et al., Chem. Phys. Left., Vol. 243:49-54 (1995); Thess, A., et al., Science, Vol. 273:483-487 (1996); Maser, W. K., et al., Chem. Phys. Left., Vol. 292:587-593 (1998); Cheng, H. M., et al., Appl.Phys.Lett., Vol. 72:3282-3284 (1998); Hafner, J. H., et al., Chemical Physics Letters, Vol. 296:195-202 (1998); Dillon, A. C., et al., &ldquo;Storage of hydrogen in single-walled carbon nanotubes&rdquo;, Nature, Vol. 386:377-379 (1997); Sloan, J., et al., &ldquo;The opening and filling of single walled carbon nanotubes (SWTs),&rdquo; Chem. Commun., Vol. 3:347-348 (1998); Jiao, J., et al., Journal of Applied Physics, Vol. 80:103-108 (1996); U.S. Pat. No. 5,456,986 to Majetich, et al.; U.S. Pat. No. 5,783,263 to Dravid, et al.; U.S. Pat. No. 5,780,101 to Nolan, et al.; Gillan, E. G., et al., Chem of Matter, Vol. 8:333-343 (1996); U.S. Pat. No. 5,110,768 to Kaner, et al.; Wiley, J. B., et al., Science, Vol. 255:1093-1097 (1992)&rsqb;. U.S. Pat. No. 5,474,591 to Wells, et al.; Dekker, C., &ldquo;Carbon Nanotubes as Molecular Quantum Wires&rdquo;, Physics Today, Vol. 52: 22-28 (1999); Ebbeson, T. W., &ldquo;Carbon Nanotubes&rdquo;, Physics Today, Vol. 49:26-32 (June 1996); Han, S., et al., Science, Vol. 277:1287 (1997); Vietze, U., et al., &ldquo;Zeolite-Dye Microlasers&rdquo;, Phys. Rev. Lett., Vol. 81:4628-4631 (1998); Service, R. F., Science, Vol. 281:940-942 (1998); and Heremans, J., et al., &ldquo;Magnetoresistance of bismuth nanowire arrays: A possible transition from one-dimensional to three-dimensional localization,&rdquo; Phys. Rev. B 58: R10091 (1998); Tans, S. J., et al., &ldquo;Room-temperature transistor based on a single carbon nanotube&rdquo;, Nature, Vol. 393:49-52 (1998); Dillon, A. C., et al., &ldquo;Storage of hydrogen in single-walled carbon nanotubes&rdquo;, Nature, Vol. 386: 377-379 (1997); Wong, S. S., et al., &ldquo;Covalently functionalized nanotubes as nanometer-sized probes in chemistry and biology,&rdquo; Nature, Vol. 394: 52-55 (1998); and Yakobson, B., et al., &ldquo;Fullerene Nanotubes: C</PDAT><HIL><SB><PDAT>1,000000 </PDAT></SB></HIL><PDAT>and Beyond,&rdquo; American Scientist, Vol. 85:324-337 (1997).</PDAT></PTEXT></PARA>
<PARA ID="P-00081" LVL="0"><PTEXT><PDAT>Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be obvious that various modifications and changes which are within the knowledge of those skilled in the art are considered to fall within the scope of the appended claims.</PDAT></PTEXT></PARA>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>What is claimed is: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00082" LVL="0"><PTEXT><PDAT>1. A displacement process for preparing a form of carbon comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>reacting a carbon compound with a compound containing metal and carbon in the presence of a catalytically effective amount of catalyst, thereby producing a form of carbon selected from the group consisting of nanotubes, encapsulated metal, or a combination thereof. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00083" LVL="0"><PTEXT><PDAT>2. The process of claim wherein said carbon compound is a halogenated hydrocarbon, a halogenated carbon or a hydrocarbon.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00084" LVL="0"><PTEXT><PDAT>3. The process of </PDAT><CLREF ID="CLM-00002"><PDAT>claim 2</PDAT></CLREF><PDAT>, wherein said halide is selected from the group consisting of fluorine, chlorine, bromine, and iodine.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00085" LVL="0"><PTEXT><PDAT>4. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said carbon compound is hexachloroethane.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00005">
<PARA ID="P-00086" LVL="0"><PTEXT><PDAT>5. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said metal compound is capable of forming a salt.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00006">
<PARA ID="P-00087" LVL="0"><PTEXT><PDAT>6. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said metal compound comprises an element selected from the group consisting of Group 1 elements Li, Na, K, Rb, and Cs; Group 2 elements Be, Mg, Ca, Sr, and Ba, and Group 13 elements B, Al, Ga, In, and Tl.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00007">
<PARA ID="P-00088" LVL="0"><PTEXT><PDAT>7. The process of </PDAT><CLREF ID="CLM-00006"><PDAT>claim 6</PDAT></CLREF><PDAT>, wherein said metal carbide is lithium acetylide.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00008">
<PARA ID="P-00089" LVL="0"><PTEXT><PDAT>8. The process of </PDAT><CLREF ID="CLM-00007"><PDAT>claim 7</PDAT></CLREF><PDAT>, wherein said catalyst is CoCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00009">
<PARA ID="P-00090" LVL="0"><PTEXT><PDAT>9. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said metal compound is a metal carbide.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00010">
<PARA ID="P-00091" LVL="0"><PTEXT><PDAT>10. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said catalyst is selected from the group consisting of CoCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, NiCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, or FeCl</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00011">
<PARA ID="P-00092" LVL="0"><PTEXT><PDAT>11. The process of </PDAT><CLREF ID="CLM-00010"><PDAT>claim 10</PDAT></CLREF><PDAT>, wherein said effective amount is 5 mole % based on the moles of total carbon in the carbon compound and compound containing metal and carbon.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00012">
<PARA ID="P-00093" LVL="0"><PTEXT><PDAT>12. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, further comprising heating the reaction, thereby initiating the reaction.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00013">
<PARA ID="P-00094" LVL="0"><PTEXT><PDAT>13. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, further comprising adding a salt to the reaction.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00014">
<PARA ID="P-00095" LVL="0"><PTEXT><PDAT>14. The process of </PDAT><CLREF ID="CLM-00013"><PDAT>claim 13</PDAT></CLREF><PDAT>, wherein the salt is NaCl or LiCl.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00015">
<PARA ID="P-00096" LVL="0"><PTEXT><PDAT>15. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the nanotubes are single-walled.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00016">
<PARA ID="P-00097" LVL="0"><PTEXT><PDAT>16. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the nanotubes are multi-walled.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00017">
<PARA ID="P-00098" LVL="0"><PTEXT><PDAT>17. A displacement process for preparing a form of carbon comprising reacting a carbon compound with a compound containing metal and carbon in the presence of a catalytically effective amount of catalyst so as to produce carbon nanotubes.</PDAT></PTEXT></PARA>
</CLM>
</CL>
</SDOCL>
<SDODR ID="DRAWINGS">
<EMI ID="EMI-D00001" ALT="embedded image" FILE="US06479028-20021112-D00001.TIF"/>
<EMI ID="EMI-D00002" ALT="embedded image" FILE="US06479028-20021112-D00002.TIF"/>
</SDODR>
</PATDOC>

<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06479285-20021112-D00001.TIF SYSTEM "US06479285-20021112-D00001.TIF" NDATA TIF>
<!ENTITY US06479285-20021112-D00002.TIF SYSTEM "US06479285-20021112-D00002.TIF" NDATA TIF>
<!ENTITY US06479285-20021112-D00003.TIF SYSTEM "US06479285-20021112-D00003.TIF" NDATA TIF>
<!ENTITY US06479285-20021112-D00004.TIF SYSTEM "US06479285-20021112-D00004.TIF" NDATA TIF>
<!ENTITY US06479285-20021112-D00005.TIF SYSTEM "US06479285-20021112-D00005.TIF" NDATA TIF>
<!ENTITY US06479285-20021112-D00006.TIF SYSTEM "US06479285-20021112-D00006.TIF" NDATA TIF>
<!ENTITY US06479285-20021112-D00007.TIF SYSTEM "US06479285-20021112-D00007.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06479285</PDAT></DNUM></B110>
<B130><PDAT>B1</PDAT></B130>
<B140><DATE><PDAT>20021112</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>09108843</PDAT></DNUM></B210>
<B211US><PDAT>09</PDAT></B211US>
<B220><DATE><PDAT>19980701</PDAT></DATE></B220>
</B200>
<B500>
<B510>
<B511><PDAT>C12N  500</PDAT></B511>
<B512><PDAT>C12N 1500</PDAT></B512>
<B512><PDAT>C12N 1563</PDAT></B512>
<B512><PDAT>C07H 2104</PDAT></B512>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>435377</PDAT></B521>
<B522><PDAT>4353201</PDAT></B522>
<B522><PDAT>435325</PDAT></B522>
<B522><PDAT>435455</PDAT></B522>
<B522><PDAT>435459</PDAT></B522>
<B522><PDAT>435461</PDAT></B522>
<B522><PDAT>435375</PDAT></B522>
<B522><PDAT>536 231</PDAT></B522>
<B522><PDAT>536 235</PDAT></B522>
<B522><PDAT>800 21</PDAT></B522>
<B522><PDAT>800 23</PDAT></B522>
<B522><PDAT>800 25</PDAT></B522>
</B520>
<B540><STEXT><PDAT>p53 as a regulator of cell differentiation</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5843780</PDAT></DNUM>
<DATE><PDAT>19981200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Thomson</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435363</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>0518650</PDAT></DNUM>
<DATE><PDAT>19921200</PDAT></DATE>
<CTRY><PDAT>EP</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 91/13150</PDAT></DNUM>
<DATE><PDAT>19910900</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 92/11874</PDAT></DNUM>
<DATE><PDAT>19920700</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 93/20238</PDAT></DNUM>
<DATE><PDAT>19931000</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 95/14777</PDAT></DNUM>
<DATE><PDAT>19950600</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 97/11367</PDAT></DNUM>
<DATE><PDAT>19970300</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B562><NCIT><STEXT><PDAT>Verma et al., Gene therapy-promises, problems and prospects, 1997, Nature, vol. 389, pp. 239-242.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Anderson et al., Human gene therapy, 1998, Nature, vol. 392, pp. 25-30.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Rosenberg et al., Gene therapist, heal thyself, 2000, Science, vol. 287, pp. 1751.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Keller et al., Human embryonic stem cells: the fiture is now, 1999, Nature Medicine, vol. 5, pp. 151-152.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Svendsen et al., New prospects for human stem-cell therapy in the nervous system, 1999, Trends Neurosci., vol. 22, pp. 357-364.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Zanjani et al., Prospects for in utero human gene therapy, 1999, Science, vol. 285, pp. 2084-2088.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Armstrong et al., &ldquo;High-frequency developmental abnormalities in p53-deficient mice,&rdquo; </PDAT><HIL><ITALIC><PDAT>Curr. Biol.</PDAT></ITALIC></HIL><PDAT>, 5:931-936, 1995. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Carroll and Vize, &ldquo;Wilms tumor suppressor gene is involved in the development of disparate kidney forms: evidence from expression in the </PDAT><HIL><ITALIC><PDAT>Xenopus pronephros</PDAT></ITALIC></HIL><PDAT>,&rdquo; </PDAT><HIL><ITALIC><PDAT>Dev. Dynamics</PDAT></ITALIC></HIL><PDAT>, 206:131-138, 1996. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Cho et al., &ldquo;Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations,&rdquo; Science, 265:346-355, 1994. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Cox,et al., &ldquo;Xenopus p53 is biochemically similar to the human tumour suppressor protein p53 and is induced upon DNA damage in somatic cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>Oncogene</PDAT></ITALIC></HIL><PDAT>, 9:2951-2959, 1994. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Dittmer et al., &ldquo;Gain-of-function mutations in p53,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature Genetics</PDAT></ITALIC></HIL><PDAT>, 4:42-46, 1993. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Donehower and Bradley, &ldquo;The tumor suppressor p53,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochim. Biophys. Acta</PDAT></ITALIC></HIL><PDAT>, 1155:181-205, 1993. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Donehower et al., &ldquo;Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature</PDAT></ITALIC></HIL><PDAT>, 356:215-221, 1992. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Dong et al., &ldquo;AP-1/jun is required for early Xenopus development and mediates mesoderm induction by fibroblast growth factor but not by activin,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem.</PDAT></ITALIC></HIL><PDAT>, 271:9942-9946, 1996. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Eliyahu et al., &ldquo;Overproduction of p53 antigen makes established cells highly tumorigenic,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature</PDAT></ITALIC></HIL><PDAT>, 316:158-60, 1985. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Ferkol et al., &ldquo;Regulation of the phosphoenolpyruvate carboxykinase/human factor IX gene introduced into the livers of adult rats by receptor-mediated gene transfer&rdquo;, </PDAT><HIL><ITALIC><PDAT>FASEB J.</PDAT></ITALIC></HIL><PDAT>, 7:1081-1091, 1993. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Finlay et al., &ldquo;The p53 proto-oncogene can act as a suppressor of transformation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell</PDAT></ITALIC></HIL><PDAT>, 57:1083-1093, 1989. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Gottlieb and Oren, &ldquo;p53 in growth control and neoplasia,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochem. Biophys. Acta</PDAT></ITALIC></HIL><PDAT>, 1287:77-102, 1996. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Haffner and Oren, &ldquo;Biochemical properties and biological effects of p53,&rdquo; </PDAT><HIL><ITALIC><PDAT>Curr. Op. Genet. Dev.</PDAT></ITALIC></HIL><PDAT>, 1995, 5:84-90. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Hall and Lane, &ldquo;Tumor suppressors: a developing role for p53&quest;,&rdquo; </PDAT><HIL><ITALIC><PDAT>Curr. Biol.</PDAT></ITALIC></HIL><PDAT>, 7:R144-R147, 1997. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Harvey et al., &ldquo;A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature Genetics</PDAT></ITALIC></HIL><PDAT>, 9:305-311, 1995. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Haupt et al., &ldquo;Mdm2 promotes the rapid degradation of p53,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature</PDAT></ITALIC></HIL><PDAT>, 387:296-299, 1997. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Hoever et al., &ldquo;Overexpression of wild-type p53 interferes with normal development in </PDAT><HIL><ITALIC><PDAT>Xenopus laevis </PDAT></ITALIC></HIL><PDAT>embryos,&rdquo; </PDAT><HIL><ITALIC><PDAT>Oncogene</PDAT></ITALIC></HIL><PDAT>, 9:109-120, 1994. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Jenkins et al., &ldquo;Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature</PDAT></ITALIC></HIL><PDAT>, 312:651-654, 1984. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Jones et al., &ldquo;Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature</PDAT></ITALIC></HIL><PDAT>, 378:206-208, 1995. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Komarova et al., &ldquo;Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines readiation and drug sensitivty in vivo,&rdquo; </PDAT><HIL><ITALIC><PDAT>EMBO J.</PDAT></ITALIC></HIL><PDAT>, 16:1391-1400, 1997. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kubbutat et al., &ldquo;Regulation of p53 stability in Mdm2&rdquo;, </PDAT><HIL><ITALIC><PDAT>Nature</PDAT></ITALIC></HIL><PDAT>, 387:299-303, 1997. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kussie et al., &ldquo;Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science</PDAT></ITALIC></HIL><PDAT>, 274:948-953, 1996. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Mercer et al., &ldquo;Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA</PDAT></ITALIC></HIL><PDAT>, 87:6166-6170, 1990. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Momand et al., &ldquo;The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell</PDAT></ITALIC></HIL><PDAT>, 69:1237-1245, 1992. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Montenarh, &ldquo;Biochemical properties of the growth suppressor/oncoprotein p53,&rdquo; </PDAT><HIL><ITALIC><PDAT>Oncogene</PDAT></ITALIC></HIL><PDAT>, 7(9):1673-1680, 1992. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Montes de Oca Luna et al., &ldquo;Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature</PDAT></ITALIC></HIL><PDAT>, 378:203-206, 1995. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Newport and Kirschner, &ldquo;A major developmental transition in early Xenopus embryos: II. Control of the onset of transcription,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell</PDAT></ITALIC></HIL><PDAT>, 30:687-696, 1982b. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Nigro et al., &ldquo;Mutations in the p53 gene occur in diverse human tumor types,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature</PDAT></ITALIC></HIL><PDAT>, 342:705-708, 1989. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Parada et al., &ldquo;Cooperation between gene ecoding p53 tumour antigen and ras in cellular transformation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature</PDAT></ITALIC></HIL><PDAT>, 312:649-651, 1984. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Rotter et al., &ldquo;Does wild-type p53 play a role in normal cell differentiation&quest;,&rdquo; </PDAT><HIL><ITALIC><PDAT>Sem. Cancer Biol.</PDAT></ITALIC></HIL><PDAT>, 5:229-236, 1994. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Sah et al., &ldquo;A subset of p53 deficient mice exhibit exencephally,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature Genetics</PDAT></ITALIC></HIL><PDAT>, 10:175-180, 1995. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Scheffner et al., &ldquo;The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53&rdquo;, </PDAT><HIL><ITALIC><PDAT>Cell</PDAT></ITALIC></HIL><PDAT>, 63:1129-1136, 1990. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Scheffner et al., &ldquo;the HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53&rdquo;, </PDAT><HIL><ITALIC><PDAT>Cell</PDAT></ITALIC></HIL><PDAT>, 75:495-505, 1993. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Schmid et al., &ldquo;Expression of p53 during mouse embryogenesis,&rdquo; </PDAT><HIL><ITALIC><PDAT>Development</PDAT></ITALIC></HIL><PDAT>, 113:857-865, 1991. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Shaulusky et al., &ldquo;Involvement of wild-type p53 in pre-B-cell differentiation in vitro,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA</PDAT></ITALIC></HIL><PDAT>, 88:8982-8986, 1991. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Sun et al., &ldquo;Dosage dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma,&rdquo; </PDAT><HIL><ITALIC><PDAT>FASEB J.</PDAT></ITALIC></HIL><PDAT>, 7:944-950, 1994. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Suzuki et al., &ldquo;The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cancer Res.</PDAT></ITALIC></HIL><PDAT>, 52:734-736, 1992. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Tchang et al., &ldquo;Stabilization and expression of high levels of p53 during early development in </PDAT><HIL><ITALIC><PDAT>Xenopus laevis</PDAT></ITALIC></HIL><PDAT>,&rdquo; </PDAT><HIL><ITALIC><PDAT>Dev. Biol.</PDAT></ITALIC></HIL><PDAT>, 159:163-172, 1993. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Wang et al., &ldquo;</PDAT><HIL><ITALIC><PDAT>Xenopus laevis </PDAT></ITALIC></HIL><PDAT>p53 protein: sequence-specific DNA binding, transcriptional egulation and oligomerization are evolutionarily conserved,&rdquo; </PDAT><HIL><ITALIC><PDAT>Oncogene</PDAT></ITALIC></HIL><PDAT>, 19:779-784, 1995. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Wallingford et al., &ldquo;Precocious Expression of the Wilms&apos; Tumor Gene xWT1 Inhibits Embryonic Kidney Development in </PDAT><HIL><ITALIC><PDAT>Xenopus laevis</PDAT></ITALIC></HIL><PDAT>,&rdquo; </PDAT><HIL><ITALIC><PDAT>Dev. Biol.</PDAT></ITALIC></HIL><PDAT>, 202:103-112, 1998. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Wallingfrod et al., &ldquo;p53 is essential for normal development in Xenopus,&rdquo; </PDAT><HIL><ITALIC><PDAT>Current Biology</PDAT></ITALIC></HIL><PDAT>, 7:747-757, 1997. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Whitman and Melton, &ldquo;Involvement of p21ras in Xenopus mesoderm induction,&rdquo; 357:252-254, 1992. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Yang et al., &ldquo;p63, a p53 Homolog at 3q27-29, Encoded Multiple Products with Transactivating, Death-Inducing,and Dominant-Negative Activities,&rdquo; </PDAT><HIL><ITALIC><PDAT>Molecular Cell</PDAT></ITALIC></HIL><PDAT>, 2:305-316, 1998. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Yew and Berk, &ldquo;Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein&rdquo;, </PDAT><HIL><ITALIC><PDAT>Nature</PDAT></ITALIC></HIL><PDAT>, 357, 82-85, 1992. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Sabapathy et al., &ldquo;Regulation of ES differentiation by functional and conformational modulation of p53,&rdquo; </PDAT><HIL><ITALIC><PDAT>EMBO J.</PDAT></ITALIC></HIL><PDAT>, 16(20):6217-6219, 1997. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>pg,10 </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Brodsky et al., &ldquo;Drosophila p53 binds a damage response element at the reaper Locus,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell</PDAT></ITALIC></HIL><PDAT>, 101:103-113, 2000. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Derry et al., &ldquo;Caenorhabditis elegans p53: role in apoptosis, meiosis, and stress resistance,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science</PDAT></ITALIC></HIL><PDAT>, 294:591-595, 2001. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Ollmann et al., &ldquo;Drosophila p53 is a structural and functional homolog of the tumor suppressor p53,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell</PDAT></ITALIC></HIL><PDAT>, 101:91-101, 2000. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Schumacher et al., &ldquo;The C. elegans homolog of the p53 tumor suppressor is required for DNA damage-induced apoptosis,&rdquo; </PDAT><HIL><ITALIC><PDAT>Current Biology</PDAT></ITALIC></HIL><PDAT>, 11:1722-1727, 2001.</PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
</B560>
<B570>
<B577><PDAT>13</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>435  6</PDAT></B582>
<B582><PDAT>435455</PDAT></B582>
<B582><PDAT>435459</PDAT></B582>
<B582><PDAT>435461</PDAT></B582>
<B582><PDAT>4353201</PDAT></B582>
<B582><PDAT>435325</PDAT></B582>
<B582><PDAT>435375</PDAT></B582>
<B582><PDAT>435377</PDAT></B582>
<B582><PDAT>424  91</PDAT></B582>
<B582><PDAT>424  92</PDAT></B582>
<B582><PDAT>424 931</PDAT></B582>
<B582><PDAT>424 932</PDAT></B582>
<B582><PDAT>800 21</PDAT></B582>
<B582><PDAT>800 23</PDAT></B582>
<B582><PDAT>800 25</PDAT></B582>
<B582><PDAT>536 231</PDAT></B582>
<B582><PDAT>536 235</PDAT></B582>
</B580>
<B590><B595><PDAT>7</PDAT></B595><B596><PDAT>17</PDAT></B596></B590>
</B500>
<B600>
<B680US><DOC><DNUM><PDAT>60/051549</PDAT></DNUM><DATE><PDAT>19970702</PDAT></DATE><KIND><PDAT>00</PDAT></KIND></DOC></B680US>
</B600>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Peter D.</PDAT></FNM><SNM><STEXT><PDAT>Vize</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Austin</PDAT></CITY>
<STATE><PDAT>TX</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>John B.</PDAT></FNM><SNM><STEXT><PDAT>Wallingford</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Houston</PDAT></CITY>
<STATE><PDAT>TX</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Board of Regents, The University of Texas System</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>Austin</PDAT></CITY><STATE><PDAT>TX</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Fulbright &amp; Jaworski</PDAT></STEXT></ONM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>Scott D.</PDAT></FNM><SNM><STEXT><PDAT>Priebe</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B747>
<PARTY-US>
<NAM><FNM><PDAT>Sumesh</PDAT></FNM><SNM><STEXT><PDAT>Kaushal</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B747>
<B748US><PDAT>1636</PDAT></B748US>
</B745>
</B700>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>The present invention involves the role of p53 in the differentiation of embryonic tissues. More particularly, the present invention provides methods of the blocking of p53 function in embryonic tissues, and the use of these tissues as screening tools for substances that are capable of overcoming the p53-related block in differentation, both in vitro and in vivo. The similarities between undifferentiated embryonic cells and tumor cells is evident, and thus these assays serve as a model for possible cancer therapeutics. In addition, methods for identifying additional cellular components that interact p53 or p53-related pathways are provided.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<RELAPP>
<BTEXT>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>This application is a non-provisional application of provisional Serial No. 60/051,549, filed Jul. 2, 1997.</PDAT></PTEXT></PARA>
</BTEXT>
</RELAPP>
<GOVINT>
<BTEXT>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>The government may own certain rights in this invention pursuant to a grant number IBN-9630621 from the National Science Foundation.</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BACKGROUND OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>A. Field of the Invention</PDAT></PTEXT></PARA>
<PARA ID="P-00005" LVL="0"><PTEXT><PDAT>The present invention relates generally to the fields of oncology, embryology, molecular biology and genetics. More specifically, the invention relates to the tumor biology of p53 mutants, molecules that interact with p53, and agents that are able to block p53-related defects in cellular differentiation.</PDAT></PTEXT></PARA>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>B. Description of Related Art</PDAT></PTEXT></PARA>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>Many mutant p53 alleles are oncogenic, and p53 was in fact first thought to be an oncogene as the first clones isolated corresponded to mutant forms expressed in immortalized cell lines. Expression of mutant p53 immortalizes primary fibroblasts, and in combination with mutant ras, transforms such cells (Jenkins et al., 1984; Parada et al., 1984; Eliyahu et al., 1985). Normal p53, however, functions as a tumor suppressor and its overexpression can inhibit the growth of various tumor cell lines and can block the transforming activity of a variety of oncogenes (Finlay et al., 1989; Donehower and Bradley, 1993).</PDAT></PTEXT></PARA>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>p53 possesses several different biochemical activities, including transcriptional activation and repression, single-stranded DNA binding, and interaction with several heterologous proteins (Donehower and Bradley, 1993; Gottlieb and Oren, 1996; Haffner and Oren, 1995). These activities regulate a diverse array of biological processes, for example cell cycle transitions, apoptosis, and response to DNA damage (Donehower and Bradley, 1993; Gottlieb and Oren, 1996; Haffner and Oren, 1995). Elimination of p53 activity is thought to contribute to the initiation or progression of tumorigenesis by loss of cell cycle control, genomic instability, and the acquisition of novel properties, such as resistance to hypoxia (Donehower and Bradley, 1993; Gottlieb and Oren, 1996; Haffner and Oren, 1995; Graeber et al., 1996). Given this involvement in numerous fundamental processes, it is quite surprising that p53-null mice develop to term in the majority of cases (Donehower et al., 1992; Armstrong et al., 1995; Sah et al., 1995). However, p53 is expressed during early murine development in a pattern consistent with a role in differentiation (Schmid et al., 1991; Komarova et al., 1997), and the precise regulation of expression appears to be essential for normal development (Montes de Oca Luna et al., 1995; Jones et al., 1995).</PDAT></PTEXT></PARA>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>Thus, although it is clear that p53 plays a key role in tumor development, and may be involved in differentiation as well, the particular mechanisms by which this molecule functions remain undefined. Moreover, it is unclear whether the role play by p53 in these two activities is related.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00010" LVL="0"><PTEXT><PDAT>The present invention involves the role of p53 in the differentiation of embryonic tissues. More particularly, the present invention provides methods of the blocking of p53 function in embryonic tissues, and the use of these tissues as screening tools for substances that are capable of overcoming the p53-related block in differentiation, both in vitro and in vivo. These assays serve as a model for possible cancer therapeutics. In addition, methods for identifying additional cellular components that interact p53 or p53-related pathways are provided.</PDAT></PTEXT></PARA>
<PARA ID="P-00011" LVL="0"><PTEXT><PDAT>There is provided in the present invention a method of screening for agents that inhibit a p53-related block of embryonic cell differentiation comprising the steps of providing an undifferentiated embryonic cell; blocking the function of p53 in the cell such that the cell fails to differentiate; contacting the cell with a candidate agent; and comparing the differentiation of the contacted cell after the contacting with the differentiation of the cell in the absence of the candidate agent whereby an increase in differentiation indicates that the candidate agent is an inhibitor of the p53-related block of differentiation.</PDAT></PTEXT></PARA>
<PARA ID="P-00012" LVL="0"><PTEXT><PDAT>In particular embodiments, the method further comprises the step of comparing the differentiation of the cell after the contacting with the differentiation of the undifferentiated embryonic cell. In more particular embodiments, the cell may be an amphibian cell. In still more particular embodiments, amphibian cell is a </PDAT><HIL><ITALIC><PDAT>Xenopus laevis </PDAT></ITALIC></HIL><PDAT>cell. In other specific embodiments, the cell is an insect cell. In more particular embodiments, the insect cell is a </PDAT><HIL><ITALIC><PDAT>Drosophila melanogaster </PDAT></ITALIC></HIL><PDAT>cell. In further embodiments, it is contemplated that the cell may be a mammalian cell. In specific embodiments the cell may be a mouse cell, in alternate embodiments the mammalian cell is a human cell.</PDAT></PTEXT></PARA>
<PARA ID="P-00013" LVL="0"><PTEXT><PDAT>In particular aspects, the blocking is achieved by introducing into the cell a nucleic acid encoding a dominant negative mutant of p53. More specifically, the introducing may be achieved via electroporation, microinjection, particle bombardment, liposome transfer or viral infection. In certain aspects, the nucleic acid is a DNA; in other aspects, the nucleic acid is an RNA.</PDAT></PTEXT></PARA>
<PARA ID="P-00014" LVL="0"><PTEXT><PDAT>In certain specific embodiments, the blocking is achieved by introducing into the cell a nucleic acid encoding double minute-2 or a ortholog thereof. In other embodiments, the blocking is achieved by introducing into the cell an antisense nucleic acid for p53. In specific aspects, the candidate agent is a nucleic acid. In other embodiments, the candidate agent is polypeptide. In particular embodiments, the candidate agent is produced by a neighboring cell. In other embodiments, the neighboring cell is a second undifferentiated embryonic cell into which the candidate agent has been introduced.</PDAT></PTEXT></PARA>
<PARA ID="P-00015" LVL="0"><PTEXT><PDAT>In particular aspects, the differentiation is determined by culture of the undifferentiated embryonic cell in vitro under conditions where the cell differentiates.</PDAT></PTEXT></PARA>
<PARA ID="P-00016" LVL="0"><PTEXT><PDAT>More particularly the differentiation is determined by development of an embryo in vitro or in vivo.</PDAT></PTEXT></PARA>
<PARA ID="P-00017" LVL="0"><PTEXT><PDAT>Also provided is a method for identifying genes involved in p53-mediated embryonic cell differentiation comprising the steps of providing a plurality of undifferentiated </PDAT><HIL><ITALIC><PDAT>Drosophila melanogaster </PDAT></ITALIC></HIL><PDAT>embryonic cells; contacting the cells with a gene encoding a dominant negative mutant of p53 operably linked to a developmentally regulated promoter responsible for a given trait; mutagenizing the contacted cells; assessing development of the trait in the resulting flies; and determining the identity of a mutated cellular product in flies exhibiting trait development.</PDAT></PTEXT></PARA>
<PARA ID="P-00018" LVL="0"><PTEXT><PDAT>In certain embodiments, the mutagenizing may comprise radiation of the cells. In other embodiments, the mutagenizing may comprise contacting the cells with a DNA damaging agent. In still further embodiments, the mutagenizing comprises introducing mRNA into the cells.</PDAT></PTEXT></PARA>
<PARA ID="P-00019" LVL="0"><PTEXT><PDAT>In particular aspects of the present invention, the contacting comprises microinjection of a P-element comprising the mutant p53 gene and the promoter. In particular aspects, the promoter is the eyeless promoter and the trait is eye development.</PDAT></PTEXT></PARA>
<PARA ID="P-00020" LVL="0"><PTEXT><PDAT>In other aspects of the present invention, there is provided a method for identifying genes involved iri p53-mediated embryonic cell differentiation comprising the steps of providing a plurality of pluripotent embryonic stem cells transformed with a gene encoding a dominant negative mutant of p53 operably linked to an inducible promoter; contacting the cells with nucleic acid encoding a polypeptide and a factor that induces the inducible promoter; culturing the contacted cells under conditions permitting differentiation; and assessing the differentiation of the cells, wherein differentiation in a cell identifies a polypeptide involved in p53-mediated cell differentiation.</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="0"><PTEXT><PDAT>In preferred aspects, the method further comprises contacting the cells with a plurality of nucleic acids encoding polypeptides. In certain embodiments, the plurality of nucleic acids is an expression vector library.</PDAT></PTEXT></PARA>
<PARA ID="P-00022" LVL="0"><PTEXT><PDAT>In particular embodiments, the inducible promoter is the ecdysone response promoter and the factor is ecdysone. In alternate embodiments, the inducible promoter is the metallothionein promoter and the factor is a heavy metal. In yet another embodiment, the inducible promoter is the tetracycline promoter and the factor is tetracycline. In still another alternative embodiment, the inducible promoter is a heat shock promoter and the factor is heat.</PDAT></PTEXT></PARA>
<PARA ID="P-00023" LVL="0"><PTEXT><PDAT>In particular aspects, the conditions include culture without LIF. In preferred embodiments, the differentiation comprises formation of hematopoietic cells, macrophages and cardiac cells. In other embodiments, the conditions further include culture on bacterial grade plastic and the differentiation comprises formation of erythroid cells. In other embodiments the conditions further include culture with retinoic acid and the differentiation comprises formation of neural cells. In still another embodiments, the conditions further include culture with erythropoietin and the differentiation comprises formation of hematopoietic cells. In a further alternative embodiments, the conditions further include culture with interleukin 3 and the differentiation comprises formation of macrophages, neutrophils and mast cells. In yet another alternative, the conditions further include culture with interleukin 3, interleukin 1, and macrophage colony stimulating factor or granulocyte-macrophage colony stimulating factor and the differentiation comprises macrophages. In other embodiments, the conditions further include culture with bone morphogenetic protein 4 and the differentiation comprises hematopoietic cells.</PDAT></PTEXT></PARA>
<PARA ID="P-00024" LVL="0"><PTEXT><PDAT>In particular aspects, the the embryonic stem cells are mammalian cells. The mammalian cells may be mouse cells. In those embodiments, where the cells are mouse cells, the culturing may comprise injected the contacted cells into a mouse blastocyst and implanting the blastocyst in a foster mother. Alternatively, the mammalian cells are human cells. In other preferred embodiments, the embryonic stem cells are amphibian cells. In particular embodiments, the amphibian cells are </PDAT><HIL><ITALIC><PDAT>Xenopus laevis </PDAT></ITALIC></HIL><PDAT>cells. In an alternate preferred embodiments the embryonic stem cells are insect cells. More particularly the insect cells may be </PDAT><HIL><ITALIC><PDAT>Drosophila melanogaster </PDAT></ITALIC></HIL><PDAT>cells.</PDAT></PTEXT></PARA>
<PARA ID="P-00025" LVL="0"><PTEXT><PDAT>Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DRWDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BRIEF DESCRIPTION OF THE DRAWINGS</PDAT></STEXT></H>
<PARA ID="P-00026" LVL="0"><PTEXT><PDAT>The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein:</PDAT></PTEXT></PARA>
<PARA ID="P-00027" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1A</PDAT></FGREF><PDAT>, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1B</PDAT></FGREF><PDAT>, FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>C and FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>D. Expression of dominant-negative p53 inhibits differentiation and results in the formation of developmental tumors. FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>A. Experimental protocol. Xenopus embryos were fertilized in vitro. At the 32-cell stage, a single blastomere was either co-injected with &bgr;-galactosidase and mutant p53 mRNAs, or injected with &bgr;-galactosidase alone. Embryos were injected into one side only, allowing the uninjected side to act as an internal control for normal development. Injected embryos were reared to the swimming tadpole stage, fixed, and stained to detect the presence of &bgr;-galactosidase activity. Cells expressing p53</PDAT><HIL><SP><PDAT>Thr280 </PDAT></SP></HIL><PDAT>and &bgr;-galactosidase (light blue) did not contribute to normal embryonic structures and clumped together into large cell masses, or tumors (arrows). FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>B. Transverse section through an embryo injected with &bgr;-galactosidase and p53</PDAT><HIL><SP><PDAT>Thr280 </PDAT></SP></HIL><PDAT>mRNAs. The tumor is continuous with the spinal cord and is partially covered by pigmented melanocytes (red arrows), as is the spinal cord. Note that the somite ventral to the tumor is reduced in size compared to the somite on the uninjected (control) side. Specimen stained with hematoxylin and eosin. FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>C. Transverse section through the same specimen as in B, stained with Sytox green to visualize nuclei. The tumor is nucleated and contains cells of approximately normal size. FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>D. Transverse section through an embryo injected with p53</PDAT><HIL><SP><PDAT>Thr280 </PDAT></SP></HIL><PDAT>and &bgr;-galactosidase mRNAs and stained with the neural-specific antibody 2G9 (dark purple histochemical substrate). The spinal cord is strongly stained, but the tumor cells (black arrows, light blue/green stain), including those intimately associated with the spinal cord, do not express the antigen. A melanocyte associated with the tumor is indicated with a red arrow.</PDAT></PTEXT></PARA>
<PARA ID="P-00028" LVL="0"><PTEXT><PDAT>FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>A and FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>B. Wild-type p53 rescues the mutant p53 phenotype. FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>A&mdash;Embryo injected with 125 pg of p53</PDAT><HIL><SP><PDAT>Thr280 </PDAT></SP></HIL><PDAT>mRNA plus &bgr;-galactosidase mRNA and stained for &bgr;-galactosidase activity; cells expressing &bgr;-galactosidase (blue) clump together into distinct cell masses or tumors (arrow). FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>B&mdash;Embryo injected with 125 pg p53</PDAT><HIL><SP><PDAT>Thr280 </PDAT></SP></HIL><PDAT>plus 500 pg of human wild-type p53 and &bgr;-galactosidase as a lineage tracer; cells expressing &bgr;-galactosidase are distributed normally across the embryo and incorporated into normal tissues.</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 3A</PDAT></FGREF><PDAT>, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3B</PDAT></FGREF><PDAT>, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3C</PDAT></FGREF><PDAT>, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3D</PDAT></FGREF><PDAT>, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3E</PDAT></FGREF><PDAT>, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3F</PDAT></FGREF><PDAT>, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3G</PDAT></FGREF><PDAT>, and FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>H. Morphology of developmental tumors (transverse sections). The left side of embryo was injected in all cases. Schematic representation of each panel is shown below in </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>E-H. FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>A&mdash;p53</PDAT><HIL><SP><PDAT>Thr280</PDAT></SP></HIL><PDAT>-induced tumor. The tumor bulges out from the lateral surface of the spinal cord. The somite on the injected side is restricted ventrally (compare to uninjected control side). FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>B&mdash;p53</PDAT><HIL><SP><PDAT>His175</PDAT></SP></HIL><PDAT>-induced tumor. The tumor is continuous with the dorsal spinal cord and the overlying epidermis, and occupies much of an extracellular-matrix-filled space lateral to the spinal cord where the somite is normally present. FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>C&mdash;p53</PDAT><HIL><SP><PDAT>TrP248</PDAT></SP></HIL><PDAT>-induced tumor. The tumor is integrated into the dorsal neural tube and extends ventrolaterally where somite is normally present. FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>D&mdash;Xdm-2 induced tumor. The tumor is integrated into the epidermis dorsal to the hindbrain. Tumors in all cases contain a high density of yolk platelets and appear to be undifferentiated. Scale bar&equals;100 microns. Scale is similar in A-C. ecm&equals;extracellular matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00030" LVL="0"><PTEXT><PDAT>FIG. </PDAT><HIL><BOLD><PDAT>4</PDAT></BOLD></HIL><PDAT>A and FIG. </PDAT><HIL><BOLD><PDAT>4</PDAT></BOLD></HIL><PDAT>B. Developmental tumor associated with multiple tissues. Transverse section (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 4A</PDAT></FGREF><PDAT>) and schematic diagram (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 4B</PDAT></FGREF><PDAT>) illustrating a tumor (in this case p53</PDAT><HIL><SP><PDAT>Trp248</PDAT></SP></HIL><PDAT>-induced) which is associated closely with the neural tube, extends under the notochord and is associated with the pronephros on the opposite side of the embryo. The right side was injected with mutant p53 mRNA. The presence of tumor cells on both sides of the midline is probably a consequence of the movement of loosely adherent cells driven by normal morphogenetic movements, rather than the undifferentiated cells possessing any invasive properties.</PDAT></PTEXT></PARA>
<PARA ID="P-00031" LVL="0"><PTEXT><PDAT>FIG. </PDAT><HIL><BOLD><PDAT>5</PDAT></BOLD></HIL><PDAT>. Dominant-negative p53 does not inhibit the mid-blastula transition. 4-cell stage embryos were injected with p53</PDAT><HIL><SP><PDAT>Thr280 </PDAT></SP></HIL><PDAT>mRNA into all four cells (&plus; samples), control embryos were uninjected (&minus; samples). At stage 6 (lane 1-2), p53</PDAT><HIL><SP><PDAT>Thr280 </PDAT></SP></HIL><PDAT>mRNA injected embryos (&plus;) and uninjected embryos (&minus;) both express low levels of EF-1a, but do not express goosecoid or brachyury. Following the MBT, at stage 10.5 (lane 4-5) and stage 13 (lane 6-7), EF-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>a expression is upregulated and zygotic expression of goosecoid and brachyury commences equally in injected (&plus;) and uninjected (&minus;) embryos. &minus;RT&equals;no reverse transcriptase control.</PDAT></PTEXT></PARA>
</BTEXT>
</DRWDESC>
<DETDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT</PDAT></STEXT></H>
<PARA ID="P-00032" LVL="0"><PTEXT><PDAT>Cancer accounts the death of over half a million people each year in the United States alone. The causes for cancer are multifactorial, however, it is known that aberrations in controlled cell death result in uncontrolled cell proliferation and hence contribute to many cancer. The p53 gene is well recognized as possessing tumor suppressor capabilities and mutations in wild-type p53 are correlated to a variety of cancers. However, the interaction of p53 with other cellular factors is not well characterized, and in fact, many of these factors remain undefined. It is not surprising that, in light of the lack of significant information on p53 function, there is an incomplete understanding of the pathways through which p53 regulates tumor development.</PDAT></PTEXT></PARA>
<PARA ID="P-00033" LVL="7"><PTEXT><PDAT>A. The Present Invention</PDAT></PTEXT></PARA>
<PARA ID="P-00034" LVL="0"><PTEXT><PDAT>The present inventors have examined the role of p53 in differentiation of cells as a way of better understanding the growth regulatory properties of this molecule. It now has been demonstrated that blocking p53 function in embryonic cells halts differentiation. By using different kinds of p53 mutations and by differing blocks to p53 function, one can assess the different functional aspects of p53 as it relates to differentiation. Furthermore, one can use differentiation as a measure of different agents to overcome this p53-mediated block in differentiation.</PDAT></PTEXT></PARA>
<PARA ID="P-00035" LVL="0"><PTEXT><PDAT>Certain biological systems are particularly well-adapted to exploit this approach. For example, the developmental biology of Xenopus and Drosophila are extremely well characterized, easily reproduced, and suitable for large scale screening methods. Murine systems also provide a fruitful, if somewhat more complex, system in which to explore the functions of p53. In addition, it is anticipated that human embryonic cells may be utilized in vitro for various of the experiments described herein.</PDAT></PTEXT></PARA>
<PARA ID="P-00036" LVL="0"><PTEXT><PDAT>In general terms, the present invention decribes blocking differentiation in embryonic cells by inhibiting, mutating, blocking, or otherwise abrogating p53 activity. The differentiation ability of the cells may be rescued by introducing a gene, gene product or phamaceutical compound which can bypass the mutant p53 mediated block and identifying those cells which have undergone differentiation in the presence of mutant p53.</PDAT></PTEXT></PARA>
<PARA ID="P-00037" LVL="0"><PTEXT><PDAT>In particular, it is anticipated that one can screen large numbers of potential pharmaceuticals, small molecule libraries and expression libraries for active compounds. The compounds will be screened for their ability to permit differentiation of cells which otherwise remain undifferentiated. The dysplastic nature of these cells is remarkably similar to that of tumor cells arising from p53 defects, and thus the overcoming of this block appears, in certain aspects, analogous to treatment of tumors, although most conventional treatments are designed to kill tumors, not correct defects. Thus, it is believed that the present invention provides a unique approach to the identification of factors, exogenous and endogenous, that can serve as therapeutics for cancers and other developmentally-related diseases.</PDAT></PTEXT></PARA>
<PARA ID="P-00038" LVL="7"><PTEXT><PDAT>B. p53 Polypeptides and Nucleic Acids Coding Therefor</PDAT></PTEXT></PARA>
<PARA ID="P-00039" LVL="0"><PTEXT><PDAT>p53 currently is recognized as a tumor suppressor gene (Montenarh, 1992). High levels of mutant p53 have been found in many cells transformed by chemical carcinogenesis, ultraviolet radiation, and several viruses, including SV40. The p53 gene is a frequent target of mutational inactivation in a wide variety of human tumors and is already documented to be the most frequently-mutated gene in common human cancers (Mercer, 1992). It is mutated in over 50% of human NSCLC (Hollestein et al., 1991) and in a wide spectrum of other tumors.</PDAT></PTEXT></PARA>
<PARA ID="P-00040" LVL="0"><PTEXT><PDAT>The p53 gene encodes a 393-amino-acid phosphoprotein that can form complexes with viral proteins such as. large-T antigen and E1B. The protein is found in normal tissues and cells, but at concentrations which are minute by comparison with transformed cells or tumor tissue. Interestingly, wild-type p53 appears to be important in regulating cell growth and division. Overexpression of wild-type p53 has been shown in some cases to be anti-proliferative in human tumor cell lines. Thus, p53 can act as a negative regulator of cell growth (Weinberg, 1991) and may directly suppress uncontrolled cell growth or activate genes that suppress this growth. Thus, absence or inactivation of wild-type p53 may contribute to transformation. However, some studies indicate that the presence of mutant p53 may be necessary for full expression of the transforming potential of the gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00041" LVL="0"><PTEXT><PDAT>Casey and colleagues have reported that transfection of DNA encoding wild-type p53 into two human breast cancer cell lines restores growth suppression control in such cells (Casey et al., 1991). A similar effect has also been demonstrated on transfection of wild-type, but not mutant, p53 into human lung cancer cell lines (Takahasi et al., 1992). p53 appears dominant over the mutant gene and will select against proliferation when transfected into cells with the mutant gene. Normal expression of the transfected p53 does not affect the growth of cells with endogenous p53. Thus, such constructs might be taken up by normal cells without adverse effects. It is thus proposed that the treatment of p53-associated cancers with wild type p53 will reduce the number of malignant cells or their growth rate. Clinical. data using retroviral p53 to treat cancer also have been presented (Roth et al., 1996)</PDAT></PTEXT></PARA>
<PARA ID="P-00042" LVL="0"><PTEXT><PDAT>i) p53 in Differentiation</PDAT></PTEXT></PARA>
<PARA ID="P-00043" LVL="0"><PTEXT><PDAT>Observations from both transgenic mice and tissue culture experiments have raised the possibility that p53 may be required for normal differentiation in some cell types. Foremost among these observations is the high incidence of neural tube and craniofacial abnormalities observed in p53-null mice (Armstrong et al., 1995; Sah et al., 1995). Other observations consistent with a developmental role include the under-representation of transgenic mice in the offspring of transgenics containing mutant p53 alleles (Harvey et al., 1995) and a possible involvement of p53 in B-cell differentiation (Hall and Lane, 1997; Rotter et al., 1994). These results suggest that either p53 plays a role in some aspect of differentiation, or that the lack of p53 activity results in the accumulation of genetic lesions which in turn inhibit normal development.</PDAT></PTEXT></PARA>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>The Xenopus embryo provides an excellent model for the rapid development of embryonic cells. Xenopus p53 is biochemically and biologically similar to human p53 (Cox et al., 1994), and Xenopus embryos contain a ubiquitous maternal stockpile of p53 mRNA, and protein (Hoever et al., 1994; Tchang et al., 1993). Elimination of protein function in Xenopus has been most effectively achieved by overexpression of dominant-negative mutants (Hemmatti-Brivanlou and Melton, 1992; Levine et al., 1994; Molenaar et al., 1996; Dong et al, 1996), and many mutant forms of p53 have been shown to act in a dominant-negative manner (Baker et al., 1989; Nigro et al., 1989).</PDAT></PTEXT></PARA>
<PARA ID="P-00045" LVL="0"><PTEXT><PDAT>ii) Methods of InhibitingpS3 Function</PDAT></PTEXT></PARA>
<PARA ID="P-00046" LVL="0"><PTEXT><PDAT>According to the present invention, one will seek to block the expression and/or function of p53 as it relates to differentiation of embryonic cells. In so doing, cells engineered or treated in this manner will have a p53-mediated block in differentiation. This accomplished, it then remains to determine what factors are capable of overriding this effect.</PDAT></PTEXT></PARA>
<PARA ID="P-00047" LVL="0"><PTEXT><PDAT>Missense mutations are common for the p53 gene and are essential for the transforming ability of the oncogene. A single genetic change prompted by point mutations can create carcinogenic p53. Unlike other oncogenes, however, p53 point mutations are known to occur in at least 30 distinct codons, often creating dominant alleles that produce shifts in cell phenotype without a reduction to homozygosity. Additionally, these &ldquo;dominant negative&rdquo; alleles appear to be tolerated in the organism and passed on in the germ line. Various mutant alleles appear to range from minimally dysfunctional to strongly penetrant, dominant negative alleles (Weinberg, 1991).</PDAT></PTEXT></PARA>
<PARA ID="P-00048" LVL="0"><PTEXT><PDAT>In one embodiment, blocking of p53 function is achieved by providing to a cell containing a wild-type p53 gene a dominant negative mutant of p53. Unlike some p53 mutants, which merely are inactivated (i.e., lacking the normal tumor suppressor function) and can be rescued by provision of a wild-type gene, dominant negative mutants will &ldquo;override&rdquo; the actions of a wild-type gene. Thus, no &ldquo;knock-out&rdquo; or other anti-p53 modifications are required, only the provision of a dominant negative mutant.</PDAT></PTEXT></PARA>
<PARA ID="P-00049" LVL="0"><PTEXT><PDAT>Typically, this is achieved by transforming a cell (discussed further, below) with a gene encoding a dominant negative mutant of p53. Below (Table 1), there is listed a series of p53 mutants that function as dominant negative mutants.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00001">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 1</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Dominant Negative p53 Mutants</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="offset" colwidth="21pt" align="left"/>
<colspec colname="1" colwidth="56pt" align="left"/>
<colspec colname="2" colwidth="35pt" align="center"/>
<colspec colname="3" colwidth="105pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>Mutation</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Location</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Classification</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>Arg&rarr;His</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>175</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>dominant negative</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>Arg&rarr;Trp</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>248</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>dominant negative</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>Arg&rarr;Thr</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>280</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>dominant negative</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="3" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00050" LVL="0"><PTEXT><PDAT>Another method of blocking p53 function, in a manner similar to that discussed above, is the provision of a p53 binding protein that will inactivate wild-type p53 that is present in the embryonic cell. Such a binding protein is the so-called &ldquo;double minute-2,&rdquo; a oncoprotein that binds to and inhibits the transcriptional activation domain of p53. Orthologs have been identified in the mouse (mdm-2), Xenopus (Xdm-2) and human (Oliner et al., 1992). MDM-2 also can inhibit p53 activity by targeting the p53 protein for ubiquitin-mediated degradation (Kubbutat et al, 1997; Haupt et al., 1997).</PDAT></PTEXT></PARA>
<PARA ID="P-00051" LVL="0"><PTEXT><PDAT>Inhibition of p53 activity also may be achieved by expression of p53-binding proteins encoded by viral oncogenes. One such protein is the E6 protein of human papillomvirus types 16 or 18. This protein binds to p53, and in combination with the a cellular protein, the 100 kd E6 assosciated protein (E6-AP), targets p53 protein for ubiquitin-mediated degradation (Scheffner et al., 1990; 1993). One could envision expressing either E6 alone or E6 in addition to E6-AP in order to inhibit p53 activity. Likewise, the adenovirus 55K early 1B (E1B 55K) protein binds to p53 and inhibits its transcriptional activation activity and its tumor suppressor functions (Sarnow et al., 1982; Yew and Berk, 1992). Expression of EIB therefore also may be used to inhibit p53 activity in the present invention.</PDAT></PTEXT></PARA>
<PARA ID="P-00052" LVL="0"><PTEXT><PDAT>In various other embodiments, one may utilize antisense methodologies to inhibit the expression of p53. Antisense methodology takes advantage of the fact that nucleic acids tend to pair with &ldquo;complementary&rdquo; sequences. By complementary, it is meant that polynucleotides are those which are capable of base-pairing according to the standard Watson-Crick complementarity rules. That is, the larger purines will base pair with the smaller pyrimidines to formn combinations of guanine paired with cytosine (G:C) and adenine paired with either thymine (A:T) in the case of DNA, or adenine paired with uracil (A:U) in the case of RNA. Inclusion of less common bases such as inosine, 5-methylcytosine, 6-methyladenine, hypoxanthine and others in hybridizing sequences does not interfere with pairing.</PDAT></PTEXT></PARA>
<PARA ID="P-00053" LVL="0"><PTEXT><PDAT>Targeting double-stranded (ds) DNA with polynucleotides leads to triple-helix formation; targeting RNA will lead to double-helix formation. Antisense polynucleotides, when introduced into a target cell, specifically bind to their target polynucleotide and interfere with transcription, RNA processing, transport, translation and/or stability. Antisense RNA constructs, or DNA encoding such antisense RNA&apos;s, may be employed to inhibit gene transcription or translation or both within a host cell, either in vitro or in vivo, such as within a host animal, including a human subject.</PDAT></PTEXT></PARA>
<PARA ID="P-00054" LVL="0"><PTEXT><PDAT>As stated above, &ldquo;complementary&rdquo; or &ldquo;antisense&rdquo; means polynucleotide sequences that are substantially complementary over their entire length and have very few base mismatches. For example, sequences of fifteen bases in length may be termed complementary when they have complementary nucleotides at thirteen or fourteen positions. Naturally, sequences which are completely complementary will be sequences which are entirely complementary throughout their entire length and have no base mismatches. Other sequences with lower degrees of homology also are contemplated. For example, an antisense construct which has limited regions of high homology, but also contains a non-homologous region (e.g., ribozyme; see below) could be designed. These molecules, though having less than 50% homology, would bind to target sequences under appropriate conditions.</PDAT></PTEXT></PARA>
<PARA ID="P-00055" LVL="0"><PTEXT><PDAT>Yet another manner of disrupting normal p53 function in a cell is to provide that cell with a ribozyme construct that cleaves wild-type p53 transcripts, thereby preventing translation of a complete p53 product. Although proteins traditionally have been used for catalysis of nucleic acids, another class of macromolecules has emerged as useful in this endeavor. Ribozymes are RNA-protein complexes that cleave nucleic acids in a site-specific fashion. Ribozyme s have specific catalytic domains that possess endonuclease activity (Kim and Cech, 1987; Gerlach et al., 1987; Forster and Symons, 1987). For example, a large number of ribozymes accelerate phosphoester transfer reactions with a high degree of specificity, often cleaving only one of several phosphoesters in an oligonucleotide substrate (Cech et al., 1981; Michel and Westhof, 1990; Reinhold-Hurek and Shub, 1992). This specificity has been attributed to the requirement that the substrate bind via specific base-pairing interactions to the internal guide sequence (&ldquo;IGS&rdquo;) of the ribozyme prior to chemical reaction.</PDAT></PTEXT></PARA>
<PARA ID="P-00056" LVL="0"><PTEXT><PDAT>Ribozyme catalysis has primarily been observed as part of sequence-specific cleavage/ligation reactions involving nucleic acids (Joyce, 1989; Cech et al., 1981). For example, U.S. Pat. No. 5,354,855 reports that certain ribozymes can act as endonucleases with a sequence specificity greater than that of known ribonucleases and approaching that of the DNA restriction enzymes. Thus, sequence-specific ribozyme-mediated inhibition of gene expression may be particularly suited to therapeutic applications (Scanlon et al., :1991; Sarver et al., 1990). Recently, it was reported that ribozymes elicited genetic changes in some cells lines to which they were applied; the altered genes included the oncogenes H-ras, c-fos and genes of HIV. Most of this work involved the modification of a target mRNA, based on a specific mutant codon that is cleaved by a specific ribozyme.</PDAT></PTEXT></PARA>
<PARA ID="P-00057" LVL="7"><PTEXT><PDAT>C. Expression Constructs</PDAT></PTEXT></PARA>
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>According to the present invention, various genes will be expressed, both in vitro and in vivo. Synthetic mRNA encoding a gene product of interest, or a pool of synthetic mRNAs generated from a pool of template DNAs can be synthesized in vitro using purified bacterial or bactiophage RNA polymerases. Such mRNA(s) can be introduced into cells directly by microinjection or by any of the transfection methods used to introduce DNA into a cell. In order to enhance the translation of synthetic mRNA in a cell it is important to synthesize the mRNA incorporating a 5&prime; cap. cDNAs to be translated into mRNA are also often cloned into specific vectors which contain 5&prime; and 3&prime; untranslated sequences from efficiently translated mRNAs to enhance the translational efficiency of the synthesized mRNA. Sequences which enhance the polyadenylation of introduced mRNAs are also sometimes incorporated into vectors used for in vitro mRNA synthesis.</PDAT></PTEXT></PARA>
<PARA ID="P-00059" LVL="0"><PTEXT><PDAT>Expression of genes of interest calls for the use of expression vectors which provide for the replication, amplification and expression of constructs contained therein. Replication and amplification usually require an origin of replication. Expression requires appropriate signals in the vectors, and which include various regulatory elements, such as enhancers/promoters from both viral and mammalian sources that drive expression of the genes of interest in host cells. Elements designed to optimize messenger RNA stability and translatability in host cells also are defined. The conditions for the use of a number of dominant drug selection markers for establishing permanent, stable cell clones expressing the products are also provided, as is an element that links expression of the drug selection markers to expression of the polypeptide.</PDAT></PTEXT></PARA>
<PARA ID="P-00060" LVL="0"><PTEXT><PDAT>i) Regulatory Elements</PDAT></PTEXT></PARA>
<PARA ID="P-00061" LVL="0"><PTEXT><PDAT>Throughout this application, the term &ldquo;expression construct&rdquo; is meant to include any type of genetic construct containing a nucleic acid coding for a gene product in which part or all of the nucleic acid encoding sequence is capable of being transcribed. The transcript may be translated into a protein, but it need not be. In certain embodiments, expression includes both transcription of a gene and translation of mRNA into a gene product. In other embodiments, expression only includes transcription of the nucleic acid encoding a gene of interest.</PDAT></PTEXT></PARA>
<PARA ID="P-00062" LVL="0"><PTEXT><PDAT>In preferred embodiments, the nucleic acid encoding a gene product is under transcriptional control of a promoter. A &ldquo;promoter&rdquo; refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene. The phrase &ldquo;under transcriptional control&rdquo; means that the promoter is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00063" LVL="0"><PTEXT><PDAT>The term promoter will be used here to refer to a group of transcriptional control modules that are clustered around the initiation site for RNA polymerase II. Much of the thinking about how promoters are organized derives from analyses of several viral promoters, including those for the HSV thymidine kinase (tk) and SV40 early transcription units. These studies, augmented by more recent work, have shown that promoters are composed of discrete functional modules, each consisting of approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator or repressor proteins.</PDAT></PTEXT></PARA>
<PARA ID="P-00064" LVL="0"><PTEXT><PDAT>At least one module in each promoter functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation.</PDAT></PTEXT></PARA>
<PARA ID="P-00065" LVL="0"><PTEXT><PDAT>Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located-in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either co-operatively or independently to activate transcription.</PDAT></PTEXT></PARA>
<PARA ID="P-00066" LVL="0"><PTEXT><PDAT>The particular promoter employed to control the expression of a nucleic acid sequence of interest is not believed to be important, so long as it is capable of direction the expression of the nucleic acid in the targeted cell. Thus, where a human cell is targeted, it is preferable to position the nucleic acid coding region adjacent to and under the control of a promoter that is capable of being expressed in a human cell. Generally speaking, such a promoter might include either a human or viral promoter.</PDAT></PTEXT></PARA>
<PARA ID="P-00067" LVL="0"><PTEXT><PDAT>In various embodiments, the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter, the Rous sarcoma virus long terminal repeat, rat insulin promoter and glyceraldehyde-3-phosphate dehydrogenase can be used to obtain high-level expression of the coding sequence of interest. The use of other viral or mammalian cellular or bacterial phage promoters which are well-known in the art to achieve expression of a coding sequence of interest is contemplated as well, provided that the levels of expression are sufficient for a given purpose. By employing a promoter with well-known properties, the level and pattern of expression of the protein of interest following transfection or transformation can be optimized. Further, selection of a promoter that is regulated in response to specific physiologic signals can permit inducible expression of the gene product.</PDAT></PTEXT></PARA>
<PARA ID="P-00068" LVL="0"><PTEXT><PDAT>In particular embodiments, the present invention encompasses the use of Drosophila promoters such as eyeless. In this context, the promoters are associated with development of various traits and hence may be classified as &ldquo;tissue specific&rdquo; promoters, i.e., is expressed in certain tissues and not others.</PDAT></PTEXT></PARA>
<PARA ID="P-00069" LVL="0"><PTEXT><PDAT>Enhancers are genetic elements that increase transcription from a promoter located at a distant position. on the same molecule of DNA. Enhancers are organized much like promoters. That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins.</PDAT></PTEXT></PARA>
<PARA ID="P-00070" LVL="0"><PTEXT><PDAT>The basic distinction between enhancers and promoters is operational. An enhancer region as a whole must be able to stimulate transcription at a distance; this need not be true of a promoter region or its component elements. On the other hand, a promoter must have one or more elements that direct initiation of RNA synthesis at a particular site and in a particular orientation, whereas enhancers lack these specificities. Promoters and enhancers are. often overlapping and contiguous, often seeming to have a very similar modular organization. Any promoter/enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of the gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00071" LVL="0"><PTEXT><PDAT>Where a cDNA insert is employed, one will typically desire to include a polyadenylation signal to effect proper polyadenylation of the gene transcript. The nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and any such sequence may be employed such as human growth hormone and SV40 polyadenylation signals. Also contemplated as an element of the expression cassette is a terminator. These elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.</PDAT></PTEXT></PARA>
<PARA ID="P-00072" LVL="0"><PTEXT><PDAT>ii) Markers</PDAT></PTEXT></PARA>
<PARA ID="P-00073" LVL="0"><PTEXT><PDAT>In certain embodiments of the invention, the cells contain nucleic acid constructs of the present invention, a cell may be identified in vitro or in vivo by including a marker in the expression construct. Such markers would confer an identifiable change to the cell permitting easy identification of cells containing the expression construct. Usually, the inclusion of a drug selection marker aids in cloning and in the selection of transformants, for example, genes that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and histidinol are useful selectable markers. Alternatively, enzymes such as herpes simplex virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT) may be employed. Alternatively, the markers may be utilized simply for identification purpose. Enzymes that provide fluorimetric or calorimetric changes include &bgr;-galactosidase, green fluorescent protein and luciferase. Further examples of markers are well known to one of skill in the art.</PDAT></PTEXT></PARA>
<PARA ID="P-00074" LVL="0"><PTEXT><PDAT>iii) Multigene Constructs and IRES</PDAT></PTEXT></PARA>
<PARA ID="P-00075" LVL="0"><PTEXT><PDAT>In certain embodiments of the invention, the use of internal ribosome entry site (IRES) elements are used to create multigene, or polycistronic, messages. IRES elements are able to bypass the ribosome scanning model of 5&prime; methylated Cap dependent translation and begin translation at internal sites (Pelletier and Sonenberg, 1988). IRES elements from two members of the picanovirus family (polio and encephalomyocarditis) have been described (Pelletier and Sonenberg, 1988), as well an IRES from a mammalian message (Macejak and Sarnow, 1991). IRES elements can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages. By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter/enhancer to transcribe a single message.</PDAT></PTEXT></PARA>
<PARA ID="P-00076" LVL="0"><PTEXT><PDAT>Any heterologous open reading frame can be linked to IRES elements. This includes genes for secreted proteins, multi-subunit proteins, encoded by independent genes, intracellular or memrbrane-bound proteins and selectable markers. In this way, expression of several proteins can be simultaneously engineered into a cell with a single construct and a single selectable marker.</PDAT></PTEXT></PARA>
<PARA ID="P-00077" LVL="0"><PTEXT><PDAT>iv) Viral Vectors</PDAT></PTEXT></PARA>
<PARA ID="P-00078" LVL="0"><PTEXT><PDAT>Another useful variation of the expression vector is the viral vector. The ability of certain viruses to enter cells via receptor-mediated endocytosis, to integrate into host cell genome and express viral genes stably and efficiently have made them attractive candidates for the transfer of foreign genes into mammalian cells (Ridgeway, 1988; Nicolas and Rubenstein, 1988; Baichwal and Sugden, 1986; Temin, 1986). The first viruses used as gene vectors were DNA viruses including the papovaviruses (simian virus 40, bovine papilloma virus, and polyoma) (Ridgeway, 1988; Baichwal and Sugden, 1986) and adenoviruses (Ridgeway, 1988; Baichwal and Sugden, 1986). These have a relatively low capacity for foreign DNA sequences and have a restricted host spectrum. Furthermore, their oncogenic potential and cytopathic effects in permissive cells raise safety concerns. They can accommodate only up to 8 kb of foreign genetic material but can be readily introduced in a variety of cell lines and laboratory animals (Nicolas and Rubenstein, 1988; Temin, 1986).</PDAT></PTEXT></PARA>
<PARA ID="P-00079" LVL="0"><PTEXT><PDAT>One of the preferred methods for in vivo delivery involves the use of an adenovirus expression vector. &ldquo;Adenovirus expression vector&rdquo; is meant to include those constructs containing adenovirus sequences sufficient to (a) support packaging of the construct and (b) to express a polynucleotide (sense or antisense) that has been cloned therein. In this context, expression does not require that the gene product be synthesized.</PDAT></PTEXT></PARA>
<PARA ID="P-00080" LVL="0"><PTEXT><PDAT>The expression vector comprises a genetically engineered form of adenovirus. Knowledge of the genetic organization of adenovirus, a 36 kb, linear, double-stranded DNA virus, allows substitution of large pieces of adenoviral DNA with foreign sequences up to 7 kb (Grunhaus and Horwitz, 1992). In contrast to retrovirus, the adenoviral infection of host cells does not result in chromosomal integration because adenoviral DNA can replicate in an episomal manner without potential genotoxicity. Also, adenoviruses are structurally stable, and no genome rearrangement has been detected after extensive amplification. Adenovirus can infect virtually all epithelial cells regardless of their cell cycle stage. So far, adenoviral infection appears to be linked only to mild disease such as acute respiratory disease in humans.</PDAT></PTEXT></PARA>
<PARA ID="P-00081" LVL="0"><PTEXT><PDAT>Adenovirus is particularly suitable for use as a gene transfer vector because of its mid-sized genome, ease of manipulation, high titer, wide target cell range and high infectivity. Both ends of the viral genome contain 100-200 base pair inverted repeats (ITRs), which are cis elements necessary for viral DNA replication and packaging. The early (E) and late (L) regions of the genome contain different transcription units that are divided by the onset of viral DNA replication. The E1 region (E1A and E1B) encodes proteins responsible for the regulation of transcription of the viral genome and a few cellular genes. The expression of the E2 region (E2A and E2B) results in the synthesis of the proteins for viral DNA replication. These proteins are involved in DNA replication, late gene expression and host cell shut-off (Renan, 1990). The products-of the late genes, including the majority of the viral capsid proteins, are expressed only after significant processing of a single primary transcript issued by the major late promoter (MLP). The MLP, (located at 16.8 m.u.) is particularly efficient during the late phase of infection, and all the mRNA&apos;s issued from this promoter possess a 5&prime;-tripartite leader (TPL) sequence which makes them preferred mRNA&apos;s for translation.</PDAT></PTEXT></PARA>
<PARA ID="P-00082" LVL="0"><PTEXT><PDAT>In a current system, recombinant adenovirus is generated from homologous recombination between shuttle vector and provirus vector. Due to the possible recombination between two proviral vectors, wild-type adenovirus may be generated from this process. Therefore, it is critical to isolate a single clone of virus from an individual plaque and examine its genomic structure.</PDAT></PTEXT></PARA>
<PARA ID="P-00083" LVL="0"><PTEXT><PDAT>Generation and propagation of the current adenovirus vectors, which are replication deficient, depend on a unique helper cell line, designated 293, which was transformed from human embryonic kidney cells by Ad5 DNA fragments and constitutively expresses E1 proteins (Graham et al., 1977). Since the E3 region is dispensable from the adenovirus genome (Jones and Shenk, 1978), the current adenovirus vectors, with the help of 293 cells, carry foreign DNA in either the E1, the D3 or both regions (Graham and Prevec, 1991). In nature, adenovirus can package approximately 105% of the wild-type genome (Ghosh-Choudhury et al, 1987), providing capacity for about 2 extra kb of DNA. Combined with the approximately 5.5 kb of DNA that is replaceable in the E1 and E3 regions, the maximum capacity of the current adenovirus vector is under 7.5 kb, or about 15% of the total length of the vector. More than 80% of the adenovirus viral genome remains in the vector backbone and is the source of vector-borne cytotoxicity. Also, the replication deficiency of the E1-deleted virus is incomplete. For example, leakage of viral gene expression has been observed with the currently available vectors at high multiplicities of infection (MOI) (Mulligan, 1993).</PDAT></PTEXT></PARA>
<PARA ID="P-00084" LVL="0"><PTEXT><PDAT>Helper cell lines may be derived from human cells such as human embryonic kidney cells, muscle cells, hematopoietic cells or other human embryonic mesenchymal or epithelial cells. Alternatively, the helper cells may be derived from the cells of other mammalian species that are permissive for human adenovirus. Such cells include, e.g., Vero cells or other monkey embryonic mesenchymal or epithelial cells. As stated above, the preferred helper cell line is 293.</PDAT></PTEXT></PARA>
<PARA ID="P-00085" LVL="0"><PTEXT><PDAT>Recently, Racher et al. (1995) disclosed improved methods for culturing 293 cells and propagating adenovirus. In one format, natural cell aggregates are grown by inoculating individual cells into 1 liter siliconized spinner flasks (Techne, Cambridge, UK) containing 100-200 ml of medium. Following stirring at 40 rpm, the cell viability is estimated with trypan blue. In another format, Fibra-Cel microcarriers (Bibby Sterlin, Stone, UK) (5 g/l) is employed as follows. A cell inoculum, resuspended in 5 ml of medium, is added to the carrier (50 ml) in a 250 ml Erlenmeyer flask and left stationary, with occasional agitation, for 1 to 4 h. The medium is then replaced with 50 ml of fresh medium and shaking initiated. For virus production, cells are allowed to grow to about 80% confluence, after which time the medium is replaced (to 25% of the final volume) and adenovirus added at an MOI of 0.05. Cultures are left stationary overnight, following which the volume is increased to 100% and shaking commenced for another 72 h.</PDAT></PTEXT></PARA>
<PARA ID="P-00086" LVL="0"><PTEXT><PDAT>Other than the requirement that the adenovirus vector be replication defective, or at least conditionally defective, the nature of the adenovirus vector is not believed to be crucial to the successful practice of the invention. The adenovirus may be of any of the 42 different known serotypes or subgroups A-F. Adenovirus type 5 of subgroup C is the preferred starting material in order to obtain the conditional replication-defective adenovirus vector for use in the present invention. This is because Adenovirus type 5 is a human adenovirus about which a great deal of biochemical and genetic information is known, and it has historically been used for most constructions employing adenovirus as a vector.</PDAT></PTEXT></PARA>
<PARA ID="P-00087" LVL="0"><PTEXT><PDAT>As stated above, the typical vector according to the present invention is replication defective and will not have an adenovirus E1 region. Thus, it will be most convenient to introduce the polynucleotide encoding the gene of interest at the position from which the E1-coding sequences have been removed. However, the position of insertion of the construct within the adenovirus sequences is not critical to the invention. The polynucleotide encoding the gene of interest also may be inserted in lieu of the deleted E3 region in E3 replacement vectors as described by Karlsson et al., (1986) or in the E4 region where a helper cell line or helper virus complements the E4 defect.</PDAT></PTEXT></PARA>
<PARA ID="P-00088" LVL="0"><PTEXT><PDAT>Adenovirus is easy to grow and manipulate and exhibits broad host range in vitro and in vivo. This group of viruses can be obtained in high titers, e.g., 10</PDAT><HIL><SP><PDAT>9</PDAT></SP></HIL><PDAT>-10</PDAT><HIL><SP><PDAT>11 </PDAT></SP></HIL><PDAT>plaque-forming units per ml, and they are highly infective. The life cycle of adenovirus does not require integration into the host cell genome. The foreign genes delivered by adenovirus vectors are episomal and, therefore, have low genotoxicity to host cells. No side effects have been reported in studies of vaccination with wild-type adenovirus (Couch et al., 1963; Top et al., 1971), demonstrating their safety and therapeutic potential as in vivo gene transfer vectors.</PDAT></PTEXT></PARA>
<PARA ID="P-00089" LVL="0"><PTEXT><PDAT>Adenovirus vectors have been used in eukaryotic gene expression (Levrero et al., 1991; Gomez-Foix et al., 1992) and vaccine development (Grunhaus and Horwitz, 1992; Graham and Prevec, 1992). Recently, animal studies suggested that recombinant adenovirus could be used for gene therapy (Stratford-Perricaudet and Perricaudet, 1991; Stratford-Perricaudet et al., 1990; Rich et al., 1993). Studies in administering recombinant adenovirus to different tissues include trachea instillation (Rosenfeld et al., 1991; Rosenfeld et al., 1992), muscle injection (Ragot et al., 1993), peripheral intravenous injections (Herz and Gerard, 1993) and stereotactic inoculation into the brain (Le Gal La Salle et al., 1993).</PDAT></PTEXT></PARA>
<PARA ID="P-00090" LVL="0"><PTEXT><PDAT>The retroviruses are a group of single-stranded RNA viruses characterized by an ability to convert their RNA to double-stranded DNA in infected cells by a process of reverse-transcription (Coffin, 1990). The resulting DNA then stably integrates into cellular chromosomes as a provirus and directs synthesis of viral proteins. The integration results in the retention of the viral gene sequences in the recipient cell and its descendants. The retroviral genome contains three genes, gag, pol, and env that code for capsid proteins, polymerase enzyme, and envelope components, respectively. A sequence found upstream from the gag gene contains a signal for packaging of the genome into virions. Two long terminal repeat (LTR) sequences are present at the 5&prime; and 3&prime; ends of the viral genome. These contain strong promoter and enhancer sequences and are also required for integration in the host cell genome (Coffin, 1990).</PDAT></PTEXT></PARA>
<PARA ID="P-00091" LVL="0"><PTEXT><PDAT>In order to construct a retroviral vector, a nucleic acid encoding a gene of interest is inserted into the viral genorne in the place of certain viral sequences to produce a virus that is replication-defective. In order to produce virions, a packaging cell line containing the gag, pol, and env genes but without the LTR and packaging components is constructed (Mann et al; 1983). When a recombinant plasmid containing a cDNA, together with the retroviral LTR and packaging sequences is introduced into this cell line (by calcium phosphate precipitation for example), the packaging sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media (Nicolas and Rubenstein, 1988; Temin, 1986; Mann et al., 1983). The media containing the recombinant retroviruses is then collected, optionally concentrated, and used for gene transfer. Retroviral vectors are able to infect a broad variety of cell types. However, integration and stable expression require the division of host cells (Paskind et al., 1975).</PDAT></PTEXT></PARA>
<PARA ID="P-00092" LVL="0"><PTEXT><PDAT>A novel approach designed to allow specific targeting of retrovirus vectors was recently developed based on the chemical modification of a retrovirus by the chemical addition of lactose residues to the viral envelope. This modification could permit the specific infection of hepatocytes via sialoglycoprotein receptors.</PDAT></PTEXT></PARA>
<PARA ID="P-00093" LVL="0"><PTEXT><PDAT>A different approach to targeting of recombinant retroviruses was designed in which biotinylated antibodies against a retroviral envelope protein and against a specific cell receptor were used. The antibodies were coupled via the biotin components by using streptavidin (Roux et al., 1989). Using antibodies against major histocompatibility complex class I and class II antigens, they demonstrated the infection of a variety of human cells that bore those surface antigens with an ecotropic virus in vitro (Roux et al., 1989).</PDAT></PTEXT></PARA>
<PARA ID="P-00094" LVL="0"><PTEXT><PDAT>There are certain limitations to the use of retrovirus vectors in all aspects of the present invention. For example, retrovirus vectors usually integrate into random sites in the cell genome. This can lead to insertional mutagenesis through the interruption of host genes or through the insertion of viral regulatory sequences that can interfere with the function of flanking genes (Varmus et al., 1981). Another concern with the use of defective retrovirus vectors is the potential appearance of wild-type replication-competent virus in the packaging cells. This can result from recombination events in which the intact- sequence from the recombinant virus inserts upstream from the gag, pol, env sequence integrated in the host cell genome. However, new packaging cell lines are now available that should greatly decrease the likelihood of recombination (Markowitz et al., 1988; Hersdorffer et al., 1990).</PDAT></PTEXT></PARA>
<PARA ID="P-00095" LVL="0"><PTEXT><PDAT>Other viral vectors may be employed as expression constructs in the present invention. Vectors derived from viruses such as vaccinia virus (Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar et al., 1988) adeno-associated virus (AAV) (Ridgeway, 1988; Baichwal and Sugden, 1986; Hermonat and Muzycska, 1984) and herpesviruses may be employed. They offer several attractive features for various mammalian cells (Friedmann, 1989; Ridgeway, 1988; Bajchwal and Sugden, 1986; Coupar et al., 1988; Horwich et al., 1990).</PDAT></PTEXT></PARA>
<PARA ID="P-00096" LVL="0"><PTEXT><PDAT>With the recent recognition of defective hepatitis B viruses, new insight was gained into the structure-function relationship of different viral sequences. In vitro studies showed that the virus could retain the ability for helper-dependent packaging and reverse transcription despite the deletion of up to 80% of its genome (Horwich et al., 1990). This suggested that large portions of the genome could be replaced with foreign genetic material. The hepatotropism and persistence (integration) were particularly attractive properties for liver-directed gene transfer. Chang et al., recently introduced the chloramphenicol acetyltransferase (CAT) gene into duck hepatitis B virus genome in the place of the polymerase, surface, and pre-surface coding sequences. It was cotransfected with wild-type virus into an avian hepatoma cell line. Culture media containing high titers of the recombinant virus were used to infect primary duckling hepatocytes. Stable CAT gene expression was detected for at least 24 days after transfection (Chang et al., 1991).</PDAT></PTEXT></PARA>
<PARA ID="P-00097" LVL="7"><PTEXT><PDAT>D. Methods of Transforming Cells</PDAT></PTEXT></PARA>
<PARA ID="P-00098" LVL="0"><PTEXT><PDAT>In order to effect expression of sense or antisense gene constructs, the expression construct must be delivered into a cell. This delivery may be accomplished in vitro, as in laboratory procedures for transforming cells lines, or in vivo or ex vivo, as in the treatment of certain disease states. One mechanism for delivery is via viral infection where the expression construct is encapsidated in an infectious viral particle.</PDAT></PTEXT></PARA>
<PARA ID="P-00099" LVL="0"><PTEXT><PDAT>Several non-viral methods for the transfer of expression constructs into cultured mammalian cells also are contemplated by the present invention. These include calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe et al., 1990) DEAE-dextran (Gopal, 1985), electroporation (Tur-Kaspa et al., 1986; Potter et al., 1984), direct microinjection (Harland and Weintraub, 1985), DNA-loaded liposomes (Nicolau and Sene, 1982; Fraley et al., 1979) and lipofectamine-DNA complexes, cell sonication (Fechheimer et al., 1987), gene bombardment using high velocity microprojectiles (Yang et al., 1990), and receptor-mediated transfection (Wu and Wu, 1987; Wu and Wu, 1988). Some of these techniques may be successfully adapted for in vivo or ex vivo use. RNA compositions also may be delivered to cells using these methods. RNA, for example, a pool of in vitro synthesized mRNA may be complexed similarly to the DNA complexes described above, for delivery into cells.</PDAT></PTEXT></PARA>
<PARA ID="P-00100" LVL="0"><PTEXT><PDAT>Once the expression construct has been delivered into the cell the nucleic acid encoding the gene of interest may be positioned and expressed at different sites. In certain embodiments, the nucleic acid encoding the gene may be stably integrated into the genome of the cell. This integration may be in the cognate location and orientation via homologous recombination (gene replacement) or it may be integrated in a random, non-specific location (gene augmentation). In yet futher embodiments, the nucleic acid may be stably maintained in the cell as a separate, episomal segment of DNA. Such nucleic acid segments or &ldquo;episomes&rdquo; encode sequences sufficient to permit maintenance and replication independent of or in synchronization with the host cell cycle. How the expression construct is delivered to a cell and where in the cell the nucleic acid remains is dependent on the type of expression construct employed.</PDAT></PTEXT></PARA>
<PARA ID="P-00101" LVL="0"><PTEXT><PDAT>The introduction of DNA, mRNA or protein into cells by microinjection can be used to screen for molecules capable of imparting novel characteristics to the injected cell, or to rescue defects in the injected cell. Microinjection is performed by puncturing the cell with an injection needle or pipette containing the DNA, mRNA or protein of interest, and forcing a portion of these contents into the cell by applying positive pressure. In Xenopus embryos the most commonly introduced material is in vitro synthesized mRNA (Vize etal., 1991), but expression plasmids and even antibodies also may be used. The basic experiment is performed by:</PDAT></PTEXT></PARA>
<PARA ID="P-00102" LVL="2"><PTEXT><PDAT>1. Performing an in vitro fertilization of Xenopus eggs;</PDAT></PTEXT></PARA>
<PARA ID="P-00103" LVL="2"><PTEXT><PDAT>2. removing the jelly coat of the fertilized embryos;</PDAT></PTEXT></PARA>
<PARA ID="P-00104" LVL="2"><PTEXT><PDAT>3. culture of embryos in a simple saline solution until the required stage. This is usually somewhere between the 2 cell stage (approx. 80 minutes post-fertilization) and the 64-cell stage;</PDAT></PTEXT></PARA>
<PARA ID="P-00105" LVL="2"><PTEXT><PDAT>4. embrydos are placed in a solution of Ficoll then microinjected with the molecule(s) of interest</PDAT></PTEXT></PARA>
<PARA ID="P-00106" LVL="2"><PTEXT><PDAT>5. embryos are allowed to recover in Ficoll solution for a number of hours then returned to simple saline buffer</PDAT></PTEXT></PARA>
<PARA ID="P-00107" LVL="2"><PTEXT><PDAT>6. embryos are raised to the stage of interest then examined for an effect of the injected molecules by analyzing gene expression in repose to the introduced molecule(s) or by analyzing the morphology of the embryo in response to the introduced molecule(s).</PDAT></PTEXT></PARA>
<PARA ID="P-00108" LVL="0"><PTEXT><PDAT>In certain embodiments, the inventors contemplate introducing a molecule that alters the developmental fate of an embryonic cell. The cells at the animal pole (the top, darkly pigmented portion) of Xenopus embryos will normally form the epidermis and neural tissue of the tadpole, and the frog which will develop from the tadpole. The animal pole can be cut off from an early stage embryo and cultured in a simple saline solution in isolation from the remainder of the embryo. Under such circumstances the animal pole will differentiate into a ball of epidermal cells. The cells have not yet received the necessary signals from the bottom half of the embryos which instruct a portion of the animal pole cells to form the nervous system. Such animal pole explants do not form any mesodermal tissue, such as muscle or notochord. The animal pole cells are naive embryonic cells: they are not yet differentiated but have the potential to form many different types of cell.</PDAT></PTEXT></PARA>
<PARA ID="P-00109" LVL="0"><PTEXT><PDAT>The ability of a gene or gene product to encode a specific pathway of differentiation can be tested by introducing the gene into the animal pole of an early embryo. If the animal pole of such an embryo is then removed and cultured in isolation the ability of the injected molecule to alter cell fate from epidermal (the default) can be examined. For example, the Brachyury gene plays a key role in the development of mesodermal cells, including muscle. If an mRNA encoding Brachury is injected into the animal pole of early Xenopus embryos, the embryos are grown to blastula stage, and the animal pole is removed and cultured in isolation, the pole cells will differentiate into both epidermal cells (the default) and mesodermal cells including muscle cells. The differentiation of muscle can be detected by assaying for the expression of muscle specific gene expression or by histology to directly visualize the formation of embryonic muscle blocks, or somites (O&apos;Reilly et al., 1995).</PDAT></PTEXT></PARA>
<PARA ID="P-00110" LVL="0"><PTEXT><PDAT>Pools of mRNA from embryonic tissue also can be microinjected into the animal pole and induce the formation of cells which would not normally form in isolated animal cells. Examples include ovary mRNA and mRNA from Xenopus cultured cell lines which leads to the formation of mesodermal cells (Woodland and Jones, 1987). Although such complex pools have not been fractionated to yield specific gene products with mesoderm inducing activities (these mesoderm inducing molecules were identified by other means making the screen redundant) such a screen is very feasible.</PDAT></PTEXT></PARA>
<PARA ID="P-00111" LVL="0"><PTEXT><PDAT>In other embodiments, the inventors contemplate rescue of an embryonic deficiency by microinjection of mRNA. Defects in embryos can be rescued by supplying the defective embryo with a gene product capable of providing, or compensating for, factors missing in the embryo. A commonly used system in Xenopus is the generation of ventralized embryos by irradiating early embryos with ultraviolet light. The UV light disrupts cytoplasmic rearrangements which under normal circumstances lead to the activation of genes required for the development of dorsal cell types. Such embryos lack dorsal structures such as a head, notochord and muscle.</PDAT></PTEXT></PARA>
<PARA ID="P-00112" LVL="0"><PTEXT><PDAT>If UV-irradiated embryos are microinjected with an mRNA encoding a gene capable of directing cells to form dorsal structures, the injected mRNA can rescue the deficiency in such structures and result in normal development. Single cloned gene products with rescuing activity work under such circumstances, for example Xwnt-8, (Sokol et al., 1991, Smith and Harland, 1991), as do complex mixtures of embryonic mRNA enriched for genes expressed in dorsal tissues (Smith and Harland 1992). When complex mixtures of mRNA with UV rescuing activity were identified the fractionation of such mRNA pools eventually led to the identification of novel gene products involved in specifying dorsal development (Smith and Harland, 1991, 1992).</PDAT></PTEXT></PARA>
<PARA ID="P-00113" LVL="0"><PTEXT><PDAT>In specific embodiments, the inventors contemplate using a combination of these approaches. The inventors contemplate introduction of a single mRNA (mutant p53) to induce a defect plus a pool of mixed mRNAs which may be able to rescue the defect. By screening hundreds of such complex pools the inventors can identify gene products capable of overriding the requirement for p53 in differentiation. Once such active pools are identified, they can be broken down into subpools which can then be retested. These will once again be broken down until single gene products is identified.</PDAT></PTEXT></PARA>
<PARA ID="P-00114" LVL="0"><PTEXT><PDAT>In yet another embodiment of the invention, the expression construct may simply consist of naked recombinant DNA or plasmids. Transfer of the construct may be performed by any of the methods mentioned above which physically or chemically permeabilize the cell membrane. This is particularly applicable for transfer in vitro but it may be applied to in vivo use as well. Dubensky et al. (1984) successfully injected polyomavirus DNA in the form of calcium phosphate precipitates into liver and spleen of adult and newborn mice demonstrating active viral replication and acute infection. Benvenisty and Neshif (1986) also demonstrated that direct intraperitoneal injection of calcium phosphate-precipitated plasmids results in expression of the transfected genes. It is envisioned that DNA encoding a gene of interest also may be transferred in a similar manner in vivo and express the gene product.</PDAT></PTEXT></PARA>
<PARA ID="P-00115" LVL="0"><PTEXT><PDAT>In still another embodiment of the invention for transferring a naked DNA expression construct into cells may involve particle bombardment. This method depends on the ability to accelerate DNA-coated microprojectiles to a high velocity allowing them to pierce cell membranes and enter cells without killing them (Klein et al., 1987). Several devices for accelerating small particles have been developed. One such device relies on a high voltage discharge to generate an electrical current, which in turn provides the motive force (Yang et al., 1990). The microprojectiles used have consisted of biologically inert substances such as tungsten or gold beads.</PDAT></PTEXT></PARA>
<PARA ID="P-00116" LVL="0"><PTEXT><PDAT>Selected organs including the liver, skin, and muscle tissue of rats and mice have been bombarded in vivo (Yang et al., 1990; Zelenin et al., 1991). This may require surgical exposure of the tissue or cells, to eliminate any intervening tissue between the gun and the target organ, i.e., ex vivo treatment. Again, DNA encoding a particular gene may be delivered via this method and still be incorporated by the present invention.</PDAT></PTEXT></PARA>
<PARA ID="P-00117" LVL="0"><PTEXT><PDAT>In a further embodiment of the invention, the expression construct may be entrapped in a liposome. Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh and Bachhawat, 1991). Also contemplated are lipofectamine-DNA complexes.</PDAT></PTEXT></PARA>
<PARA ID="P-00118" LVL="0"><PTEXT><PDAT>Liposome-mediated nucleic acid delivery and expression of foreign DNA in vitro has been very successful. Wong et al., (1980) demonstrated the feasibility of liposome-mediated delivery and expression of foreign DNA in cultured chick embryo, HeLa and hepatoma cells. Nicolau et al., (1987) accomplished successful liposome-mediated gene transfer in rats after intravenous injection.</PDAT></PTEXT></PARA>
<PARA ID="P-00119" LVL="0"><PTEXT><PDAT>In certain embodiments of the invention, the liposome may be complexed with a hemagglutinating virus (HVJ). This has been shown to facilitate fusion with the cell membrane and promote cell entry of liposome-encapsulated DNA (Kaneda et al., 1989). In other embodiments, the liposome may be complexed or employed in conjunction with nuclear non-histone chromosomal proteins (HMG-1) (Kato et al., 1991). In yet further embodiments, the liposome may be complexed or employed in conjunction with both HVJ and HMG-1. In that such expression constructs have been successfully employed in transfer and expression of nucleic acid in vitro and in vivo, then they are applicable for the present invention. Where a bacterial promoter is employed in the DNA construct, it also will be desirable to include within the liposome an appropriate bacterial polymerase.</PDAT></PTEXT></PARA>
<PARA ID="P-00120" LVL="0"><PTEXT><PDAT>Other expression constructs which can be employed to deliver a nucleic acid encoding a particular gene into cells are receptor-mediated delivery vehicles. These take advantage of the selective uptake of macromolecules by receptor-mediated endocytosis in almost all eukaryotic cells. Because of the cell type-specific distribution of various receptors, the delivery can be highly specific (Wu and Wu, 1993).</PDAT></PTEXT></PARA>
<PARA ID="P-00121" LVL="0"><PTEXT><PDAT>Receptor-mediated gene targeting vehicles generally consist of two components: a cell receptor-specific ligand and a DNA-binding agent. Several ligands have been used for receptor-mediated gene transfer. The most extensively characterized ligands are asialoorosomucoid (ASOR) (Wu and Wu, 1987) and transferrin (Wagner et al, 1990). Recently, a synthetic neoglycoprotein, which recognizes the same receptor as ASOR, has been used as a gene delivery vehicle (Ferkol et al., 1993; Perales et al., 1994) and epidermal growth factor (EGF) has also been used to deliver genes to squamous carcinoma cells (Myers, EPO 0273085).</PDAT></PTEXT></PARA>
<PARA ID="P-00122" LVL="0"><PTEXT><PDAT>In other embodiments, the delivery vehicle may comprise a ligand and a liposome. For example, Nicolau et al, (1987) employed lactosyl-ceramide, a galactose-terminal asialganglioside, incorporated into liposomes and observed an increase in the uptake of the insulin gene by hepatocytes. Thus, it is feasible that a nucleic acid encoding a particular gene also may be specifically delivered into a cell type such as lung, epithelial or tumor cells, by any number of receptor-ligand systems with or without liposomes. For example, epidermal growth factor (EGF) may be used as the receptor for mediated delivery of a nucleic acid encoding a gene in many tumor cells that exhibit upregulation of EGF receptor. Mannose can be used to target the mannose receptor on liver cells. Also, antibodies to CD5 (CLL), CD22 (lymphoma), CD25 (T-cell leukemia) and MAA (melanoma) can similarly be used as targeting moieties.</PDAT></PTEXT></PARA>
<PARA ID="P-00123" LVL="7"><PTEXT><PDAT>E. Assay Formats According to the Present Invention</PDAT></PTEXT></PARA>
<PARA ID="P-00124" LVL="0"><PTEXT><PDAT>The present invention involves the monitoring of p53, as a regulator of differentiation, in the screening of compounds for the ability to overcome blocks in p53 function. A variety of different formats are available, utilizing both in vitro and in vivo approaches. These are discussed, generally, below.</PDAT></PTEXT></PARA>
<PARA ID="P-00125" LVL="0"><PTEXT><PDAT>i) In vitro</PDAT></PTEXT></PARA>
<PARA ID="P-00126" LVL="0"><PTEXT><PDAT>In vitro assays have a distinct advantage over in vivo assays in that the requirements for cell culture are less stringent, and often less expensive, than for in vivo systems. However, they suffer, in some contexts from the fact that whole organism models are, by their very nature, more reflective of the developmental patterns seen in nature. Nonetheless, in vitro models are powerful tools, especially when the screening involves large numbers of compounds.</PDAT></PTEXT></PARA>
<PARA ID="P-00127" LVL="0"><PTEXT><PDAT>In a first embodiment, the present invention encompasses the use of pluriopotent embryonic cells in various culture assays. These cells may be obtained from the blastocoel of virtually any organism by needle aspiration. Culture of these undifferentiated, totipotent cells is performed in the presence of a factor that will prevent their differentiation. An example of such a factor is LIF or alternatively by culturing on embryonic feeder cells which provides the LIF. In the presence of LIF, embryonic cells remain totipotent and undifferentiated. Removal of LIF from the culture permits differentiation.</PDAT></PTEXT></PARA>
<PARA ID="P-00128" LVL="0"><PTEXT><PDAT>Other culture parameters for embryonic stem cells include culture in methylcellulose, fetal calf serum and monothioglycerol, &bgr;-mercaptoethanol or other reducing agent.</PDAT></PTEXT></PARA>
<PARA ID="P-00129" LVL="0"><PTEXT><PDAT>Depending on other culture conditions, the type of differentiation will vary. For example, ES cells are maintained in LIF or embryonic feeder cells on culture grade plastic. To induce differentiation they are palced on bacterial grade plastic in a medium containing fetal calf serum, and usually a reducing agent for example BME or MTG. The FCS is required for differnetiation to occur. Often, this differentiation is performed in semi-solid media conatining methylcellulose. Variations of these culture conditions which give rise to other cell types are usually variations in tissue culturgrade palstic, methylcellulose semi-solid media, FCS, reducing agents and other chemicals and growth factors. For example, culture with retinoic acid gives rise to neural cells. Culture with erythropoietin causes hematopoietic cells to form. Culture with interleukin 3 causes formation of macrophages, neutrophils and mast cells. Culture with interleukin 3, interleukin 1, and macrophage colony stimulating factor or granulocyte-macrophage colony stimulating factor results in the formation of macrophages. Culture with bone morphogenetic protein 4 gives rise to hematopoietic cells.</PDAT></PTEXT></PARA>
<PARA ID="P-00130" LVL="0"><PTEXT><PDAT>Once the culture system is established, one may bring the candidate test substance into contact with the cells. At such a time, the differentiation-inhibiting factor is removed, and the effects of the candidate substance on differentiation are observed. Proper controls include culturing cells in the absence of the factor, but without the candidate substance. Dose range and escalation studies also are contemplated. Depending on the nature of the candidate substance, the contacting may comprise merely coculturing the cells with the substance. Other substances should be delivered to the inside of the cell. This can be accomplished by microinjection or, in the case of nucleic acids, by the methods set forth above.</PDAT></PTEXT></PARA>
<PARA ID="P-00131" LVL="0"><PTEXT><PDAT>Sufficient culture time is required following the contacting of the candidate substance with the embryonic cells. Depending on the cell, this time will vary considerably, but the appropriate time may easily be ascertained by removing the differentiation-inhibiting factor from untreated cells and determining the period need for differentiation of these cells into the expected cell type. For murine cells, the typical time is approximately 10 days. Amphibian (Xenophus) cells require, generally, about 2 days, and insect (Drosophila) cells differentiate in about 12 days.</PDAT></PTEXT></PARA>
<PARA ID="P-00132" LVL="0"><PTEXT><PDAT>ii) In vivo</PDAT></PTEXT></PARA>
<PARA ID="P-00133" LVL="0"><PTEXT><PDAT>An alternative to in vitro assays is an in vivo. While more complex and expensive than in vitro assays, in vivo assays may more accurately reflect the natural state, and thereby provide more accurate information, at least with respect to some properties. A number of different assays are contemplated. The examples discussed below are not intended to be all inclusive of the systems which may be utilized, as virtually any biological system can be adapated for the purposes of the present invention.</PDAT></PTEXT></PARA>
<PARA ID="P-00134" LVL="7"><PTEXT><PDAT>1. Xenopus</PDAT></PTEXT></PARA>
<PARA ID="P-00135" LVL="0"><PTEXT><PDAT>In one embodiment, the </PDAT><HIL><ITALIC><PDAT>Xenopus laevis </PDAT></ITALIC></HIL><PDAT>system is employed. As indicated above, Xenopus p53 is very similar to human p53, and Xenopus embryos contain a ubiquitous maternal stockpile of p53 mRNA and protein. In order to inactivate the endogenous p53, mRNA encoding a dominant negative form of p53 can be microinjected into a single or multiple blastomere(s). Preferred is injection into the 32-cell stage blastomere, into presumptive mesodermal tissue. However, other stages of development also may be employed, for example, 8, 16, 32, 64 or 128 cell stages will work at differing efficiencies. A particular advantage of c lturing Xenopus embryos is that such cultures are markedly less expensive than culturing mammalian cells in vitro.</PDAT></PTEXT></PARA>
<PARA ID="P-00136" LVL="0"><PTEXT><PDAT>Alternatively, one can inactive the resident p53 by providing, to the blastomere cell, a double minute-2 oncoprotein. This molecule binds to the transcriptional activation domain of p53 and inactivates its function. Again, mRNA encoding the double minute-2 molecule is injected into the blastomere cell, and expression of the corresponding polypeptide will block p53 function.</PDAT></PTEXT></PARA>
<PARA ID="P-00137" LVL="0"><PTEXT><PDAT>Another advantageous embodiment includes the injection into cells of a marker gene. Such a gene permits tracing of the lineage of injected cells in later development. Examples include &bgr;-galactosidase, green fluorescent protein and luciferase. When embryos reach tadpole stage, tissues can be fixed and stained, for example, for &bgr;-galactosidase activity using an appropriate chromogenic substrate.</PDAT></PTEXT></PARA>
<PARA ID="P-00138" LVL="0"><PTEXT><PDAT>Histological analysis of tissues injected with either dominant negative p53 mutants or the double minute-2 oncoprotein show cell masses that resemble tumors and also are reminiscent of undifferentiated embryonic cells. Abnormal nuclear morphologies also were observed. Histologically, these tissues are considered to be blastomas.</PDAT></PTEXT></PARA>
<PARA ID="P-00139" LVL="0"><PTEXT><PDAT>According to the present invention, it is contemplated that this model for tumor development can be used to screen for agents that inhibit p53-related tumor development. In various embodiments, candidate inhibitors are contacted with the engineered cells. Depending on the candidate agent, the route of delivery will vary. For example, merely contacting the cell with an organo-pharmnaceutical may be sufficient, whereas the preferred mode of contacting for nucleic acids, both RNA&apos;s and DNA&apos;s, is to transfer the nucleic acid into the cell. This can be accomplished by any of the techniques mentioned above.</PDAT></PTEXT></PARA>
<PARA ID="P-00140" LVL="0"><PTEXT><PDAT>It then remains only to monitor the development of the ensuing tissues, which can be traced by use of a marker gene like &bgr;-galactosidase, and determine their histology as compared to tissues that develop normally and those that develop without the benefit of the developmental control of p53. Typical methods of monitoring include histologic analysis (microscopic, immunohistochemistry), protein analysis (Western blot, SDS-PAGE, 2D PAGE), TUNEL analysis. Assays for markers of terminal differentiation are also contemplated. These markers can be measured as expression of genes or proteins expressed in differentiated cells. Gene expression can be assayed using techniques well known to those of skill in the art, for example, by Northern Blotting, RNase protection assays, RT-PCR or a variety of other techniques. Proteins expressed can be assayed visually (e.g. the production of hemoglobin in differentiating ES cells) or by the other assays listed above.</PDAT></PTEXT></PARA>
<PARA ID="P-00141" LVL="7"><PTEXT><PDAT>2. Drosophila</PDAT></PTEXT></PARA>
<PARA ID="P-00142" LVL="0"><PTEXT><PDAT>Another system that may advantageously be employed in an in vivo context is </PDAT><HIL><ITALIC><PDAT>Drosophila melanogaster. </PDAT></ITALIC></HIL><PDAT>Drosophila genetics have been extensively studied and, thus, provide a fruitful starting point for analysis. One embodiment employs use of tissue specific promoters in Drosophila to drive the expression of a dominant negative p53 gene or a double minute-2 gene, thereby knocking out p53 functions in these cells. Because only certain tissues will be targeted, one can monitor the development, or lack thereof, of these tissues. Preferably, the tissues to be targeted are non-essential, i.e., the fly can develop and live, at least temporarily, without them. One example of such a promoter is the eyeless promoter. This regulatory element is specifically turned on in tissues destined for eye development. The activation of this promoter, when linked to a mutant p53 or double minute-2 gene, will result in the absence of eye tissue formation. This is a non-lethal defect that is easily observed. Other promoters that may prove useful include but are not limited to gal4 responsive promoter, heat shock promoter and hairy promoter.</PDAT></PTEXT></PARA>
<PARA ID="P-00143" LVL="0"><PTEXT><PDAT>As discussed above, the engineering of blastomeres primarily relies on transfer of gene (mutant p53, double minute-2) to cells, with or without marker genes. Once transformed in this manner, the developmental pattern of the cells will be disrupted by virtue of the developmentally regulated expression of the blocking gene. In the case of eyeless, the absence of eye development will indicate that the blocking gene is expressed and operating. Provision of a candidate inhibitor substance that is sufficient to override the block well permit eye development.</PDAT></PTEXT></PARA>
<PARA ID="P-00144" LVL="7"><PTEXT><PDAT>3. Mouse</PDAT></PTEXT></PARA>
<PARA ID="P-00145" LVL="0"><PTEXT><PDAT>Mice were the first transgenic mammals and this system remains one of the best tested systems for gene transfer into developing embryos. This system is more complex than the amphibian and insect systems described above, but the large amount of work that has been done provides a very high level of expertise in manipulating murine embryonic cells. Essentially, mouse embryo cells may be manipulated as described above.</PDAT></PTEXT></PARA>
<PARA ID="P-00146" LVL="0"><PTEXT><PDAT>Another option with this system in the generation of chimeric mice having both p53-blocked and unblocked cells. In some tissues the lack of p53 ultimately leads to death of the organism, but the present invention is useful in that chimeric mice may be generated that house lethally defective cells. Pluripotent stems cells can be removed from blastocysts and cultured in the presence of LIF to maintain totipotency. Once engineered to establish a p53 block (as discussed above), the cells can be introduced into a blastocoel. Implantation of the blastocyst into a foster mother, followed by gestation, results in a chimeric animal that has embryonic stem cells with both blocked an unblocked p53 differentiation patterns. Such animals may then provide in vivo models and be examined for abnormalities development arising from p53 abrogation.</PDAT></PTEXT></PARA>
<PARA ID="P-00147" LVL="0"><PTEXT><PDAT>Thus a transgenic mouse expressing mutant p53 can be generated and tested for its developmental abilities. Such an animal may be used to test the effectiveness of compounds isolated from other screens or for screening new compounds useful in blocking p53-related defects in cellular differentiation. The transgenic mouse can be generated by direct microinjection of DNA or mRNA encoding mutant p53, or by introducing ES cells expressing mutant p53 into embryos, then testing the compounds directly on these embryos following transplantation.</PDAT></PTEXT></PARA>
<PARA ID="P-00148" LVL="7"><PTEXT><PDAT>F. Candidate Substances</PDAT></PTEXT></PARA>
<PARA ID="P-00149" LVL="0"><PTEXT><PDAT>According to the present invention, one may screen any kind of candidate substance for activity in the assays described above. Although drug design principles may be employed, one of the advantages of the present invention is that large numbers of compounds may be screened</PDAT></PTEXT></PARA>
<PARA ID="P-00150" LVL="0"><PTEXT><PDAT>i) Pharmaceuticals</PDAT></PTEXT></PARA>
<PARA ID="P-00151" LVL="0"><PTEXT><PDAT>Any classic pharmaceutical may be tested according to the present invention. Useful compounds in this regard will include those compounds, and compounds related thereto, that are known to affect cellular development and tumorigenesis. Many classic pharmaceuticals are derived from naturally occurring compounds, and also may include fragments or parts of naturally-occurring compounds, or may be only found as active combinations of known compounds which are otherwise inactive.</PDAT></PTEXT></PARA>
<PARA ID="P-00152" LVL="0"><PTEXT><PDAT>Particularly fruitful sources for pharmaceuticals include bacteria, fungi, plant sources, including leaves and bark, and marine samples may be assayed as candidates for the presence of potentially useful pharmaceutical agents. It will be understood that the pharmaceutical agents to be screened could also be derived or synthesized from chemical compositions or man-made compounds.</PDAT></PTEXT></PARA>
<PARA ID="P-00153" LVL="0"><PTEXT><PDAT>ii) Expression Libraries</PDAT></PTEXT></PARA>
<PARA ID="P-00154" LVL="0"><PTEXT><PDAT>Expression libraries, also known as cDNA libraries, comprises complementary DNA copies of mRNA&apos;s from a selected cell or tissue. These libraries represent the genetic information that is transcribed in the cells. The cDNA&apos;s are cloned into plasmids such that they are positioned under the control of regulatory signals that permit the transcription and translation of the mRNA produced therefrom.</PDAT></PTEXT></PARA>
<PARA ID="P-00155" LVL="0"><PTEXT><PDAT>In one embodiment, expression libraries may be used in a random fashion. These libraries are contacted with cells have a p53-related block in differentiation. After monitoring the effects that the library has on individual cells, cells which exhibit the desired characteristics can be isolated, and DNA therein analyzed. In this manner, the expression plasmid can be identified and the gene responsible for the desired characteristic sequenced.</PDAT></PTEXT></PARA>
<PARA ID="P-00156" LVL="0"><PTEXT><PDAT>In other embodiments, candidate members of an expression library may be utilized selectively, thereby obviating the need for later identification. This approach is more time consuming and permits only testing of selected clones. This generally requires that some additional criteria be used to narrow the candidate clones or genes.</PDAT></PTEXT></PARA>
<PARA ID="P-00157" LVL="0"><PTEXT><PDAT>iii) mRNA Pools</PDAT></PTEXT></PARA>
<PARA ID="P-00158" LVL="0"><PTEXT><PDAT>Messenger RNA&apos;s encode various proteins within a cell. It is possible to isolate mRNA&apos;s that are homogenous, or substantially homogeneous and use these molecules in &ldquo;gene&rdquo; transfer experiments, as discussed above. For example, it is possible to generate mRNA&apos;s in cell free systems using DNA&apos;s with the appropriate regulatory signals as the template. Large amounts of homogeneous RNA can be produced in this fashion.</PDAT></PTEXT></PARA>
<PARA ID="P-00159" LVL="0"><PTEXT><PDAT>Another approach to the production of mRNA&apos;s is to isolate whole cell or poly-A RNA&apos;s from tissues which have mRNA profiles that are predominated by a single species. This single species can be further purified in order to minimize the amount and number of contaminating minor species. Methods for isolating and handling mRNA&apos;s are well known to those of skill in the art.</PDAT></PTEXT></PARA>
<PARA ID="P-00160" LVL="0"><PTEXT><PDAT>iv) Small Molecule Libraries</PDAT></PTEXT></PARA>
<PARA ID="P-00161" LVL="0"><PTEXT><PDAT>Small molecule libraries include both peptides and organochemicals. These compounds generally are generated in an automated fashion. For example, peptides may be synthesized to substitute all possible variations at a single position. Series of peptides substituting for each residue in a peptide permit &ldquo;scanning&rdquo; of peptides for active sites. Similarly, organic molecules utilize substitution of various R-groups with structurally similar, but distinct, chemical units, such as alkyl, aryl, alkenyl, etc. Many such libraries are commercially available.</PDAT></PTEXT></PARA>
<PARA ID="P-00162" LVL="0"><PTEXT><PDAT>G. Mutagenesis</PDAT></PTEXT></PARA>
<PARA ID="P-00163" LVL="0"><PTEXT><PDAT>In a variation on the assays described above, another embodiment of the present invention involves the use of engineered embryonic cells to screen for molecules that are involved with p53 and its function as a regulator of differentiation. Basically, the initial steps are as described above&mdash;obtaining an undifferentiated embryonic cell and blocking the function of p53 therein. Rather than attempting to overcome the block by virtue of a drug, nucleic acid or protein, the engineered embryonic cell is mutagenized, for example, with radiation or a chemical DNA damaging agent. If the mutagenesis effects a change that results in the differentiation of the previously blocked cell, identification of the mutation should reveal a gene or regulatory sequence that interacts with p53 or plays a role in a p53-related process.</PDAT></PTEXT></PARA>
<PARA ID="P-00164" LVL="0"><PTEXT><PDAT>Identification of the mutagenized gene involves segregating the trait by means of breeding. Briefly, the mutagensis can be performed using chemical mutagens, irradiation and by P-element mediated mutagenesis to generate insertional mutants (Bingham et al., 1982, Cooley et al., 1988).</PDAT></PTEXT></PARA>
<PARA ID="P-00165" LVL="0"><PTEXT><PDAT>Once mutations, which can either enhance or suppress the developmental defect caused by expression of mutant p53, have been generated, they can be characterized using standard genetic methods. Firstly, the position of the mutation which genetically interacts with mutant p53 gene will be mapped by determining with which genetic markers it co-segregates. Meiotic recombination frequencies will then be used to map the genetic position of the mutation within the identified chromosome. Once the position of the mutation has been refined candidate genes will be identified, if possible, from the detailed genetic and DNA data bases available on Drosophila. If known genes or mutations map to the identified region, these will be obtained from the laboratories which identified them. If candidate genes or mutants can be obtained from other laboratories, these will be tested in genetic crosses to determine if they correspond to the identified mutation. If the mutations map in regions containing no previously identified genes or mutations the region will be cloned and analyzed in order to identify the responsible genes.</PDAT></PTEXT></PARA>
<PARA ID="P-00166" LVL="0"><PTEXT><PDAT>Cloning of the interacting mutants can be done in a number of ways. If the mutations have a phenotype in the absence of the mutant p53 P-element cloning can be achieved via a P-element mediated mutagenesis screen, whereby the transposition of endogenous P-elements is used to disrupt the genome via insertional mutagenesis (Cooley et al., 1988). If a P-element insertion in trans to the p53 interacting mutation generates the same phenotype as the interacting mutation in trans to itself, the insertion site is probably within the gene being sought. A genomic library can be made from these flies and the P-element DNA sequences used to isolated genomic fragments adjacent to the insertion site. If the mutations only generate a phenotype in the presence of the mutant p53 P-element the analysis will be more complex. In this instance fine genetic mapping followed by chromosome walking will be required to identify the responsible gene. Chromosome walking is achieved by making a stepwise progression through a genomic library using the extreme end of one clone to identify overlapping clones which correspond to sequences further along the chomosome. The extreme end of this new clone is then used to identify even more distant sequences, and so on.</PDAT></PTEXT></PARA>
<PARA ID="P-00167" LVL="0"><PTEXT><PDAT>Two classes of mutations can be identified in a screen such as the one described. Mutations which rescue (suppress) the block to differentiation imposed by mutant p53, and mutations which enhance the block to differentiation. Of course, mutations in the introduced P-element disrupting the introduced p53 gene will also be generated, but these will be detected and will be discarded from the screen. Mutations which enhance the mutant p53 mediated block to differentiation probably act with p53. during the normal differentiation process, and mutations inactivating such cofactors will contribute to the inhibition of differentiation. In this instance the mutations will be loss-of-function mutants, whereby the mutation has inactivated an interacting gene. Such loss-of-function muations may well have a developmental phenotype when in trans to themselves, even in the absense of the mutant p53 P-element, which will make their genetic and molecular characterization much more straightforward. Mutations which suppress the mutant p53 phenotype will probably be caused by gain-of-function (neomorphic) mutations. Such mutations either increase the level or activity of a gene or gene product in such a way as to over-ride the ability of mutant p53 to suppress this activity. Gain-of-function mutations also can impart novel activities upon a gene or gene product. Such mutants may or may not require the mutant p53 gene in order to cause a developmental defect.</PDAT></PTEXT></PARA>
<PARA ID="P-00168" LVL="0"><PTEXT><PDAT>Examples of genes which could be identified by such screening methods described above include mdm-2 null mice which die very early in development, and p53 null mice which survive. Mdm-2 null mice develop normally in a p53 null genetic background. In this example the p53 mutation suppresses, or negates, the requirement for mdm-2 activity. A mutagenesis study of mdm-2 null mice would have identified the p53 gene. In the examples proposed herein above the opposite approach is being taken: generate a p53 null phenotype, then screen for interacting genes.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>H. EXAMPLES</PDAT></STEXT></H>
<PARA ID="P-00169" LVL="0"><PTEXT><PDAT>The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>Example 1</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Materials and Methods</PDAT></STEXT></H>
<PARA ID="P-00170" LVL="0"><PTEXT><PDAT>Mutant and wild-type p53 cDNAs, and Xdm-2 cDNA, were subcloned into the Xenopus expression vector pSP64TS which provides Xenopus globin 3&prime; and 5&prime; untranslated regions that significantly improve translation efficiency, with the exception of p53</PDAT><HIL><SP><PDAT>His175</PDAT></SP></HIL><PDAT>, which was used in pBS-SK (Stratagene). Capped mRNA was transcribed in vitro (Krieg and Melton, 1984), and embryo handling, microinjections (2 to 5 nl) and &bgr;-galactosidase assays were performed as previously described (Vize et al., 1991). Embryos were staged according to P. Nieuwkoop and J. Faber (Nieuwkoop and Faber, 1994).</PDAT></PTEXT></PARA>
<PARA ID="P-00171" LVL="0"><PTEXT><PDAT>Embryos were fixed in MEMFA, stained for &bgr;-galactosidase activity (Vize et al., 1991) and processed in one of two ways. Some specimens were stained for antibodies 2G9 (neural), 12/101 (muscle), 3G8 (pronephros), or EPA (epidermis) using whole-mount immunocytochemistry, embedded in JB-4 (Polysciences), sectioned at 5&mgr;, and counterstained with Sytox&trade; green (Molecular Probes) or hematoxylin and eosin (Sigma). Other specimens were embedded in Paraplast, sectioned at 10&mgr;, and stained for antibodies 2G9, 12/101, or 3G8 using serial-section immunochemistry. This procedure yielded better penetration of the antibody into the specimens.</PDAT></PTEXT></PARA>
<PARA ID="P-00172" LVL="0"><PTEXT><PDAT>RT-PCR: Embryos were injected with 0.5 ng p53-</PDAT><HIL><SP><PDAT>Thr280 </PDAT></SP></HIL><PDAT>into the marginal zone of all four cells at the four cell-stage; control embryos were uninjected. Total RNA was extracted from 5 embryo equivalents at stages 6, 10.5, and 13 and reverse transcribed. PCR was performed using one tenth of each reverse transcription reaction, Taq polymerase, 1 Ci of </PDAT><HIL><SP><PDAT>32</PDAT></SP></HIL><PDAT>P-dATP, and primer sets listed below; cycle temperatures were 92&deg; C., 55&deg; C., and 72&deg; C.; EF-1a for 16 cycles; goosecoid and brachyury for 19 cycles. Primer sets were as follows: EF-1&agr;: CAGATTGGTGCTGGATATGC (SEQ ID NO:1) and ACTGCCTTGATGACTCCTAG (SEQ ID NO:2); goosecoid: ACAACTGGAAGCACTGGA (SEQ ID NO:3) and TCTTATTCCAGAGGAACC (SEQ ID NO:4); brachyury: GGATCGTTATCACCTCTG (SEQ ID NO:5) and GTGTAGTCTGTAGCAGCA (SEQ ID NO:6) One fifth of each PCR reaction was then electrophoresed on a 5% non-denaturing acrylamide gel and autoradiographed.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>Example 2</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Blocking Endogenous p53 Function in Xenopus Embryonic Cells</PDAT></STEXT></H>
<PARA ID="P-00173" LVL="0"><PTEXT><PDAT>In order to inactivate the maternal stockpile of Xenopus p53, mRNA encoding a dominant-negative mutant form of p53 was introduced into developing embryos by microinjection. Synthetic mRNA encoding a dominant-negative form of human p53, p53</PDAT><HIL><SP><PDAT>Thr280 </PDAT></SP></HIL><PDAT>(Sun et al., 1994), was microinjected into a single blastomere in the presumptive mesoderm of 32-cell stage embryos along with mRNA encoding nuclear &bgr;-galactosidase as a lineage tracer (Vize et al., 1991). These embryos were then raised to tadpole stages, fixed, and stained for &bgr;-galactosidase activity (FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>). Injection of &bgr;-galactosidase mRNA alone had no effect on development (Table 2); and in such control experiments, &bgr;-galactosidase-positive cells were found evenly incorporated into axial. However, in embryos co-injected with p53</PDAT><HIL><SP><PDAT>Thr280 </PDAT></SP></HIL><PDAT>mRNA, the &bgr;-galactosidase-positive cells derived from the injected blastomere were found to be clustered into large cell masses, with no organization into axial structures (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>; Table 2).</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00002">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 2</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Frequency of developmental tumor formation in response to ectopic</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>expression of tumor-suppressors or proto-oncogenes.</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="5">
<colspec colname="offset" colwidth="14pt" align="left"/>
<colspec colname="1" colwidth="56pt" align="left"/>
<colspec colname="2" colwidth="77pt" align="center"/>
<colspec colname="3" colwidth="21pt" align="center"/>
<colspec colname="4" colwidth="49pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>Injected mRNA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Tumor Frequency</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&num; Expts.</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="4" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="5">
<colspec colname="offset" colwidth="14pt" align="left"/>
<colspec colname="1" colwidth="56pt" align="left"/>
<colspec colname="2" colwidth="77pt" align="center"/>
<colspec colname="3" colwidth="21pt" align="char" char="."/>
<colspec colname="4" colwidth="49pt" align="char" char="."/>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>0.5 ng &bgr;-gal</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>66</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>8</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>0.5 ng p53</PDAT><HIL><SP><PDAT>Thr280</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>67%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>120</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>0.5 ng p53</PDAT><HIL><SP><PDAT>Trp248</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>71%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>34</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>0.5 ng Hp53</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>94</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>0.5 ng Xp53</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>38</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>1.0 ng xWT1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>106</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>11</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>1.5 ng p53</PDAT><HIL><SP><PDAT>His175</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>54%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>114</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>1.5 ng Xdm-2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>30%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>249</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="4" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="4" align="left"><PTEXT><FOO ID="FOO-00001"><PTEXT><PDAT>Table 2. Wild-type tumor suppressors p53 (both human and Xenopus) and WT1 (Xenopus) do not induce tumor formation. Mutant p53 and wild-type Xdm-2 cause developmental tumors in a large percentage of injected embryos. The distribution of &bgr;-galactosidase-positive cells (see Table 3 and </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2A</PDAT></FGREF><PDAT>) was used to score the frequency of tumor formation, and tumor phenotypes were confirmed by histology. p53</PDAT><HIL><SP><PDAT>His175 </PDAT></SP></HIL><PDAT>was not cloned into the expression vector 64TS and mRNA was generated from pBS, such mRNA </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT># will have a significantly lower translation efficiency (Vize et al., 1991), which may explain the reduced frequency of tumor formation for this mutant. Abbreviations: &bgr;-gal, &bgr;-galactosidase; Xp53, Xenopus wild-type p53; Hp53, human wild-type p53; xWT1, Xenopus wild-type WT1 (Carroll and Vize, 1996). </PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<CWU>
<TABLE-US ID="TABLE-US-00003">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 3</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Wild-type p53 rescues the mutant p53 phenotype.</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="1" colwidth="126pt" align="left"/>
<colspec colname="2" colwidth="42pt" align="center"/>
<colspec colname="3" colwidth="21pt" align="center"/>
<colspec colname="4" colwidth="28pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>&num; of</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Injected mRNA(s)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Tumor Freq.</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Expts.</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>125 pg p53</PDAT><HIL><SP><PDAT>thr280</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>66%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>249</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>8</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>125 pg p53</PDAT><HIL><SP><PDAT>thr280 </PDAT></SP></HIL><PDAT>&plus; 500 pg Xenopus p53</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>30%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>113</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>125 pg p53</PDAT><HIL><SP><PDAT>thr280 </PDAT></SP></HIL><PDAT>&plus; 500 pg human p53</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>32%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>128</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
<row>
<entry namest="1" nameend="4" align="left"><PTEXT><FOO ID="FOO-00002"><PTEXT><PDAT>Table 3. The distribution of &bgr;-galactosidase-positive cells (as shown in FIG. 2A and </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2B</PDAT></FGREF><PDAT>) was used to score the frequency of tumor formation in this assay, and tumor phenotypes were confirmed by histology. Four-fold overexpression of either Xenopus or human wild-type p53 reduced tumor frequency by more than half. </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00174" LVL="0"><PTEXT><PDAT>Histological analysis revealed that the cell masses formed by cells expressing p53</PDAT><HIL><SP><PDAT>thr280 </PDAT></SP></HIL><PDAT>resembled tumors in a number of ways. The cell masses were nucleated and the cells within them were of approximately normal size and retained large numbers of yolk platelets, reminiscent of undifferentiated cells (FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>). Furthermore, abnormal nuclear morphologies were observed (FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>), and the undifferentiated cell masses were sometimes surrounded by an epithelial capsule and were often adjacent to large deposits of extracellular matrix. Immunohistochemistry with antibodies that detect neural- (FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>), muscle-, epidermal- or pronephric-specific antigens failed to detect expression of any markers of terminal differentiation within p53</PDAT><HIL><SP><PDAT>thr280</PDAT></SP></HIL><PDAT>-induced tumors. These cells remained undifferentiated through the latest stage examined (the feeding tadpole stage). As these tumors are derived from embryonic cells that have failed to differentiate, rather than from cells that have undergone dedifferentiation, they can be classified as blastomas, or undifferentiated embryonic-derived tumors.</PDAT></PTEXT></PARA>
<PARA ID="P-00175" LVL="0"><PTEXT><PDAT>Blocking p53 activity did not overtly interfere with or promote proliferation. As Xenopus early development proceeds without growth, cell division results in the formation of smaller and smaller cells with each cell cycle. When a single blastomere was injected with mutant p53, it gave rise to tumors containing hundreds of cells of approximately normal size, indicating that they have undergone a normal number of cell divisions. Although some tumor nuclei may be pycnotic, extensive apoptosis was not triggered by blocking p53 activity, as evidenced by the continued presence of &bgr;-galactosidase-positive tumor cells. These observations show that the formation of tumors is not the result of hyperproliferation, but rather is the result of the failure of cells to be incorporated into normal tissues and to undergo differentiation.</PDAT></PTEXT></PARA>
<PARA ID="P-00176" LVL="0"><PTEXT><PDAT>The phenotype elicited by mutant p53 was not due to non-specific effects caused by mRNA toxicity, as overexpression of wild-type human or Xenopus p53 did not induce tumor formation or inhibit normal differentiation (Table 2). While it has been previously reported that overexpression of wild-type Xenopus p53 results in cell cycle arrest (Hoever et al., 1994), the doses required to elicit such effects were extremely high, the lowest dose being more than double the highest dose injected here. In this study, injections of up to 1 ng of Xenopus or human wild-type p53 did not elicit cell cycle arrest or tumor formation. Likewise, injection of &bgr;-galactosidase mRNA alone, even at very high doses, had no effect on development (Table 2). Furthermore, no tumors have been reported in Xenopus embryos in previous studies where other gene products were ectopically expressed, including other tumor-suppressors such as APC (Vleminckx et al., 1997) and WT1 (Table 2), proto-oncogenes such as jun (Dong et al., 1996) and ras (Whitman and Melton, 1992), viral oncogenes such as polyoma middle T (Whitman and Melton, 1989) and v-ras (Whitman and Melton, 1992), or cyclins such as cyclin B2 (Hartley et al., 1996).</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>Example 3</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Wild-type p53 Suppresses the Tumor-inducing Activity of Mutant p53</PDAT></STEXT></H>
<PARA ID="P-00177" LVL="0"><PTEXT><PDAT>Although mutant human p53 was overexpressed in these experiments, Xenopus p53 is similar in structure and function to human p53 and can form functional heterotetramers with human p53 (Tchang et al., 1993; Wang et al., 1995). If the mutant p53 blocks differentiation by oligomerizing with and inhibiting the activity of the endogenous Xenopus p53 protein, the effect should be abrogated by coinjection with excess wild-type p53. Indeed, when an excess of either human or Xenopus wild-type p53 was coinjected with p53</PDAT><HIL><SP><PDAT>thr280</PDAT></SP></HIL><PDAT>, the frequency of tumor formation was dramatically reduced (FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT> and Table 3). Considering that p53 functions as a tetramer, most oligomers formed from a 4:1 mixture of wild-type to mutant p53 protein will contain at least one mutant subunit. This fact, in addition to the enhanced stability of mutant p53 proteins (Olson and Levine, 1994; Blagosklonny et al., 1995) may explain the inability of wild-type p53 to completely rescue the tumor phenotype.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>Example 4</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Different p53 Mutants Elicit a Similar Developmental Phenotype</PDAT></STEXT></H>
<PARA ID="P-00178" LVL="0"><PTEXT><PDAT>It is possible that the tumor phenotype was the result of an activity unique to p53</PDAT><HIL><SP><PDAT>thr280</PDAT></SP></HIL><PDAT>. Therefore, the activity of other p53 dominant-negative mutants was evaluated using identical protocols. The original mutant tested, p53</PDAT><HIL><SP><PDAT>thr280</PDAT></SP></HIL><PDAT>, disrupts an essential base contact in the DNA-binding domain (Sun et al., 1994; Cho et al., 1994). Another mutant, p53</PDAT><HIL><SP><PDAT>trp248</PDAT></SP></HIL><PDAT>, disrupts DNA binding by eliminating essential minor groove contacts (Cho et al., 1994). Expression of p53</PDAT><HIL><SP><PDAT>Trp248 </PDAT></SP></HIL><PDAT>elicited a tumor phenotype identical to that of p53</PDAT><HIL><SP><PDAT>Thr280 </PDAT></SP></HIL><PDAT>in terms of frequency (Table 2), size, gross morphology, and histology (FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>). A third mutant, p53</PDAT><HIL><SP><PDAT>His175 </PDAT></SP></HIL><PDAT>which disrupts protein folding in the DNA-binding domain (Cho et al., 1994), also elicited a similar tumor phenotype (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT>, Table 2).</PDAT></PTEXT></PARA>
<PARA ID="P-00179" LVL="0"><PTEXT><PDAT>When embryos were injected into the presumptive somitic mesoderm, cells expressing a dominant-negative p53 were often displaced dorsally and lay adjacent to the neural tube just below the epidermis (FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>). In many instances, such tumors were integrated into the differentiated cells of the adjacent epidermis or neural tube (FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>). Many tumors had associated melanocytes, either superficial or integrated. The only other tissue in this region of the embryo with which melanocytes are commonly associated is the neural tube. In many cases where tumors were found lateral to the neural tube, the somite on the injected side of the embryo was restricted ventrally and greatly reduced in size (FIGS. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT> and </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>). Although it is possible that this reduction of the somite may be a result of tissue distortion caused by the presence of the tumor, it is more likely due to the failure of p53</PDAT><HIL><SP><PDAT>thr280</PDAT></SP></HIL><PDAT>-expressing cells to differentiate and consequent failure of these cells to contribute to the somitic tissue.</PDAT></PTEXT></PARA>
<PARA ID="P-00180" LVL="0"><PTEXT><PDAT>Tumors were also, though more rarely, found associated with mesodermal tissues such as somite and pronephros (FIG. </PDAT><HIL><BOLD><PDAT>4</PDAT></BOLD></HIL><PDAT>). Because of the association of tumors with a number of different tissues, the ability of p53</PDAT><HIL><SP><PDAT>thr280 </PDAT></SP></HIL><PDAT>expression to block differentiation was tested in several cell lineages. Expression of p53</PDAT><HIL><SP><PDAT>thr280 </PDAT></SP></HIL><PDAT>inhibited differentiation and elicited tumor formation in presumptive somite, brain, spinal cord, pronephros, and epidermal lineages when assayed by histology and immunohistochemistry. Tumors derived from all cell types were similar to those described above for presumptive somite.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>Example 5</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Ectopic Xdm-2 Causes Tumor Formation</PDAT></STEXT></H>
<PARA ID="P-00181" LVL="0"><PTEXT><PDAT>The observation that wild-type p53 can block the activity of a mutant protein and that three different p53 mutants induce similar tumors argues that the mutant human p53 proteins block differentiation by inhibiting the activity of endogenous Xenopus p53. However, it is possible that these different proteins possess a common gain-of-function (neomorphic) activity and act via other proteins not normally associated with wild-type p53. The inventors therefore sought to repress p53 activity without introducing mutant proteins.</PDAT></PTEXT></PARA>
<PARA ID="P-00182" LVL="0"><PTEXT><PDAT>The murine double minute-2 (mdm-2) gene encodes an oncoprotein which binds to and inhibits the activity of the p53 transcriptional activation domain (Kussie et al., 1996; Momand et al., 1992). In order to eliminate p53 activity, mRNA injection was used to overexpress the Xengpus ortholog of mdm-2, Xdm-2 (Kussie et al., 1996), in developing embryos. The expression of Xdm-2 during normal Xenopus development has not yet been described, however the developmental expression of this gene is not relevant to the experiments described here, as microinjected Xdm-2 was used only to interfere with the maternal stockpile of p53, not endogenous Xdm-2.</PDAT></PTEXT></PARA>
<PARA ID="P-00183" LVL="0"><PTEXT><PDAT>Overexpression of Xdm-2 mRNA elicited a tumor phenotype similar to that of mutant p53 (FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>), although at a lower frequency (Table 2). These tumors were again identified initially by the failure of &bgr;-galactosidase-positive cells to incorporate normally into axial structures of the embryo. Tumors resulting from Xdm-2 overexpression were in general smaller than those elicited by mutant p53; however, histological analysis revealed that Xdm-2-induced tumors were similar in morphology to those resulting from mutant p53 expression (FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>). Xdm-2-induced tumors tended to be located in aberrantly dorsal positions, contained yolk-filled, nucleated cells, and were sometimes integrated into the neural tube or epidermis (FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>).</PDAT></PTEXT></PARA>
<PARA ID="P-00184" LVL="0"><PTEXT><PDAT>It is possible that Xdm-2 induces tumors at a lower frequency than mutant p53 because of differences in protein stability, stoichiometry of inhibitory mechanisms, or because Xdm-2 only possesses a subset of the activities of mutant p53. Xdm-2 may induce tumors by blocking endogenous p53 activity, while mutant p53 proteins may function both by blocking endogenous p53 and by gain-of-function activities (Dittmer et al., 1993). The early lethality observed in mdm-2 null mice can be rescued by generating such mice in a p53 null background, arguing that the only essential function of mdm-2 during normal development is the regulation of p53 activity (Montes de Oca Luna et al., 1995; Jones et al., 1995). Given this observation, it would seem that the Xdm-2 induced developmental tumors represent the minimal consequence of blocking p53 activity in Xenopus.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>Example 6</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Mutant p53 Does Not Interfere with the Mid-Blastula Transition</PDAT></STEXT></H>
<PARA ID="P-00185" LVL="0"><PTEXT><PDAT>In Xenopus embryos, the first 12 cell cycles do not contain G1 or G2 phases; the cell cycle acquires these phases only after the mid-blastula transition (MBT), concomitant with the onset of zygotic gene expression and the loss of cell cycle synchrony (Newport and Kirschner, 1982; Newport and Kirschner, 1982b). One possible role for p53 in early amphibian development could be to implement G1 and G2 cell cycle control at the MBT. In order to examine this possibility, the MBT was analyzed in embryos injected with p53</PDAT><HIL><SP><PDAT>thr280 </PDAT></SP></HIL><PDAT>into all cells at the four-cell stage. Zygotic transcription was activated normally (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT>) and the cell cycle became asynchronous at the MBT in embryos expressing p53</PDAT><HIL><SP><PDAT>280 </PDAT></SP></HIL><PDAT>in all cells, indicating that the MBT occurred normally. Not only does general transcriptional activation commence normally, as indicated by the activation of a housekeeping gene, EF-1a (Krieg et al., 1989), but mesodermal gene expression also commences normally, as evidenced by the activation of Brachyury (Smith et al., 1991) and Goosecoid (Cho et al., 1991) expression. This indicates that the mutant p53 is not blocking mesoderm induction. Rather, mutant p53 seems to be acting by blocking cells&apos; ability to act on these signals and differentiate into mesoderm.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>Example 7</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>A Role for p53 in Development</PDAT></STEXT></H>
<PARA ID="P-00186" LVL="0"><PTEXT><PDAT>Taken together, the results presented herein suggest a crucial role for p53 in early Xenopus development. Although dominant-negative p53 mutants may have gain-of-function activities, the Xdm-2. results argue that the mutant proteins are likely to be acting by interfering with endogenous p53. If a gain-of-function activity is responsible, this activity must be shared by three different mutants and a distinct tumor phenotype must be elicited by ectopic Xdm-2. Although this would be an extraordinary coincidence, the inventors aim to eliminate this possibility by interfering with p53 activity by other methods. The most likely explanation for the data presented here is that p53 activity is essential for normal development in Xenopus, and that interfering with p53 function results in blocking the ability of embryonic cells to differentiate.</PDAT></PTEXT></PARA>
<PARA ID="P-00187" LVL="0"><PTEXT><PDAT>How can p53 be essential to frog development but dispensable during murine development&quest; One possibility is that p53 is required for a developmental process that is not utilized during murine development. The mostly likely candidate process was the mid-blastula transition, which is critical to frog development but has no true equivalent in mice. However, the data shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT> indicate that the MBT occurs normally and so cannot explain the incongruence between mouse and frog observations. The Xenopus embryonic cell cycle undergoes a second transition period a few cycles after the MBT. This second transition is known as the early gastrula transition (EGT) and is characterized by a significant lengthening of the gap phases of the cell cycle (Howe et al., 1995). This lengthening may reflect the acquisition of additional check points or other cell cycle properties, and it may be these additional properties which are essential for differentiation. The timing of the EGT is consistent with the defects observed in response to blocking p53 activity, as the first stage at which defects have been identified are early neurulae, shortly after the end of gastrulation.</PDAT></PTEXT></PARA>
<PARA ID="P-00188" LVL="0"><PTEXT><PDAT>Xenopus contain a large maternal stockpile of p53 mRNA and protein (Cox et al., 1994), while mammalian embryos express only low levels of p53 (Komarova et al., 1997) and maternal stocks of p53 have not yet been described. A maternal stockpile of p53 protein in p53 null mice cannot explain the lack of an early effect on mouse development as p53 null mice can be crossed and produce viable offspring (Armstrong et al., 1995). It is possible that the Xenopus stockpile is utilized for some as yet uncharacterized, but essential, developmental process.</PDAT></PTEXT></PARA>
<PARA ID="P-00189" LVL="0"><PTEXT><PDAT>Another possibility is that mice have genetic redundancies not present in frogs, making Xenopus more sensitive to p53 inhibition. For example, in mammals mutation of MyoD or Myf-5 does not disrupt myogenesis, but combination of the two mutants does (Rudnicki et al., 1993). The detailed analysis of MyoD alone would not have predicted a role for this important gene in muscle development in mice. Another useful example is the activins, which appear to be essential for mesoderm induction in Xenopus (Hemmatti-Brivanlou and Melton, 1992) but which are not required for mesoderm formation in mice (Matzuk et al., 1995a;. 1995b). Once again, excluding a role for this gene in development based solely upon the mouse mutant phenotype would have been premature. Lower vertebrates may have less complex redundancies protecting proliferation and differentiation, making them more dependent on p53 function. It is interesting to note that developmental defects in p53 null mice occur at different frequencies in different genetic backgrounds (Armstrong et al., 1995; Sah et al., 1995), implying that at least some such functional redundancies exist, and that without these redundancies p53 function is necessary for normal development.</PDAT></PTEXT></PARA>
<PARA ID="P-00190" LVL="0"><PTEXT><PDAT>High level expression of a potent dominant-negative p53 during early murine development may well have more penetrant effects than targeted p53 disruption, especially if mutant proteins possess a weak gain-of-function activity in addition to their dominant-negative activity. The commonly used p53</PDAT><HIL><SP><PDAT>Val135 </PDAT></SP></HIL><PDAT>transgenic mice express a rather weak temperature sensitive mutant under the control of the p53 promoter (Harvey et al., 1995). As mutant proteins must be present in excess to interfere effectively with wild-type protein (Gottlieb and Oren, 1996), these mice may not really address this question. The inventors are presently examining the activity of p5 3</PDAT><HIL><SP><PDAT>thr280 </PDAT></SP></HIL><PDAT>on very early murine development to explore this issue. If the existence of genetic redundancies is the reason for the lack of a penetrant phenotype in p53 null mice, the lack of such redundancies in Xenopus may provide a system in which the redundant genes can be identified. Microinjection of mutant p53 mRNA plus pools of mRNAs from mammalian cell lines and screening for the ability of such pools to suppress tumor formation may allow the identification of such genes. The identification of such genes, will be extremely relevant to the study of human tumorigenesis.</PDAT></PTEXT></PARA>
<PARA ID="P-00191" LVL="0"><PTEXT><PDAT>All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>REFERENCES</PDAT></STEXT></H>
<PARA ID="P-00192" LVL="0"><PTEXT><PDAT>The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference:</PDAT></PTEXT></PARA>
<PARA ID="P-00193" LVL="1"><PTEXT><PDAT>Armnstrong, et al., &ldquo;High-frequency developmental abnormalities in p53-deficient mice,&rdquo; </PDAT><HIL><ITALIC><PDAT>Curr. Biol., </PDAT></ITALIC></HIL><PDAT>5:931-936, 1995.</PDAT></PTEXT></PARA>
<PARA ID="P-00194" LVL="1"><PTEXT><PDAT>Baichwal and Sugden, &ldquo;Vectors for gene transfer derived from animal DNA viruses:</PDAT></PTEXT></PARA>
<PARA ID="P-00195" LVL="0"><PTEXT><PDAT>Transient and stable expression of transferred genes&rdquo; In: </PDAT><HIL><ITALIC><PDAT>Gene Transfer, </PDAT></ITALIC></HIL><PDAT>Kucherlapati R, ed., New York, Plenum Press, pp. 117-148, 1986.</PDAT></PTEXT></PARA>
<PARA ID="P-00196" LVL="1"><PTEXT><PDAT>Baker, et al., &ldquo;Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>244: 217-221, 1989.</PDAT></PTEXT></PARA>
<PARA ID="P-00197" LVL="1"><PTEXT><PDAT>Benvenisty &amp; Neshif, &ldquo;Direction introduction of genes into rats and expression of the genes,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Nat. Acad Sci. USA, </PDAT></ITALIC></HIL><PDAT>83:9551 -9555, 1986.</PDAT></PTEXT></PARA>
<PARA ID="P-00198" LVL="1"><PTEXT><PDAT>Bingham, et al., &ldquo;The molecular basis of P-M hybrid dysgenesis: the role of the P element, a P-strain-specific transposon family&rdquo;, </PDAT><HIL><ITALIC><PDAT>Cell </PDAT></ITALIC></HIL><PDAT>29(3):995-1004, 1982.</PDAT></PTEXT></PARA>
<PARA ID="P-00199" LVL="1"><PTEXT><PDAT>Blagosklonny, et al., &ldquo;Geldapamycin selectively destabilizes and conformationally alters mutated p53,</PDAT><HIL><ITALIC><PDAT>&rdquo; Oncogene, </PDAT></ITALIC></HIL><PDAT>11:933-939, 1995.</PDAT></PTEXT></PARA>
<PARA ID="P-00200" LVL="1"><PTEXT><PDAT>Carroll and Vize, &ldquo;Wilms tumor suppressor gene is involved in the development of disparate kidney forms: evidence from expression in the Xenopus pronephros,&rdquo; </PDAT><HIL><ITALIC><PDAT>Dev. Dynamics, </PDAT></ITALIC></HIL><PDAT>206:131-138, 1996.</PDAT></PTEXT></PARA>
<PARA ID="P-00201" LVL="1"><PTEXT><PDAT>Casey et al., &ldquo;Growth suppressor of human breast cancer cells by the introduction of a wild-type p53 gene,&rdquo; </PDAT><HIL><ITALIC><PDAT>Oncogene, </PDAT></ITALIC></HIL><PDAT>6:1791-1797, 1991.</PDAT></PTEXT></PARA>
<PARA ID="P-00202" LVL="1"><PTEXT><PDAT>Cech et al., &ldquo;In vitro splicing of the ribosomal RNA precursor of Tetrahymena: involvement of a guanosine nucleotide in the excision of the intervening sequence.&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell, </PDAT></ITALIC></HIL><PDAT>27 (3 Pt 2) p487-96, 1981.</PDAT></PTEXT></PARA>
<PARA ID="P-00203" LVL="1"><PTEXT><PDAT>Chang et al., Foreign gene delivery and expression in hepatocytes using a hepatitis B virus vector. </PDAT><HIL><ITALIC><PDAT>Hepatology, </PDAT></ITALIC></HIL><PDAT>14:124A, 1991.</PDAT></PTEXT></PARA>
<PARA ID="P-00204" LVL="1"><PTEXT><PDAT>Chen and Okayama, &ldquo;High-efficiency transfection of mammalian cells by plasmid DNA,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol. Cell Biol., </PDAT></ITALIC></HIL><PDAT>7:2745-2752, 1987.</PDAT></PTEXT></PARA>
<PARA ID="P-00205" LVL="1"><PTEXT><PDAT>Cho, et al., &ldquo;Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations,&rdquo; Science, 265:346-355, 1994.</PDAT></PTEXT></PARA>
<PARA ID="P-00206" LVL="1"><PTEXT><PDAT>Cho, et al., &ldquo;Molecular nature of Spemann&apos;s organizer: the role of the Xenopus homeobox gene goosecoid,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell, </PDAT></ITALIC></HIL><PDAT>67:1111-1120, 1991.</PDAT></PTEXT></PARA>
<PARA ID="P-00207" LVL="1"><PTEXT><PDAT>Coffin, &ldquo;Retroviridae and their replication,&rdquo; In: Fields B N, Knipe D M, ed. Virology. New York: Raven Press, pp. 1437-1500, 1990.</PDAT></PTEXT></PARA>
<PARA ID="P-00208" LVL="1"><PTEXT><PDAT>Cooley, et al., &ldquo;A. Insertional mutagenesis of the Drosophila genome with single P elements. Science. 239(4844):1121-8, 1988.</PDAT></PTEXT></PARA>
<PARA ID="P-00209" LVL="1"><PTEXT><PDAT>Couch et al., &ldquo;Immunization with types 4 and 7 adenovirus by selective infection of the intestinal tract,&rdquo; </PDAT><HIL><ITALIC><PDAT>Am. Rev. Resp. Dis., </PDAT></ITALIC></HIL><PDAT>88:394-403, 1963.</PDAT></PTEXT></PARA>
<PARA ID="P-00210" LVL="1"><PTEXT><PDAT>Coupar et al., &ldquo;A general method for the construction of recombinant vaccinia virus expressing multiple foreign genes&rdquo;, </PDAT><HIL><ITALIC><PDAT>Gene, </PDAT></ITALIC></HIL><PDAT>68:1-10, 1988.</PDAT></PTEXT></PARA>
<PARA ID="P-00211" LVL="1"><PTEXT><PDAT>Cox, et al., &ldquo;Xenopus p53 is biochemically similar to the human tumour suppressor protein p53 and is induced upon DNA damage in somatic cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>Oncogene, </PDAT></ITALIC></HIL><PDAT>9:2951-2959, 1994.</PDAT></PTEXT></PARA>
<PARA ID="P-00212" LVL="1"><PTEXT><PDAT>d van der E b, &ldquo;A new technique for the assay of infectivity of human adenovirus 5 DNA&rdquo;, </PDAT><HIL><ITALIC><PDAT>Virology, </PDAT></ITALIC></HIL><PDAT>52:456-467, 1973.</PDAT></PTEXT></PARA>
<PARA ID="P-00213" LVL="1"><PTEXT><PDAT>Dittmer, et al., &ldquo;Gain-of-function mutations in p53,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature Genetics, </PDAT></ITALIC></HIL><PDAT>4:42-46, 1993.</PDAT></PTEXT></PARA>
<PARA ID="P-00214" LVL="1"><PTEXT><PDAT>Donehower and Bradley, &ldquo;The tumor suppressor p53,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochim. Biophys. Acta, </PDAT></ITALIC></HIL><PDAT>1155:181-205,.1993.</PDAT></PTEXT></PARA>
<PARA ID="P-00215" LVL="1"><PTEXT><PDAT>Donehower, et al., &ldquo;Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>356:215-221, 1992.</PDAT></PTEXT></PARA>
<PARA ID="P-00216" LVL="1"><PTEXT><PDAT>Dong, et al., &ldquo;AP-1/jun is required for early Xenopus development and mediates mesoderm induction by fibroblast growth factor but not by activin,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem., </PDAT></ITALIC></HIL><PDAT>271:9942-9946, 1996.</PDAT></PTEXT></PARA>
<PARA ID="P-00217" LVL="1"><PTEXT><PDAT>Dubensky et al., &ldquo;Direct transfection of viral and plasmid DNA into the liver or spleen of mice,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Nat. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>81:7529-7533, 1984.</PDAT></PTEXT></PARA>
<PARA ID="P-00218" LVL="1"><PTEXT><PDAT>Eliyahu, et al., &ldquo;Overproduction of p53 antigen makes established cells highly tumorigenic,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>316:158-60, 1985.</PDAT></PTEXT></PARA>
<PARA ID="P-00219" LVL="1"><PTEXT><PDAT>Fechheimer et al., &ldquo;Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>84:8463-8467, 1987.</PDAT></PTEXT></PARA>
<PARA ID="P-00220" LVL="1"><PTEXT><PDAT>Ferkol et al., &ldquo;Regulation of the phosphoenolpyruvate carboxykinase/human factor IX gene introduced into the livers of adult rats by receptor-mediated gene transfer&rdquo;, </PDAT><HIL><ITALIC><PDAT>FASEB J., </PDAT></ITALIC></HIL><PDAT>7:1081-1091, 1993.</PDAT></PTEXT></PARA>
<PARA ID="P-00221" LVL="1"><PTEXT><PDAT>Finlay, et al., &ldquo;The p53 proto-oncogene can act as a suppressor of transformation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell, </PDAT></ITALIC></HIL><PDAT>57:1083-1093, 1989.</PDAT></PTEXT></PARA>
<PARA ID="P-00222" LVL="1"><PTEXT><PDAT>Forster &amp; Symons, &ldquo;Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell, </PDAT></ITALIC></HIL><PDAT>49:211-220, 1987.</PDAT></PTEXT></PARA>
<PARA ID="P-00223" LVL="1"><PTEXT><PDAT>Fraley et al., &ldquo;Entrapment of a bacterial plasmid in phospholipid vesicles: Potential for gene transfer,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>76:3348-3352, 1979.</PDAT></PTEXT></PARA>
<PARA ID="P-00224" LVL="1"><PTEXT><PDAT>Friedmann, &ldquo;Progress towardihuman gene therapy,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>244:1275-1281, 1989.</PDAT></PTEXT></PARA>
<PARA ID="P-00225" LVL="1"><PTEXT><PDAT>Gerlach et al., &ldquo;Construction of a plant disease resistance gene from the satellite RNA of tobacco rinspot virus,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>London</PDAT></ITALIC></HIL><PDAT>), 328:802-805, 1987.</PDAT></PTEXT></PARA>
<PARA ID="P-00226" LVL="1"><PTEXT><PDAT>Ghosh and Bachhawat, &ldquo;Targeting of liposomes to hepatocytes,&rdquo; In: Wu G, Wu C ed. Liver diseases, targeted diagnosis and therapy using specific receptors and ligands. New York: Marcel Dekker, pp. 87-104, 1991.</PDAT></PTEXT></PARA>
<PARA ID="P-00227" LVL="1"><PTEXT><PDAT>Ghosh-Choudhury et al., &ldquo;Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full-length genomes,&rdquo; </PDAT><HIL><ITALIC><PDAT>EMBO J., </PDAT></ITALIC></HIL><PDAT>6:1733-1739, 1987.</PDAT></PTEXT></PARA>
<PARA ID="P-00228" LVL="1"><PTEXT><PDAT>Gomez-Foix et al., &ldquo;Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem., </PDAT></ITALIC></HIL><PDAT>267:25129-25134, 1992.</PDAT></PTEXT></PARA>
<PARA ID="P-00229" LVL="1"><PTEXT><PDAT>Gopal, &ldquo;Gene transfer method for transient gene expression, stable transfection, and cotransfection of suspension cell cultures,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol. Cell Biol., </PDAT></ITALIC></HIL><PDAT>5:1188-1190, 1985.</PDAT></PTEXT></PARA>
<PARA ID="P-00230" LVL="1"><PTEXT><PDAT>Gottlieb and Oren, &ldquo;p53 in growth control and neoplasia,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochim. Biophys. Acta, </PDAT></ITALIC></HIL><PDAT>1287:77-102, 1996.</PDAT></PTEXT></PARA>
<PARA ID="P-00231" LVL="1"><PTEXT><PDAT>Graeber, et al., &ldquo;Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>379:88-91, 1996.</PDAT></PTEXT></PARA>
<PARA ID="P-00232" LVL="1"><PTEXT><PDAT>Graham and Prevec, &ldquo;Adenovirus-based expression vectors and recombinant vaccines,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biotechnology, </PDAT></ITALIC></HIL><PDAT>20:363-390, 1992.</PDAT></PTEXT></PARA>
<PARA ID="P-00233" LVL="1"><PTEXT><PDAT>Graham and Prevec, &ldquo;Manipulation of adenovirus vector,&rdquo; In: E. J. Murray (ed.), Methods in Molecular Biology: Gene Transfer and Expression Protocol, Clifton, N J: Humana Press, 7:109-128, 1991.</PDAT></PTEXT></PARA>
<PARA ID="P-00234" LVL="1"><PTEXT><PDAT>Graham et al., &ldquo;Translation of mammalian mRNA injected into Xenopus oocytes is specifically inhibited by antisense RNA,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Cell Biol., </PDAT></ITALIC></HIL><PDAT>101:1094-1099, 1985.</PDAT></PTEXT></PARA>
<PARA ID="P-00235" LVL="1"><PTEXT><PDAT>Graham et al., Characteristics of a human cell line transformed by DNA from human adenovirus type 5. </PDAT><HIL><ITALIC><PDAT>J. Gen. Virol., </PDAT></ITALIC></HIL><PDAT>36:59-72, 1977.</PDAT></PTEXT></PARA>
<PARA ID="P-00236" LVL="1"><PTEXT><PDAT>Grunhaus &amp; Horwitz, &ldquo;Adenovirus as cloning vector,&rdquo; </PDAT><HIL><ITALIC><PDAT>Seminar in Virology, </PDAT></ITALIC></HIL><PDAT>3:237-252, 1992.</PDAT></PTEXT></PARA>
<PARA ID="P-00237" LVL="1"><PTEXT><PDAT>Haffner and Oren, &ldquo;Biochemical properties and biological effects of p53,&rdquo; </PDAT><HIL><ITALIC><PDAT>Curr. Op. Genet. Dev., </PDAT></ITALIC></HIL><PDAT>1995, 5:84-90.</PDAT></PTEXT></PARA>
<PARA ID="P-00238" LVL="1"><PTEXT><PDAT>Hall and Lane, &ldquo;Tumor suppressors: a developing role for p53</PDAT><HIL><ITALIC><PDAT>&quest;,&rdquo; Curr. Biol., </PDAT></ITALIC></HIL><PDAT>7:R144-R147, 1997.</PDAT></PTEXT></PARA>
<PARA ID="P-00239" LVL="1"><PTEXT><PDAT>Hartley, et al., &ldquo;In vivo regulation of the early embryonic cell cycle in Xenopus,&rdquo; </PDAT><HIL><ITALIC><PDAT>Dev. Biol., </PDAT></ITALIC></HIL><PDAT>173:408-419, 1996.</PDAT></PTEXT></PARA>
<PARA ID="P-00240" LVL="1"><PTEXT><PDAT>Harvey, et al., &ldquo;A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature Genetics, </PDAT></ITALIC></HIL><PDAT>9:305-311, 1995.</PDAT></PTEXT></PARA>
<PARA ID="P-00241" LVL="1"><PTEXT><PDAT>Haupt, et al., &ldquo;Mdm2 promotes the rapid degradation of p53. </PDAT><HIL><ITALIC><PDAT>Nature. </PDAT></ITALIC></HIL><PDAT>387, 296-9. 1997</PDAT></PTEXT></PARA>
<PARA ID="P-00242" LVL="1"><PTEXT><PDAT>Hemmatti-Brivanlou and Melton, &ldquo;A truncated activin receptor inhibits mesoderm induction and formation of axial structures in Xenopus embryos,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>359:609-614, 1992.</PDAT></PTEXT></PARA>
<PARA ID="P-00243" LVL="1"><PTEXT><PDAT>Hermonat and Muzycska, &ldquo;Use of adenoassociated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Nat. Acad Sci. USA, </PDAT></ITALIC></HIL><PDAT>81:6466-6470, 1984.</PDAT></PTEXT></PARA>
<PARA ID="P-00244" LVL="1"><PTEXT><PDAT>Hersdorffer et al., &ldquo;Efficient gene transfer in live mice using a unique retroviral packaging line,&rdquo; </PDAT><HIL><ITALIC><PDAT>DNA Cell Biol., </PDAT></ITALIC></HIL><PDAT>9:713-723, 1990.</PDAT></PTEXT></PARA>
<PARA ID="P-00245" LVL="1"><PTEXT><PDAT>Herz and Gerard, &ldquo;Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>90:2812-2816, 1993.</PDAT></PTEXT></PARA>
<PARA ID="P-00246" LVL="1"><PTEXT><PDAT>Hoever, et al., &ldquo;Overexpression of wild-type p53 interferes with normal development in </PDAT><HIL><ITALIC><PDAT>Xenopus laevis </PDAT></ITALIC></HIL><PDAT>embryos,&rdquo; Oncogene, 9:109-120, 1994.</PDAT></PTEXT></PARA>
<PARA ID="P-00247" LVL="1"><PTEXT><PDAT>Horwich et al., &ldquo;Synthesis of hepadenovirus particles that contain replication-defective duck hepatitis B virus genomes in cultured HuH7 cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Virol., </PDAT></ITALIC></HIL><PDAT>64:642-650, 1990.</PDAT></PTEXT></PARA>
<PARA ID="P-00248" LVL="0"><PTEXT><PDAT>Howe, et al., &ldquo;Identification of a novel developmental timer regulating the stability of embryonic cyclin a and a new somatic a-type cyclin at gastrulation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Genes and Dev., </PDAT></ITALIC></HIL><PDAT>9:1164-1176, 1995.</PDAT></PTEXT></PARA>
<PARA ID="P-00249" LVL="1"><PTEXT><PDAT>Jenkins, et al., &ldquo;Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>312:651-654, 1984.</PDAT></PTEXT></PARA>
<PARA ID="P-00250" LVL="1"><PTEXT><PDAT>Jones &amp; Shenk, &ldquo;Isolation of deletion and substitution mutanits of adenovirus type 5,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell, </PDAT></ITALIC></HIL><PDAT>13:181-188, 1978.</PDAT></PTEXT></PARA>
<PARA ID="P-00251" LVL="1"><PTEXT><PDAT>Jones, et al., &ldquo;Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53,</PDAT><HIL><ITALIC><PDAT>&rdquo; Nature, </PDAT></ITALIC></HIL><PDAT>378:206-208, 1995.</PDAT></PTEXT></PARA>
<PARA ID="P-00252" LVL="1"><PTEXT><PDAT>Joyce, &ldquo;RNA evolution and the origins of life,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>338:217-244, 1989.</PDAT></PTEXT></PARA>
<PARA ID="P-00253" LVL="1"><PTEXT><PDAT>Kaneda et al., &ldquo;Increased expression of DNA cointroduced with nuclear protein in adult rat liver&rdquo;, </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>243:375-378, 1989.</PDAT></PTEXT></PARA>
<PARA ID="P-00254" LVL="1"><PTEXT><PDAT>Karlsson et al., </PDAT><HIL><ITALIC><PDAT>EMBO J., </PDAT></ITALIC></HIL><PDAT>5:2377-2385, 1986.</PDAT></PTEXT></PARA>
<PARA ID="P-00255" LVL="1"><PTEXT><PDAT>Kato et al., &ldquo;Expression of hepatitis &bgr; virus surface antigen in adult rat liver,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem., </PDAT></ITALIC></HIL><PDAT>266:3361-3364, 1991.</PDAT></PTEXT></PARA>
<PARA ID="P-00256" LVL="1"><PTEXT><PDAT>Kim and Cech &ldquo;Three-dimensional model of the active site of the self-splicing rRNA precursor of Tetrahymena.&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc Nati Acad Sci U S A, </PDAT></ITALIC></HIL><PDAT>84 (24) p8788-92, 1987.</PDAT></PTEXT></PARA>
<PARA ID="P-00257" LVL="1"><PTEXT><PDAT>Klein et al., &ldquo;High-velocity microprojectiles for delivering nucleic acids into living cells&rdquo;, </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>327:70-73, 1987.</PDAT></PTEXT></PARA>
<PARA ID="P-00258" LVL="1"><PTEXT><PDAT>Komarova, et al., &ldquo;Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines readiation and drug sensitivty in vivo,&rdquo; </PDAT><HIL><ITALIC><PDAT>EMBO J., </PDAT></ITALIC></HIL><PDAT>16:1391-1400, 1997.</PDAT></PTEXT></PARA>
<PARA ID="P-00259" LVL="1"><PTEXT><PDAT>Krieg and Melton, &ldquo;Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs, </PDAT><HIL><ITALIC><PDAT>Nucleic Acids Res., </PDAT></ITALIC></HIL><PDAT>12:7057-7070, 1984.</PDAT></PTEXT></PARA>
<PARA ID="P-00260" LVL="1"><PTEXT><PDAT>Krieg, et al., &ldquo;The mRNA encoding elongation factor alpha (EF1-alpha) is a major transcript at the mid-blastula transition in Xenopus,&rdquo; </PDAT><HIL><ITALIC><PDAT>Dev. Biol., </PDAT></ITALIC></HIL><PDAT>133:93-100, 1989.</PDAT></PTEXT></PARA>
<PARA ID="P-00261" LVL="1"><PTEXT><PDAT>Kubbutat, et al., &ldquo;Regulation of p53 stability by Mdm2</PDAT><HIL><ITALIC><PDAT>&rdquo;, Nature </PDAT></ITALIC></HIL><PDAT>387, 299-303, 1997 Kussie, et al., &ldquo;Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>274:948-953, 1996.</PDAT></PTEXT></PARA>
<PARA ID="P-00262" LVL="1"><PTEXT><PDAT>Le Gal La Salle et al., &ldquo;An adenovirus vector for gene transfer into neurons and glia in the brain,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>259:988-990, 1993.</PDAT></PTEXT></PARA>
<PARA ID="P-00263" LVL="1"><PTEXT><PDAT>Levine, et al., &ldquo;Selective disruption of E-cadherin function in early Xenopus embryos by a dominant negative mutant,&rdquo; </PDAT><HIL><ITALIC><PDAT>Development, </PDAT></ITALIC></HIL><PDAT>120:901-909, 1994.</PDAT></PTEXT></PARA>
<PARA ID="P-00264" LVL="1"><PTEXT><PDAT>Levrero et al., </PDAT><HIL><ITALIC><PDAT>Gene, </PDAT></ITALIC></HIL><PDAT>101: 195-202, 1991.</PDAT></PTEXT></PARA>
<PARA ID="P-00265" LVL="1"><PTEXT><PDAT>Macejak and Sarnow, </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>353:90-94, 1991.</PDAT></PTEXT></PARA>
<PARA ID="P-00266" LVL="1"><PTEXT><PDAT>Mann et al., &ldquo;Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus&rdquo;, </PDAT><HIL><ITALIC><PDAT>Cell, </PDAT></ITALIC></HIL><PDAT>33:153-159, 1983.</PDAT></PTEXT></PARA>
<PARA ID="P-00267" LVL="1"><PTEXT><PDAT>Markowitz et al., &ldquo;A safe packaging line for gene transfer: Separating viral genes on two different plasmids,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Virol., </PDAT></ITALIC></HIL><PDAT>62:1120-1124, 1988.</PDAT></PTEXT></PARA>
<PARA ID="P-00268" LVL="1"><PTEXT><PDAT>Matzuk, et al., &ldquo;Different phenotypes for mice deficient in either activins or activin recptor type II,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>374:356-360, 1995b.</PDAT></PTEXT></PARA>
<PARA ID="P-00269" LVL="1"><PTEXT><PDAT>Matzuk, et al., &ldquo;Functional analysis of activins during mammalian development,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>374:354-356, 1995a.</PDAT></PTEXT></PARA>
<PARA ID="P-00270" LVL="1"><PTEXT><PDAT>Mercer et al., &ldquo;Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad Sci. USA, </PDAT></ITALIC></HIL><PDAT>87:6166-6170, 1990.</PDAT></PTEXT></PARA>
<PARA ID="P-00271" LVL="1"><PTEXT><PDAT>Michel &amp; Westhof, &ldquo;Modeling of the three-dimensional architecture of group I catalytic introns based on comparative sequence analysis,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Mol. Biol., </PDAT></ITALIC></HIL><PDAT>216:585-610, 1990.</PDAT></PTEXT></PARA>
<PARA ID="P-00272" LVL="1"><PTEXT><PDAT>Molenaar, et al., &ldquo;XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos,&rdquo; Cell, 86:391-399, 1996.</PDAT></PTEXT></PARA>
<PARA ID="P-00273" LVL="1"><PTEXT><PDAT>Momand, et al., &ldquo;The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell, </PDAT></ITALIC></HIL><PDAT>69:1237-1245, 1992.</PDAT></PTEXT></PARA>
<PARA ID="P-00274" LVL="1"><PTEXT><PDAT>Montenarh &ldquo;Biochemical properties of the growth suppressor/oncoprotein p53.&rdquo; </PDAT><HIL><ITALIC><PDAT>Oncogene </PDAT></ITALIC></HIL><PDAT>7 (9) p1673-80, 1992.</PDAT></PTEXT></PARA>
<PARA ID="P-00275" LVL="1"><PTEXT><PDAT>Montes de Oca Luna, et al., &ldquo;Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53,</PDAT><HIL><ITALIC><PDAT>&rdquo; Nature, </PDAT></ITALIC></HIL><PDAT>378:203-206, 1995.</PDAT></PTEXT></PARA>
<PARA ID="P-00276" LVL="1"><PTEXT><PDAT>Mulligan, &ldquo;The basic science of gene therapy,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>260:926-932, 1993.</PDAT></PTEXT></PARA>
<PARA ID="P-00277" LVL="1"><PTEXT><PDAT>Myers, EP 0273085</PDAT></PTEXT></PARA>
<PARA ID="P-00278" LVL="1"><PTEXT><PDAT>Newport and Kirschner, &ldquo;A major developmental transition in early Xenopus embryos: I. characterization and timing of cellular changes at the midblastula stage,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell, </PDAT></ITALIC></HIL><PDAT>30:675-686, 1982a.</PDAT></PTEXT></PARA>
<PARA ID="P-00279" LVL="1"><PTEXT><PDAT>Newport and Kirschner, &ldquo;A major developmental transition in early Xenopus embryos: II. Control of the onset of transcription,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell, </PDAT></ITALIC></HIL><PDAT>30:687-96, 1982b.</PDAT></PTEXT></PARA>
<PARA ID="P-00280" LVL="1"><PTEXT><PDAT>Nicolas &amp; Rubenstein, &ldquo;Retroviral vectors,&rdquo; In: Vectors: </PDAT><HIL><ITALIC><PDAT>A survey of molecular cloning vectors and their uses, </PDAT></ITALIC></HIL><PDAT>Rodriguez &amp; Denhardt (eds.), Stoneham: Butterworth, pp. 493-513, 1988.</PDAT></PTEXT></PARA>
<PARA ID="P-00281" LVL="1"><PTEXT><PDAT>Nicolau et al., &ldquo;Liposomes as carriers for in vivo gene transfer and expression,&rdquo; </PDAT><HIL><ITALIC><PDAT>Methods Enzymol., </PDAT></ITALIC></HIL><PDAT>149:157-176, 1987.</PDAT></PTEXT></PARA>
<PARA ID="P-00282" LVL="1"><PTEXT><PDAT>Nieuwkoop and Faber, &ldquo;Normal Table of </PDAT><HIL><ITALIC><PDAT>Xenopus laevis </PDAT></ITALIC></HIL><PDAT>(Daudin),&rdquo; New York, Garland, 1994.</PDAT></PTEXT></PARA>
<PARA ID="P-00283" LVL="1"><PTEXT><PDAT>Nigro, et al., &ldquo;Mutations in the p53 gene occur in diverse human tumor types,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>342:705-708, 1989.</PDAT></PTEXT></PARA>
<PARA ID="P-00284" LVL="1"><PTEXT><PDAT>O&apos;Reilly, et al., &ldquo;Patterning of the mesoderm in Xenopus: dose-dependent and synergistic effects of Brachyury and Pintallavis. Development. 121(5):1351-9, 1995 May.</PDAT></PTEXT></PARA>
<PARA ID="P-00285" LVL="1"><PTEXT><PDAT>Oliner et al. Nature 358: 80-83, 1992.</PDAT></PTEXT></PARA>
<PARA ID="P-00286" LVL="1"><PTEXT><PDAT>Olson and Levine, &ldquo;The properties of p53 proteins selected for the loss of suppression of transformation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell Growth and Diff, </PDAT></ITALIC></HIL><PDAT>5:61-71, 1994.</PDAT></PTEXT></PARA>
<PARA ID="P-00287" LVL="1"><PTEXT><PDAT>Parada, et al., &ldquo;Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>312:649-651, 1984.</PDAT></PTEXT></PARA>
<PARA ID="P-00288" LVL="1"><PTEXT><PDAT>Paskind et al., &ldquo;Dependence of moloney murine leukemia virus production on cell growth&rdquo; </PDAT><HIL><ITALIC><PDAT>Virology, </PDAT></ITALIC></HIL><PDAT>67:242-248, 1975.</PDAT></PTEXT></PARA>
<PARA ID="P-00289" LVL="1"><PTEXT><PDAT>Pelletier and Sonenberg, </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>334:320-325, 1988.</PDAT></PTEXT></PARA>
<PARA ID="P-00290" LVL="1"><PTEXT><PDAT>Perales et al., &ldquo;Gene transfer in vivo: Sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake&rdquo;, </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad Sci. </PDAT></ITALIC></HIL><PDAT>91:4086-4090, 1994.</PDAT></PTEXT></PARA>
<PARA ID="P-00291" LVL="1"><PTEXT><PDAT>Potter et al., &ldquo;Enhancer-dependent expression of human k immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Nat. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>81:7161-7165, 1984.</PDAT></PTEXT></PARA>
<PARA ID="P-00292" LVL="1"><PTEXT><PDAT>Racher et al., </PDAT><HIL><ITALIC><PDAT>Biotechnology Techniques, </PDAT></ITALIC></HIL><PDAT>9:169-174, 1995.</PDAT></PTEXT></PARA>
<PARA ID="P-00293" LVL="1"><PTEXT><PDAT>Ragot et al., &ldquo;Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>361:647-650, 1993.</PDAT></PTEXT></PARA>
<PARA ID="P-00294" LVL="1"><PTEXT><PDAT>Reinhold-Hurek &amp; Shub, &ldquo;Self-splicing introns in tRNA genes of widely divergent bacteria,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>357:173-176, 1992.</PDAT></PTEXT></PARA>
<PARA ID="P-00295" LVL="1"><PTEXT><PDAT>Renan, &ldquo;Cancer genes: Current status, future prospects and applications in radiotherapy/oncology,&rdquo; </PDAT><HIL><ITALIC><PDAT>Radiother. Oncol., </PDAT></ITALIC></HIL><PDAT>19:197-218, 1990.</PDAT></PTEXT></PARA>
<PARA ID="P-00296" LVL="1"><PTEXT><PDAT>Rich et al., &ldquo;Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis,&rdquo; </PDAT><HIL><ITALIC><PDAT>Hum. Gene Ther., </PDAT></ITALIC></HIL><PDAT>4:461-476, 1993.</PDAT></PTEXT></PARA>
<PARA ID="P-00297" LVL="1"><PTEXT><PDAT>Ridgeway, &ldquo;Mammalian expression vectors,&rdquo; In: Rodriguez R L, Denhardt D T, ed. Vectors: A survey of molecular cloning vectors and their uses. Stoneham: Butterworth, pp. 467-492, 1988.</PDAT></PTEXT></PARA>
<PARA ID="P-00298" LVL="1"><PTEXT><PDAT>Rippe et al., &ldquo;DNA-mediated gene transfer into adult rat hepatocytes in primary culture,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol. Cell BioL, </PDAT></ITALIC></HIL><PDAT>10:689-695, 1990.</PDAT></PTEXT></PARA>
<PARA ID="P-00299" LVL="1"><PTEXT><PDAT>Rosenfeld et al., &ldquo;Adenovirus-mediated transfer of a recombinant &agr;1-antitrypsin gene to the lung epithelium in vivo,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>252:431-434, 1991.</PDAT></PTEXT></PARA>
<PARA ID="P-00300" LVL="1"><PTEXT><PDAT>Rosenfeld et al., &ldquo;In vivo. transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell, </PDAT></ITALIC></HIL><PDAT>68:143-155, 1992.</PDAT></PTEXT></PARA>
<PARA ID="P-00301" LVL="1"><PTEXT><PDAT>Roth et al., &ldquo;Retrovirus mediated wild-type p53 gene transfer to tumors of patients with lung cancer&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature Med. </PDAT></ITALIC></HIL><PDAT>2(9):985-991, 1996.</PDAT></PTEXT></PARA>
<PARA ID="P-00302" LVL="1"><PTEXT><PDAT>Rotter, et al., &ldquo;Does wild-type p53 play a role in normal cell differentiation&quest;,&rdquo; </PDAT><HIL><ITALIC><PDAT>Sem. Cancer Biol., </PDAT></ITALIC></HIL><PDAT>5:229-236, 1994.</PDAT></PTEXT></PARA>
<PARA ID="P-00303" LVL="1"><PTEXT><PDAT>Roux et al., &ldquo;A versatile and potentially general approach to the targeting of specific cell types by retroviruses: Application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses&rdquo;, </PDAT><HIL><ITALIC><PDAT>Proc. Nat&apos;l Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>86:9079-9083, 1989.</PDAT></PTEXT></PARA>
<PARA ID="P-00304" LVL="1"><PTEXT><PDAT>Rudnicki, et al., &ldquo;MyoD or Myf-5 is required for the formation of skeletal muscle,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell, </PDAT></ITALIC></HIL><PDAT>75:1351-1359, 1993.</PDAT></PTEXT></PARA>
<PARA ID="P-00305" LVL="1"><PTEXT><PDAT>Sah, et al., &ldquo;A subset of p53 deficient mice exhibit exencephally,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature Genetics, </PDAT></ITALIC></HIL><PDAT>10:175-180, 1995.</PDAT></PTEXT></PARA>
<PARA ID="P-00306" LVL="1"><PTEXT><PDAT>Sarnow, et al., &ldquo;Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. </PDAT><HIL><ITALIC><PDAT>Cell </PDAT></ITALIC></HIL><PDAT>28: 387-394, 1982;</PDAT></PTEXT></PARA>
<PARA ID="P-00307" LVL="1"><PTEXT><PDAT>Sarver et al., &ldquo;Ribozymes as potential anti-HIV-1 therapeutic agents,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>247:1222-1225, 1990.</PDAT></PTEXT></PARA>
<PARA ID="P-00308" LVL="1"><PTEXT><PDAT>Scanlon et al., &ldquo;Ribozyme-mediated cleavages of c-fos mRNA reduce gene expression of DNA synthesis enzymes and metallothionein,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc Natl Acad Sci USA, </PDAT></ITALIC></HIL><PDAT>88:10591-10595, 1991.</PDAT></PTEXT></PARA>
<PARA ID="P-00309" LVL="1"><PTEXT><PDAT>Scheffner, et al., &ldquo;The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53</PDAT><HIL><ITALIC><PDAT>&rdquo;, Cell </PDAT></ITALIC></HIL><PDAT>63: 1129-1136, 1990.</PDAT></PTEXT></PARA>
<PARA ID="P-00310" LVL="1"><PTEXT><PDAT>Scheffner, et al., &ldquo;the HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53</PDAT><HIL><ITALIC><PDAT>&rdquo;, Cell </PDAT></ITALIC></HIL><PDAT>75: 495-505, 1993.</PDAT></PTEXT></PARA>
<PARA ID="P-00311" LVL="1"><PTEXT><PDAT>Schmid, et al., &ldquo;Expression of p53 during mouse embryogenesis,&rdquo; </PDAT><HIL><ITALIC><PDAT>Development, </PDAT></ITALIC></HIL><PDAT>113:857-65, 1991.</PDAT></PTEXT></PARA>
<PARA ID="P-00312" LVL="1"><PTEXT><PDAT>Smith, et al., &ldquo;Expression of a Xenopus homolog of Brachyury (T) is an immediate-early response to mesoderm induction,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell, </PDAT></ITALIC></HIL><PDAT>67:79-87, 1991.</PDAT></PTEXT></PARA>
<PARA ID="P-00313" LVL="1"><PTEXT><PDAT>Smith, et al., &ldquo;Expression cloning of noggin, a new dorsalizing factor localized to the Spemann organizer in Xenopus embryos&rdquo;, </PDAT><HIL><ITALIC><PDAT>Cell:</PDAT></ITALIC></HIL><PDAT>70(5):829-40, 1992</PDAT></PTEXT></PARA>
<PARA ID="P-00314" LVL="1"><PTEXT><PDAT>Smith, et al., &ldquo;Injected Xwnt-8 RNA acts early in Xenopus embryos to promote formation of a vegetal dorsalizing center&rdquo;, </PDAT><HIL><ITALIC><PDAT>Cell. </PDAT></ITALIC></HIL><PDAT>67(4):753-65, 1991</PDAT></PTEXT></PARA>
<PARA ID="P-00315" LVL="1"><PTEXT><PDAT>Sokol, et al., &ldquo;Injected Wnt RNA induces a complete body axis in Xenopus embryos&rdquo;, </PDAT><HIL><ITALIC><PDAT>Cell. </PDAT></ITALIC></HIL><PDAT>67(4):741-52, 1991.</PDAT></PTEXT></PARA>
<PARA ID="P-00316" LVL="1"><PTEXT><PDAT>Stratford-Perricaudet &amp; Perricaudet,&rdquo; Gene transfer into animals: the promise of adenovirus,&rdquo; p. 51-61, In: Human Gene Transfer, Cohen-Haguenauer &amp; Boiron (eds.), Editions John Libbey Eurotext, France, 1991.</PDAT></PTEXT></PARA>
<PARA ID="P-00317" LVL="1"><PTEXT><PDAT>Stratford-Perricaudet et al., &ldquo;Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector&rdquo;</PDAT><HIL><ITALIC><PDAT>, Hum. Gene. Ther., </PDAT></ITALIC></HIL><PDAT>1:241-256, 1990.</PDAT></PTEXT></PARA>
<PARA ID="P-00318" LVL="1"><PTEXT><PDAT>Sun, et al., &ldquo;Dosage dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma,&rdquo; </PDAT><HIL><ITALIC><PDAT>FASEB J., </PDAT></ITALIC></HIL><PDAT>7:944-950, 1994.</PDAT></PTEXT></PARA>
<PARA ID="P-00319" LVL="1"><PTEXT><PDAT>Takahashi et al., &ldquo;The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cancer Res., </PDAT></ITALIC></HIL><PDAT>52:734-736, 1992.</PDAT></PTEXT></PARA>
<PARA ID="P-00320" LVL="1"><PTEXT><PDAT>Tchang, et al., &ldquo;Stabilization and expression of high levels of p53 during early development in </PDAT><HIL><ITALIC><PDAT>Xenopus laevis,&rdquo; Dev. Biol., </PDAT></ITALIC></HIL><PDAT>159:163-172, 1993.</PDAT></PTEXT></PARA>
<PARA ID="P-00321" LVL="1"><PTEXT><PDAT>Temin, &ldquo;Retrovirus vectors for gene transfer: Efficient integration into and expression of exogenous DNA in vertebrate cell genome,&rdquo; In: </PDAT><HIL><ITALIC><PDAT>Gene Transfer, </PDAT></ITALIC></HIL><PDAT>Kucherlapati (ed.), New York: Plenum Press, pp. 149-188, 1986.</PDAT></PTEXT></PARA>
<PARA ID="P-00322" LVL="1"><PTEXT><PDAT>Top et al., &ldquo;Immunization :with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Infect. Dis., </PDAT></ITALIC></HIL><PDAT>124:155-160, 1971.</PDAT></PTEXT></PARA>
<PARA ID="P-00323" LVL="1"><PTEXT><PDAT>Tur-Kaspa et al., &ldquo;Use of electroporation to introduce biologically active foreign genes into primary rat hepatocytes&rdquo;, </PDAT><HIL><ITALIC><PDAT>Mol. Cell Biol, </PDAT></ITALIC></HIL><PDAT>6:716-718, 1986.</PDAT></PTEXT></PARA>
<PARA ID="P-00324" LVL="1"><PTEXT><PDAT>Varmus et al., &ldquo;Retroviruses as mutagens: Insertion and excision of a nontransforming provirus alter the expression of a resident transformning provirus,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell, </PDAT></ITALIC></HIL><PDAT>25:23-36, 1981.</PDAT></PTEXT></PARA>
<PARA ID="P-00325" LVL="1"><PTEXT><PDAT>Vize, et al., &ldquo;Assays for gene function in developing Xenopus embryos,&rdquo; </PDAT><HIL><ITALIC><PDAT>Meth. Cell Biol., </PDAT></ITALIC></HIL><PDAT>36:367-387, 1991.</PDAT></PTEXT></PARA>
<PARA ID="P-00326" LVL="1"><PTEXT><PDAT>Vleminckx, et al., &ldquo;Adenomatous polyposis coli tumor suppressor protein has signalling activity in </PDAT><HIL><ITALIC><PDAT>Xenopus laevis </PDAT></ITALIC></HIL><PDAT>embryos resulting in the induction of an ectopic dorsoanterior axis,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Cell Biol., </PDAT></ITALIC></HIL><PDAT>136:411-420, 1997.</PDAT></PTEXT></PARA>
<PARA ID="P-00327" LVL="1"><PTEXT><PDAT>Wagner et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad Sci. </PDAT></ITALIC></HIL><PDAT>87(9):3410-3414, 1990.</PDAT></PTEXT></PARA>
<PARA ID="P-00328" LVL="1"><PTEXT><PDAT>Wang, et al., &ldquo;</PDAT><HIL><ITALIC><PDAT>Xenopus laevis </PDAT></ITALIC></HIL><PDAT>p53 protein: sequence-specific DNA binding, transcriptional egulation and oligomerization are evolutionarily conserved,&rdquo; </PDAT><HIL><ITALIC><PDAT>Oncogene, </PDAT></ITALIC></HIL><PDAT>19:779-784, 1995.</PDAT></PTEXT></PARA>
<PARA ID="P-00329" LVL="1"><PTEXT><PDAT>Weinberg, &ldquo;Tumor suppressor gene,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>254:1138-1145, 1991.</PDAT></PTEXT></PARA>
<PARA ID="P-00330" LVL="1"><PTEXT><PDAT>Whitman and Melton, &ldquo;Induction of mesoderm by a viral oncogene in early Xenopus embryos,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>244:803-806, 1989.</PDAT></PTEXT></PARA>
<PARA ID="P-00331" LVL="1"><PTEXT><PDAT>Whitman and Melton, &ldquo;Involvement of p21ras in Xenopus mesoderm induction,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>357:252-254, 1992.</PDAT></PTEXT></PARA>
<PARA ID="P-00332" LVL="1"><PTEXT><PDAT>Wong et al., &ldquo;Appearance of &bgr;-lactamase activity in animal cells upon liposome mediated gene transfer,&rdquo; </PDAT><HIL><ITALIC><PDAT>Gene, </PDAT></ITALIC></HIL><PDAT>10:87-94, 1980.</PDAT></PTEXT></PARA>
<PARA ID="P-00333" LVL="1"><PTEXT><PDAT>Woodland, et al., &ldquo;The development of an assay to detect mRNAs that affect early development&rdquo;, </PDAT><HIL><ITALIC><PDAT>Development. </PDAT></ITALIC></HIL><PDAT>101(4):925-30, 1987.</PDAT></PTEXT></PARA>
<PARA ID="P-00334" LVL="1"><PTEXT><PDAT>Wu and Wu, &ldquo;Evidence for targeted gene delivery to HepG2 hepatoma cells in vitro,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochemistry, </PDAT></ITALIC></HIL><PDAT>27:887-892, 1988.</PDAT></PTEXT></PARA>
<PARA ID="P-00335" LVL="1"><PTEXT><PDAT>Wu and Wu, &ldquo;Receptor-mediated in vitro gene transfections by a soluble DNA carrier system,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem., </PDAT></ITALIC></HIL><PDAT>262:4429-4432, 1987.</PDAT></PTEXT></PARA>
<PARA ID="P-00336" LVL="1"><PTEXT><PDAT>Wu and Wu, </PDAT><HIL><ITALIC><PDAT>Adv. Drug Delivery Rev., </PDAT></ITALIC></HIL><PDAT>12:159-167, 1993.</PDAT></PTEXT></PARA>
<PARA ID="P-00337" LVL="1"><PTEXT><PDAT>Yang et al., &ldquo;In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad Sci USA, </PDAT></ITALIC></HIL><PDAT>87:9568-9572, 1990.</PDAT></PTEXT></PARA>
<PARA ID="P-00338" LVL="1"><PTEXT><PDAT>Yew and Berk, &ldquo;Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein&rdquo;, </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>357, 82-85, 1992.</PDAT></PTEXT></PARA>
<PARA ID="P-00339" LVL="1"><PTEXT><PDAT>Zelenin et al., &ldquo;High-velocity mechanical DNA transfer of the chloramphenicol acetyltransferase gene into rodent liver, kidney and manmmary gland cells in organ explants and in vivo&rdquo;, </PDAT><HIL><ITALIC><PDAT>FEBS Lett., </PDAT></ITALIC></HIL><PDAT>280:94-96, 1991.</PDAT></PTEXT></PARA>
<CWU>
<SEQLST-US ID="SEQLST-1">
<SEQ-LST-NEW>
<S100>
<S160>
<PDAT>6</PDAT>
</S160>
</S100>
<S200>
<S210>
<PDAT>1</PDAT>
</S210>
<S211>
<PDAT>20</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Homo sapiens</PDAT>
</S213>
</S200>
<S400>
<PDAT> 1
cagattggtg ctggatatgc                                                 20
</PDAT>
</S400>
<S200>
<S210>
<PDAT>2</PDAT>
</S210>
<S211>
<PDAT>20</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Homo sapiens</PDAT>
</S213>
</S200>
<S400>
<PDAT> 2
actgccttga tgactcctag                                                 20
</PDAT>
</S400>
<S200>
<S210>
<PDAT>3</PDAT>
</S210>
<S211>
<PDAT>18</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Homo sapiens</PDAT>
</S213>
</S200>
<S400>
<PDAT> 3
acaactggaa gcactgga                                                   18
</PDAT>
</S400>
<S200>
<S210>
<PDAT>4</PDAT>
</S210>
<S211>
<PDAT>18</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Homo sapiens</PDAT>
</S213>
</S200>
<S400>
<PDAT> 4
tcttattcca gaggaacc                                                   18
</PDAT>
</S400>
<S200>
<S210>
<PDAT>5</PDAT>
</S210>
<S211>
<PDAT>18</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Homo sapiens</PDAT>
</S213>
</S200>
<S400>
<PDAT> 5
ggatcgttat cacctctg                                                   18
</PDAT>
</S400>
<S200>
<S210>
<PDAT>6</PDAT>
</S210>
<S211>
<PDAT>18</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Homo sapiens</PDAT>
</S213>
</S200>
<S400>
<PDAT> 6
gtgtagtctg tagcagca                                                   18
</PDAT>
</S400>
</SEQ-LST-NEW>
</SEQLST-US>
</CWU>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>What is claimed is: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00340" LVL="0"><PTEXT><PDAT>1. A method of screening for agents that inhibit a block of p53-related embryonic cell differentiation comprising the steps of:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>(i) providing an isolated, undifferentiated embryonic cell; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(ii) blocking the function of p53 in said cell such that said cell fails to differentiate; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(iii) contacting said cell with a candidate agent; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(iv) comparing the differentiation of said contacted cell after said contacting with the differentiation of said cell in the absence of said candidate agent; </PDAT></PTEXT></CLMSTEP>
<PARA ID="P-00341" LVL="7"><PTEXT><PDAT>whereby an increase in differentiation indicates that said candidate agent is an inhibitor of the block of p53-related differentiation.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00342" LVL="0"><PTEXT><PDAT>2. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, further comprising the step of comparing the differentiation of said cell after said contacting with the differentiation of said undifferentiated embryonic cell.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00343" LVL="0"><PTEXT><PDAT>3. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said cell is a mammalian cell.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00344" LVL="0"><PTEXT><PDAT>4. The method of </PDAT><CLREF ID="CLM-00003"><PDAT>claim 3</PDAT></CLREF><PDAT>, wherein said cell is a mouse cell.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00005">
<PARA ID="P-00345" LVL="0"><PTEXT><PDAT>5. The method of </PDAT><CLREF ID="CLM-00003"><PDAT>claim 3</PDAT></CLREF><PDAT>, wherein said cell is a human cell.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00006">
<PARA ID="P-00346" LVL="0"><PTEXT><PDAT>6. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said blocking is achieved by introducing into said cell a nucleic acid encoding a dominant negative mutant of p53.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00007">
<PARA ID="P-00347" LVL="0"><PTEXT><PDAT>7. The method of </PDAT><CLREF ID="CLM-00006"><PDAT>claim 6</PDAT></CLREF><PDAT>, wherein said introducing is achieved via electroporation, microinjection, particle bombardment, liposome transfer or viral infection.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00008">
<PARA ID="P-00348" LVL="0"><PTEXT><PDAT>8. The method of </PDAT><CLREF ID="CLM-00006"><PDAT>claim 6</PDAT></CLREF><PDAT>, wherein said nucleic acid is a DNA.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00009">
<PARA ID="P-00349" LVL="0"><PTEXT><PDAT>9. The method of </PDAT><CLREF ID="CLM-00006"><PDAT>claim 6</PDAT></CLREF><PDAT>, wherein said nucleic acid is an RNA.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00010">
<PARA ID="P-00350" LVL="0"><PTEXT><PDAT>10. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said candidate agent is polypeptide.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00011">
<PARA ID="P-00351" LVL="0"><PTEXT><PDAT>11. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said candidate agent is produced by a neighboring cell.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00012">
<PARA ID="P-00352" LVL="0"><PTEXT><PDAT>12. The method of </PDAT><CLREF ID="CLM-00011"><PDAT>claim 11</PDAT></CLREF><PDAT>, wherein said neighboring cell is a second undifferentiated embryonic cell into which said candidate.agent has been introduced.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00013">
<PARA ID="P-00353" LVL="0"><PTEXT><PDAT>13. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein differentiation is determined by culture of said undifferentiated embryonic cell in vitro under conditions where said cell differentiates.</PDAT></PTEXT></PARA>
</CLM>
</CL>
</SDOCL>
<SDODR ID="DRAWINGS">
<EMI ID="EMI-D00001" ALT="embedded image" FILE="US06479285-20021112-D00001.TIF" TYPE="HALFTONE"/>
<EMI ID="EMI-D00002" ALT="embedded image" FILE="US06479285-20021112-D00002.TIF" TYPE="HALFTONE"/>
<EMI ID="EMI-D00003" ALT="embedded image" FILE="US06479285-20021112-D00003.TIF" TYPE="HALFTONE"/>
<EMI ID="EMI-D00004" ALT="embedded image" FILE="US06479285-20021112-D00004.TIF"/>
<EMI ID="EMI-D00005" ALT="embedded image" FILE="US06479285-20021112-D00005.TIF" TYPE="HALFTONE"/>
<EMI ID="EMI-D00006" ALT="embedded image" FILE="US06479285-20021112-D00006.TIF"/>
<EMI ID="EMI-D00007" ALT="embedded image" FILE="US06479285-20021112-D00007.TIF" TYPE="HALFTONE"/>
</SDODR>
</PATDOC>

<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06479626-20021112-D00000.TIF SYSTEM "US06479626-20021112-D00000.TIF" NDATA TIF>
<!ENTITY US06479626-20021112-D00001.TIF SYSTEM "US06479626-20021112-D00001.TIF" NDATA TIF>
<!ENTITY US06479626-20021112-D00002.TIF SYSTEM "US06479626-20021112-D00002.TIF" NDATA TIF>
<!ENTITY US06479626-20021112-D00003.TIF SYSTEM "US06479626-20021112-D00003.TIF" NDATA TIF>
<!ENTITY US06479626-20021112-D00004.TIF SYSTEM "US06479626-20021112-D00004.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06479626</PDAT></DNUM></B110>
<B130><PDAT>B1</PDAT></B130>
<B140><DATE><PDAT>20021112</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>09260629</PDAT></DNUM></B210>
<B211US><PDAT>09</PDAT></B211US>
<B220><DATE><PDAT>19990301</PDAT></DATE></B220>
</B200>
<B500>
<B510>
<B511><PDAT>C07K  200</PDAT></B511>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>530300</PDAT></B521>
<B522><PDAT>530324</PDAT></B522>
<B522><PDAT>530350</PDAT></B522>
<B522><PDAT>435 697</PDAT></B522>
</B520>
<B540><STEXT><PDAT>Poly zinc finger proteins with improved linkers</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4990607</PDAT></DNUM>
<DATE><PDAT>19910200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Katagiri et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435 691</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5096814</PDAT></DNUM>
<DATE><PDAT>19920300</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Aivasidis et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435 41</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5096815</PDAT></DNUM>
<DATE><PDAT>19920300</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Ladner et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435 691</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5198346</PDAT></DNUM>
<DATE><PDAT>19930300</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Ladner et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435 691</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5223409</PDAT></DNUM>
<DATE><PDAT>19930600</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Ladner et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435 697</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5243041</PDAT></DNUM>
<DATE><PDAT>19930900</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Fernandez-Pol</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>536 235</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5302519</PDAT></DNUM>
<DATE><PDAT>19940400</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Blackwood et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435 691</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5324638</PDAT></DNUM>
<DATE><PDAT>19940600</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Tao et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435 691</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5324818</PDAT></DNUM>
<DATE><PDAT>19940600</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Nabel et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>530350</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5324819</PDAT></DNUM>
<DATE><PDAT>19940600</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Oppermann et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>530350</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5340739</PDAT></DNUM>
<DATE><PDAT>19940800</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Stevens et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>4352401</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5348864</PDAT></DNUM>
<DATE><PDAT>19940900</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Barbacid</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435 691</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5350840</PDAT></DNUM>
<DATE><PDAT>19940900</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Call et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>536 231</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5356802</PDAT></DNUM>
<DATE><PDAT>19941000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Chandrasegaran</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435199</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5376530</PDAT></DNUM>
<DATE><PDAT>19941200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>De The et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435  6</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5403484</PDAT></DNUM>
<DATE><PDAT>19950400</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Ladner et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>4352351</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5436150</PDAT></DNUM>
<DATE><PDAT>19950700</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Chandrasegaran</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435199</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5487994</PDAT></DNUM>
<DATE><PDAT>19960100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Chandrasegaran</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435199</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5498530</PDAT></DNUM>
<DATE><PDAT>19960300</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Schatz et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435 691</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5578483</PDAT></DNUM>
<DATE><PDAT>19961100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Evans et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>4352402</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5597693</PDAT></DNUM>
<DATE><PDAT>19970100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Evans et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435  6</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5639592</PDAT></DNUM>
<DATE><PDAT>19970600</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Evans et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435  4</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5674738</PDAT></DNUM>
<DATE><PDAT>19971000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Abramson et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>4352523</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5702914</PDAT></DNUM>
<DATE><PDAT>19971200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Evans et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435 29</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5789538</PDAT></DNUM>
<DATE><PDAT>19980800</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Rebar et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>530324</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5792640</PDAT></DNUM>
<DATE><PDAT>19980800</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Chandrsegaran</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435199</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5869618</PDAT></DNUM>
<DATE><PDAT>19990200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Lippman et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>5303871</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5871902</PDAT></DNUM>
<DATE><PDAT>19990200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Weininger et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435  5</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5871907</PDAT></DNUM>
<DATE><PDAT>19990200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Winter et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435  6</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5916794</PDAT></DNUM>
<DATE><PDAT>19990600</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Chandrasegaran</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435199</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5939538</PDAT></DNUM>
<DATE><PDAT>19990800</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Leavitt et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>536 231</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5972615</PDAT></DNUM>
<DATE><PDAT>19991000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>An et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435  6</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6001885</PDAT></DNUM>
<DATE><PDAT>19991200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Vega et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>514725</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6007988</PDAT></DNUM>
<DATE><PDAT>19991200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Choo et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435  6</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6013453</PDAT></DNUM>
<DATE><PDAT>20000100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Choo et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435  6</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6110747</PDAT></DNUM>
<DATE><PDAT>20000800</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Blaschuk et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435512</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6140466</PDAT></DNUM>
<DATE><PDAT>20001000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Barbas, III et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>530350</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>0 873 567</PDAT></DNUM>
<DATE><PDAT>19981100</PDAT></DATE>
<CTRY><PDAT>EP</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 95/19431</PDAT></DNUM>
<DATE><PDAT>19950700</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 96/06110</PDAT></DNUM>
<DATE><PDAT>19960200</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 96/06166</PDAT></DNUM>
<DATE><PDAT>19960200</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 96/11267</PDAT></DNUM>
<DATE><PDAT>19960400</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 96/20951</PDAT></DNUM>
<DATE><PDAT>19960700</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 96/32475</PDAT></DNUM>
<DATE><PDAT>19961000</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 97/27212</PDAT></DNUM>
<DATE><PDAT>19970700</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 97/27213</PDAT></DNUM>
<DATE><PDAT>19970700</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 98/53057</PDAT></DNUM>
<DATE><PDAT>19981100</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 98/53058</PDAT></DNUM>
<DATE><PDAT>19981100</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 98/53059</PDAT></DNUM>
<DATE><PDAT>19981100</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 98/53060</PDAT></DNUM>
<DATE><PDAT>19981100</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 98/54311</PDAT></DNUM>
<DATE><PDAT>19981200</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 99/36553</PDAT></DNUM>
<DATE><PDAT>19990700</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 99/41371</PDAT></DNUM>
<DATE><PDAT>19990800</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 99/42474</PDAT></DNUM>
<DATE><PDAT>19990800</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 99/45132</PDAT></DNUM>
<DATE><PDAT>19990900</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 99/47656</PDAT></DNUM>
<DATE><PDAT>19990900</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 99/48909</PDAT></DNUM>
<DATE><PDAT>19990900</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 00/23464</PDAT></DNUM>
<DATE><PDAT>20000400</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 00/27878</PDAT></DNUM>
<DATE><PDAT>20000500</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B562><NCIT><STEXT><PDAT>Smith et al. A Detailed Study of the Substrate Specificity . . . Nucleic Acids Research, vol. 27, No. 2, pp. 674-681, 1999.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Corbi et al., &ldquo;Synthesis of a New Zinc Finger Peptide; Comparison of Its &lsquo;Code&rsquo; Deduced and &lsquo;CASTing&rsquo; Derived Binding Sites,&rdquo; </PDAT><HIL><ITALIC><PDAT>FEBS Letters, </PDAT></ITALIC></HIL><PDAT>417:71-74 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Wang et al., &ldquo;Dimerization of Zinc Fingers Mediated by Peptides Evolved In Vitro from Random Sequences,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>96:9568-9573 (1999). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Wolfe et al., &ldquo;Analysis of Zinc Fingers Optimized Via Phage Display: Evaluating the Utility of a Recognition Code,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Mol. Biol., </PDAT></ITALIC></HIL><PDAT>285:1917-1934 (1999). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Klug, &ldquo;Zinc Finger Peptides for the Regulation of Gene Expression,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Mol. Biol., </PDAT></ITALIC></HIL><PDAT>293:215-218 (1999). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kang et al., &ldquo;Zinc Finger Proteins as Designer Transcription Factors,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem., </PDAT></ITALIC></HIL><PDAT>275(12):8742-8748 (2000). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Hamilton et al., &ldquo;Comparison of the DNA Binding Characteristics of the Related Zinc Finger Proteins WT1 and EGR1,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochemistry, </PDAT></ITALIC></HIL><PDAT>37:2051-2058 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kriwacki et al., &ldquo;Sequence-Specific Recognition of DNA by Zinc-Finger Peptides Derived from the Transcription Factor Sp1,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>89:9759-9763 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Nakagama et al., &ldquo;Sequence and Structural Requirements for High-Affinity DNA Binding by the WT1 Gene Product,&rdquo; </PDAT><HIL><ITALIC><PDAT>Molecular and Cellular Biology, </PDAT></ITALIC></HIL><PDAT>15(3):1489-1498 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Skerka et al., &ldquo;Coordinate Expression and Distinct DNA-Binding Characteristics of the Four EGR-Zinc Finger Proteins in Jurkat T Lymphocytes,&rdquo; </PDAT><HIL><ITALIC><PDAT>Immunobiology, </PDAT></ITALIC></HIL><PDAT>198:179-191 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kothekar, &ldquo;Computer Simulation of Zinc Finger Motifs from Cellular Nucleic Acid Binding Proteins and their Interaction with Consensus DNA Sequences,&rdquo; </PDAT><HIL><ITALIC><PDAT>FEBS Letters, </PDAT></ITALIC></HIL><PDAT>274(1,2):217-222 (1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Search of Swissprot Database performed ca. Aug. 2000. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Choo, Y. and Aaron Klug, &ldquo;Selection of DNA binding sites for zinc fingers using rationally randomized DNA reveals coded interactions,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>91:11168-11172 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Choo, Y. and Aaron Klug, &ldquo;Toward a code for the interactions of zinc fingers with DNA: Selection of randomized fingers displayed on phage,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>91:11163-11167 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Desjarlais, J.R. and Jeremy M. Berg, &ldquo;Length-encoded multiplex binding site determination: Application to zinc finger proteins,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>91:11099-11103 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Desjarlais, J.R. and Jeremy M. Berg, &ldquo;Redesigning the DNA-Binding Specificity of a Zinc Finger Protein: A Data Base-Guided Approach,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proteins: Structure, Function and Genetics, </PDAT></ITALIC></HIL><PDAT>12:101-104 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Desjarlais, J.R. and Jeremy M. Berg, &ldquo;Toward rules relating zinc finger protein sequences and DNA binding site preferences,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>89:7345-7349 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Desjarlais, J.R. and Jeremy M. Berg, &ldquo;Use of a zinc-finger consensus sequence framework and specificity rules to design specific DNA binding proteins,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>90:2256-2260 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Elrod-Erickson, M. et al., &ldquo;Zif268 protein-DNA complex refined at 1.6 &angst;: a model system for understanding zinc finger-DNA interactions,&rdquo; </PDAT><HIL><ITALIC><PDAT>Structure, </PDAT></ITALIC></HIL><PDAT>4(10):1171-1180 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Greisman, H.A. and Carl O. Pabo, &ldquo;A General Strategy for Selecting High-Affinity Zinc Finger Proteins for Diverse DNA Target Sites,&rdquo; Science, 275:657-661 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Jamieson, A.C. et al., &ldquo;In Vitro Selection of Zinc Fingers with Altered DNA-Binding Specificity,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochemistry, </PDAT></ITALIC></HIL><PDAT>33:5689-5695 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kim, J. and Carl O. Pabo, &ldquo;Getting a handhold on DNA: Design of poly-zinc finger proteins with femtomolar dissociation constants,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>95:2812-2817 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kim, J. and Carl O. Pabo, &ldquo;Transcriptional Repression by Zinc Finger Peptides,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. of Biological Chemistry, </PDAT></ITALIC></HIL><PDAT>272(47):29795-29800 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kim, J. et al., &ldquo;Design of TATA box-binding protein/zinc finger fusions for targeted regulation of gene expression,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>94:3616-3620 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kim, Y. et al., &ldquo;Hybrid restriction enzymes: Zinc finger fusions to Fok I cleavage domain,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>93:1156-1160 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Liu, Q. et al., &ldquo;Design of polydactyl zinc-finger proteins for unique addressing within complex genomes,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>94:5525-5530 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Nekludova, L. and Carl O. Pabo, &ldquo;Distinctive DNA conformation with enlarged major groove is found in Zn-finger-DNA and other protein-DNA complexes,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>91:6948-6952 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Pavletich, N.P. and Carl O. Pabo, &ldquo;Zinc Finger-DNA Recognition: Crystal Structure of a Zif268-DNA Complex at 2.1 &angst;,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>252:809-817 (1991). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Pomerantz, J.L. et al., &ldquo;Analysis of homeodomain function by structure-based design of a transcription factor,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>92:9752-9756 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Pomerantz, J.L. et al., &ldquo;Structure-Based Design of a Dimeric Zinc Finger Protein,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochemistry, </PDAT></ITALIC></HIL><PDAT>37(4):965-970 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Pomerantz, J.L. et al., &ldquo;Structure-Based Design of Transcription Factors,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>267:93-96 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Rebar, E.J. and Carl O. Pabo, &ldquo;Zinc Finger Phage: Affinity Selection of Fingers with New DNA-Binding Specificities,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>263:671-673 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Rivera, V.M. et al., &ldquo;A humanized system for pharmacologic control of gene expression,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature Medicine, </PDAT></ITALIC></HIL><PDAT>2(9):1028-1032 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Shi, Y. and Jeremy M. Berg, &ldquo;DNA Unwinding Induced by Zinc Finger Protein Binding,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochemistry, </PDAT></ITALIC></HIL><PDAT>35:3845-3848 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Wu, H. et al., &ldquo;Building zinc fingers by selection: Toward a therapeutic application,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>92:344-348 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Agarwal et al., &ldquo;Stimulation of Transcript Elongation Requires both the Zinc Finger and RNA Polymerase II Binding Domains of Human TFIIS,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochemistry, </PDAT></ITALIC></HIL><PDAT>30(31):7842-7851 (1991). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Antao et al., &ldquo;A thermodynamic study of unusually stable RNA and DNA hairpins,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nuc. Acids. Res., </PDAT></ITALIC></HIL><PDAT>19(21):5901-5905 (1991). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Barbas, C. F., &ldquo;Recent advances in phage display,&rdquo; </PDAT><HIL><ITALIC><PDAT>Curr. Opin. Biotech., </PDAT></ITALIC></HIL><PDAT>4:526-530 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Barbas et al., &ldquo;Assembly of combinatorial antibody libraries on phage surfaces: The gene III site,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>88:7978-7982 (1991). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Barbas et al., &ldquo;Semisynthetic combinatorial antibody libraries: A chemical solution to the diversity problem,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>89:4457-4461 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Beerli et al., &ldquo;Toward controlling gene expression at will: Specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>95:14628-14633 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Bellefroid et al., &ldquo;Clustered organization of homologous KRAB zinc-finger genes with enhanced expression in human T lymphoid cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>EMBO J., </PDAT></ITALIC></HIL><PDAT>12(4):1363-1374 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Berg, J. M., &ldquo;DNA Binding Specificity of Steriod Receptors,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell, </PDAT></ITALIC></HIL><PDAT>57:1065-1068 (1989). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Berg, J. M., &ldquo;Sp1 and the subfamily of zinc finger proteins with guanine-rich binding sites,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>89:11109-11110 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Berg et al., &ldquo;The Galvanization of Biology: A Growing Appreciation for the Roles of Zinc,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>271:1081-1085 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Berg, J.M., &ldquo;Letting your fingers do the walking,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature Biotechnology, </PDAT></ITALIC></HIL><PDAT>15:323 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Bergqvist et al., &ldquo;Loss of DNA-binding and new transcriptional trans-activation function in polyomavirus large T-antigen with mutation of zinc finger motif,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nuc. Acids Res., </PDAT></ITALIC></HIL><PDAT>18(9):2715-2720 (1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Blaese et al., &ldquo;Vectors in cancer therapy: how will they deliver&quest;,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cancer Gene Therapy, </PDAT></ITALIC></HIL><PDAT>2(4):291-297 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Caponigro et al., &ldquo;Transdominant genetic analysis of a growth control pathway,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>95:7508-7513 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Celenza et al., &ldquo;A Yeast Gene That Is Essential for Release from Glucose Repression Encodes a Protein Kinase,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>233:1175-1180 (1986). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Cheng et al., &ldquo;Identification of Potential Target Genes for Adr1p through Characterization of Essential Nucleotides in UAS1,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol. Cellular Biol., </PDAT></ITALIC></HIL><PDAT>14(6):3842-3852 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Cheng et al., &ldquo;A Single Amino Acid substitution in Zinc Finger 2 of Adr1p Changes its Binding Specificity at two Positions in UAS1,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Mol. Biol., </PDAT></ITALIC></HIL><PDAT>251:1-8 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Choo et al., &ldquo;A role in DNA binding for the linker sequences of the first three zinc fingers of TFIIIA,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nuc. Acids Res., </PDAT></ITALIC></HIL><PDAT>21(15):3341-3346 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Choo et al., &ldquo;Designing DNA-binding proteins on the surface of filamentous phage,&rdquo; </PDAT><HIL><ITALIC><PDAT>Curr. Opin. Biotechnology, </PDAT></ITALIC></HIL><PDAT>6:431-436 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Choo et al., &ldquo;Promoter-specific Activation of Gene Expression Directed by Bacteriophage-selected Zinc Fingers,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Mol. Biol., </PDAT></ITALIC></HIL><PDAT>273:525-532 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Choo, Y., &ldquo;Recognition of DNA methylation by zinc fingers,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature Struct. Biol., </PDAT></ITALIC></HIL><PDAT>5(4):264-265 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Choo et al., &ldquo;All wrapped up,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature Structural Biology, </PDAT></ITALIC></HIL><PDAT>5(4):253-255 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Choo, Y., &ldquo;End effects in DNA recognition by zinc finger arrays,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nuc. Acids Res., </PDAT></ITALIC></HIL><PDAT>26(2):554-557 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Choo et al., &ldquo;In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>372:642-645 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Choo et al., &ldquo;Physical basis of a protein-DNA recognition code,&rdquo; </PDAT><HIL><ITALIC><PDAT>Curr. Opin. Struct. Biol., </PDAT></ITALIC></HIL><PDAT>7(1):117-125 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Clarke et al., &ldquo;Zinc Fingers in </PDAT><HIL><ITALIC><PDAT>Caenorhabditis elegans: </PDAT></ITALIC></HIL><PDAT>Finding Families and Probing Pathways,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>282:2018-2022 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Crozatier et al., &ldquo;Single Amino Acid Exchanges in Separate Domains of the Drosophila serendipity &dgr; Zinc Finger Protein Cause Embryonic and Sex Biased Lethality,&rdquo; </PDAT><HIL><ITALIC><PDAT>Genetics, </PDAT></ITALIC></HIL><PDAT>131:905-916 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Debs et al., &ldquo;Regulation of Gene Expression in Vivo by Liposome-mediated Delivery of a Purified Transcription Factor*,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Biological Chemistry, </PDAT></ITALIC></HIL><PDAT>265(18):10189-10192 (1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Desjarlais et al., &ldquo;Redesigning the DNA-Binding Specificity of a Zinc Finger Protein: A Data Base-Guided Approach,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proteins: Structure, Function, and Genetics, </PDAT></ITALIC></HIL><PDAT>13(3):272 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>DiBello et al., &ldquo;The Drosophila Broad-ComplexEncodes a Family of Related Proteins Containing Zinc Fingers,&rdquo; </PDAT><HIL><ITALIC><PDAT>Genetics, </PDAT></ITALIC></HIL><PDAT>129:385-397 (1991). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Elrod-Erickson et al., &ldquo;High-resolution structures of variant Zif268-DNA complexes: implications for understanding zinc finger-DNA recognition,&rdquo; </PDAT><HIL><ITALIC><PDAT>Structure, </PDAT></ITALIC></HIL><PDAT>6(4):451-464 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Fairall et al., &ldquo;The crystal structure of a two zinc-finger peptide reveals an extension to the rules of zinc-finger/DNA recognition,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>366:483-487 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Frankel et al., &ldquo;Fingering Too Many Proteins,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell, </PDAT></ITALIC></HIL><PDAT>53:675 (1988). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Friesen et al., &ldquo;Phage Display of RNA Binding Zinc Fingers from Transcription Factor IIIA*,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Biological Chem., </PDAT></ITALIC></HIL><PDAT>272(17):10994-10997 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Friesen et al., &ldquo;Specific RNA binding proteins constructed from zinc fingers,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature Structural Biology, </PDAT></ITALIC></HIL><PDAT>5(7):543-546(1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Gogos et al., &ldquo;Recognition of diverse sequences by class I zinc fingers: Asymmetries and indirect effects on specificity in the interaction between CF2II and A&plus;T-rich sequence elements,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>93(5):2159-2164 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Gossen et al., &ldquo;Tight control of gene expression in mammalian cells by tetracycline-responsive promoters,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>89:5547-5551 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Hamilton et al., &ldquo;High affinity binding sites for the Wilms&apos; tumor suppressor protein WT1,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nuc. Acids. Res., </PDAT></ITALIC></HIL><PDAT>23(2):277-284 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Hanas et al., &ldquo;Internal deletion mutants of Xenopus transcription factor IIIA,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nuc. Acids Res., </PDAT></ITALIC></HIL><PDAT>17(23):9861-9870 (1989). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Hayes et al., &ldquo;Locations of Contacts between Individual Zinc Fingers of </PDAT><HIL><ITALIC><PDAT>Xenopus laevis </PDAT></ITALIC></HIL><PDAT>Transcription Factor IIIA and the Internal Control Region of a 5S RNA Gene,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochemistry, </PDAT></ITALIC></HIL><PDAT>31:11600-11605 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Heinzel et al., &ldquo;A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>387:43-48 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Hirst et al., &ldquo;Discrimination of DNA response elements for thyroid hormone and estrogen is dependant on dimerization of receptor DNA binding domains,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>89:5527-5531 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Hoffman et al., &ldquo;Structures of DNA-binding mutant zinc finger domains: Implications for DNA binding,&rdquo; </PDAT><HIL><ITALIC><PDAT>Protein Science, </PDAT></ITALIC></HIL><PDAT>2:951-965 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Isalan et al., &ldquo;Synergy between adjacent zinc fingers in sequence-specific DNA recognition,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>94(11):5617-5621 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Isalan et al., &ldquo;Comprehensive DNA Recognition through Concerted Interactions from Adjacent Zinc Fingers,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochemistry, </PDAT></ITALIC></HIL><PDAT>37:12026-12033 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Jacobs, G. H., &ldquo;Determination of the base recognition positions of zinc fingers from sequence analysis,&rdquo; </PDAT><HIL><ITALIC><PDAT>EMBO J., </PDAT></ITALIC></HIL><PDAT>11(12):4507-4517 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Jamieson et al., &ldquo;A zinc finger directory for high-affinity DNA recognition,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>93:12834-12839 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Julian et al., &ldquo;Replacement of His23 by Cys in a zinc finger of HIV-1 NCp7 led to a change in 1H NMR-derived 3D structure and to a loss of biological activity,&rdquo; </PDAT><HIL><ITALIC><PDAT>FEBS letters, </PDAT></ITALIC></HIL><PDAT>331(1,2):43-48 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kamiuchi et al., &ldquo;New multi zinc finger protein: biosynthetic design and characteristics of DNA recognition,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nucleic Acids Symposium Series, </PDAT></ITALIC></HIL><PDAT>37:153-154 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kim et al., &ldquo;Serine at Position 2 in the DNA Recognition helix of a Cys2-His2 Zinc finger Peptide is Not, in General, Responsible for Base Recognition,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Mol. Biol., </PDAT></ITALIC></HIL><PDAT>252:1-5 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kim et al., &ldquo;Site-specific cleavage of DNA-RNA hybrids by zinc finger/FokI cleavage domain fusions,&rdquo; </PDAT><HIL><ITALIC><PDAT>Gene, </PDAT></ITALIC></HIL><PDAT>203:43-49 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kim et al., &ldquo;A 2.2 &angst; resolution crystal structure of a designed zinc finger protein bound to DNA,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nat. Struct. Biol., </PDAT></ITALIC></HIL><PDAT>3(11):940-945 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kinzler et al., &ldquo;The GLI gene is a member of the Kruppel family of zinc finger proteins,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>332:371-4 (1988). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Klug, A., &ldquo;Gene Regulatory Proteins and Their Interaction with DNA,&rdquo; </PDAT><HIL><ITALIC><PDAT>Ann. NY Acad. Sci., </PDAT></ITALIC></HIL><PDAT>758:143-160 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Klug et al., &ldquo;Protein Motifs 5: Zinc Fingers,&rdquo; </PDAT><HIL><ITALIC><PDAT>FASEB J., </PDAT></ITALIC></HIL><PDAT>9:597-604 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kulda et al., &ldquo;The regulatory gene areA mediating nitrogen metabolite repression in </PDAT><HIL><ITALIC><PDAT>Aspergillus nidulans. </PDAT></ITALIC></HIL><PDAT>Mutations affecting specificity of gene activation alter a loop residue of a putative zinc finger,&rdquo; </PDAT><HIL><ITALIC><PDAT>EMBO J., </PDAT></ITALIC></HIL><PDAT>9(5):1355-1364 (1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Laird-Offringa et al., &ldquo;RNA-binding proteins tamed,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nat. Structural Biol., </PDAT></ITALIC></HIL><PDAT>5(8):665-668 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Mandel-Gutfreund et al., &ldquo;Quantitative parameters for amino acid-base interaction: implications for prediction of protein-DNA binding sites,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nuc. Acids Res., </PDAT></ITALIC></HIL><PDAT>26(10):2306-2312 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Margolin et al., &ldquo;Kruppel-associated boxes are potent transcriptional repression domains,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>91:4509-4513 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Mizushima et al., &ldquo;pEF-BOS, a powerful mammilian expression vector,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nuc. Acids Res., </PDAT></ITALIC></HIL><PDAT>18(17):5322 (1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Nardelli et al., &ldquo;Zinc finger-DNA recognition: analysis of base specificity by site-directed mutagenesis,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nuc. Acids Res., </PDAT></ITALIC></HIL><PDAT>20(16):4137-4144 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Nardelli et al., &ldquo;Base sequence discrimination by zinc-finger DNA-binding domains,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature, </PDAT></ITALIC></HIL><PDAT>349:175-178 (1991). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Orkin et al., &ldquo;Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy&rdquo; (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Pabo et al., &ldquo;Systematic Analysis of Possible Hydrogen Bonds between Amino Acid Side Chains and B-from DNA,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Biomolecular Struct. Dynamics, </PDAT></ITALIC></HIL><PDAT>1:1039-1049 (1983). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Pabo et al., &ldquo;Protein-DNA Recognition,&rdquo; </PDAT><HIL><ITALIC><PDAT>Ann. Rev. Biochem., </PDAT></ITALIC></HIL><PDAT>53:293-321 (1984). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Pabo, C. O., &ldquo;Transcription Factors: Structural Families and Principals of DNA Recognition,&rdquo; </PDAT><HIL><ITALIC><PDAT>Ann. Rev. Biochem., </PDAT></ITALIC></HIL><PDAT>61:1053-1095 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Pavletich et al., &ldquo;Crystal Structure of a Five-Finger GLI-DNA Complex: New Perspectives on Zinc Fingers,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>261:1701-1707 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Pengue et al., &ldquo;Repression of transcriptional activity at a distance by the evolutionarily conserved KRAB domain present in a subfamily of zinc finger proteins,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nuc. Acids Res., </PDAT></ITALIC></HIL><PDAT>22(15):2908-2914 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Pengue et al., &ldquo;Transcriptional Silencing of Human Immunodeficiency Virus Type 1 Long Terminal Repeat-Driven Gene Expression by the Kruppel-Associated Box Repressor Domain Targeted to the Transactivating Response Element,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Virology, </PDAT></ITALIC></HIL><PDAT>69(10):6577-6580 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Pengue et al., &ldquo;Kruppel-associated box-mediated repression of RNA polymerase II promoters is influenced by the arrangement of basal promoter elements,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>93:1015-1020 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Qian et al., &ldquo;Two-Dimensional NMR Studies of the Zinc Finger Motif: Solution Structures and Dynamics of Mutant ZFY Domains Containing Aromatic Substitutions in the Hydrophobic Core,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochemistry, </PDAT></ITALIC></HIL><PDAT>31:7463-7476 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Quigley et al., &ldquo;Complete Androgen Insensitivity Due to Deletion of Exon C of the Androgen Receptor Gene Highlights the Functional Importance of the Second Zinc Finger of the Androgen Receptor in Vivo,&rdquo; </PDAT><HIL><ITALIC><PDAT>Molecular Endocrinology, </PDAT></ITALIC></HIL><PDAT>6(7):1103-1112 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Rauscher et al., &ldquo;Binding of the Wilms&apos; Tumor Locus Zinc Finger Protein to the EGR-1 Consensus Sequence,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>250:1259-1262 (1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Ray et al., &ldquo;Repressor to activator switch by mutations in the first Zn finger of the glucocorticoid receptor: Is direct DNA binding necessary&quest;,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>88:7086-7090 (1991). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Rebar et al., &ldquo;Phage Display Methods for Selecting Zinc Finger Proteins with Novel DNA-Binding Specificities,&rdquo; </PDAT><HIL><ITALIC><PDAT>Methods in Enzymology, </PDAT></ITALIC></HIL><PDAT>267:129-149 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Reith et al., &ldquo;Cloning of the major histocompatibility complex class II promoter binding protein affected in a hereditary defect in class II gene regulation,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>86:4200-4204 (1989). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Rhodes et al., &ldquo;Zinc Fingers: They play a key part in regulating the activity of genes in many species, from yeast to humans. Fewer than 10 years ago no one knew they existed,&rdquo; </PDAT><HIL><ITALIC><PDAT>Scientific American, </PDAT></ITALIC></HIL><PDAT>268:56-65 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Rice et al., &ldquo;Inhibitors of HIV Nucleocapsid Protein Zinc Fingers as Candidates for the Treatment of AIDS,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>270:1194-1197 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Rollins et al., &ldquo;Role of TFIIIA Zinc Fingers In vivo: Analysis of Single-Finger Function in Developing Xenopus Embryos,&rdquo; </PDAT><HIL><ITALIC><PDAT>Molecular Cellular Biology, </PDAT></ITALIC></HIL><PDAT>13(8):4776-4783 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Saleh et al., &ldquo;A Novel Zinc Finger Gene on Human Chromosome 1qter That Is Alternatively Spliced in Human Tissues and Cell Lines,&rdquo; </PDAT><HIL><ITALIC><PDAT>Am. J. Hum. Genet., </PDAT></ITALIC></HIL><PDAT>52:192-203 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Shi et al., &ldquo;Specific DNA-RNA Hybrid Binding by Zinc Finger Proteins,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>268:282-284 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Shi et al., &ldquo;A direct comparison of the properties of natural and designed finger proteins,&rdquo; </PDAT><HIL><ITALIC><PDAT>Chem. </PDAT></ITALIC></HIL><PDAT>&amp; </PDAT><HIL><ITALIC><PDAT>Biol., </PDAT></ITALIC></HIL><PDAT>2(2):83-89 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Singh et al., &ldquo;Molecular Cloning of an Enhancer Binding Protein: Isolation by Screening of an Expression Library with a Recognition Site DNA,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell, </PDAT></ITALIC></HIL><PDAT>52:415-423 (1988). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>South et al., &ldquo;The Nucleocapsid Protein Isolated from HIV-1 Particles Binds Zinc and Forms Retroviral-Type Zinc Fingers,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochemistry, </PDAT></ITALIC></HIL><PDAT>29:7786-7789 (1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Suzuki et al., &ldquo;Stereochemical basis of DNA recognition by Zn fingers,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nuc. Acids Res., </PDAT></ITALIC></HIL><PDAT>22(16):3397-3405 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Suzuki et al. &ldquo;DNA recognition code of transcription factors in the helix-turn-helix, probe helix, hormone receptor, and zinc finger families,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>91:12357-12361 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Swirnoff et al., &ldquo;DNA-Binding Specificity of NGFI-A and Related Zinc Finger Transcription Factors,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol. Cell. Biol., </PDAT></ITALIC></HIL><PDAT>15(4):2275-2287 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Taylor et al, &ldquo;Designing Zinc-Finer ADR1 Mutants with Altered Specificity of DNA Binding to T in UAS1 Sequences,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochemistry, </PDAT></ITALIC></HIL><PDAT>34:3222-3230 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Thiesen et al., &ldquo;Determination of DNA binding specificities of mutated zinc finger domains,&rdquo; </PDAT><HIL><ITALIC><PDAT>FEBS Letters, </PDAT></ITALIC></HIL><PDAT>283(1):23-26 (1991). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Thiesen et al., &ldquo;Amino Acid Substitutions in the SP1 Zinc Finger Domain Alter the DNA Binding Affinity to Cognate SP1 Target Site,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biochem. Biophys. Res. Communications, </PDAT></ITALIC></HIL><PDAT>175(1):333-338 (1991). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Thukral et al., &ldquo;Localization of a Minimal Binding Domain and Activation Regions in Yeast Regulatory Protein ADR1,&rdquo; </PDAT><HIL><ITALIC><PDAT>Molecular Cellular Biology, </PDAT></ITALIC></HIL><PDAT>9(6):2360-2369 (1989). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Thukral et al., &ldquo;Two Monomers of Yeast Transcription Factor ADR1 Bind a Palindromic Sequence Symmetrically to Activate ADH2 Expression,&rdquo; </PDAT><HIL><ITALIC><PDAT>Molecular Cellular Biol., </PDAT></ITALIC></HIL><PDAT>11(3):1566-1577 (1991). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Thukral et al., &ldquo;Alanine scanning site-directed mutagenesis of the zinc fingers of transcription factor ADR1: Residues that contact DNA and that transactivate,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>88:9188-9192 (1991), &plus; correction page. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Thukral et al., &ldquo;Mutations in the Zinc Fingers of ADR1 That Change the Specificity of DNA Binding and Transactivation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol. Cell Biol., </PDAT></ITALIC></HIL><PDAT>12(6):2784-2792 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Vortkamp et al., &ldquo;Identification of Optimized Target Sequences for the GLI3 Zinc Finger Protein,&rdquo; </PDAT><HIL><ITALIC><PDAT>DNA Cell Biol., </PDAT></ITALIC></HIL><PDAT>14(7):629-634 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Webster et al., &ldquo;Conversion of the E1A Cys4 zinc finger to a nonfunctional His2, Cys2 zinc finger by a single point mutation,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>88:9989-9993 (1991). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Whyatt et al., &ldquo;The two zinc finger-like domains of GATA-1 have different DNA binding specificities,&rdquo; </PDAT><HIL><ITALIC><PDAT>EMBO J., </PDAT></ITALIC></HIL><PDAT>12(13):4993-5005 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Wilson et al., &ldquo;In Vivo Mutational analysis of the NGFI-A Zinc Fingers*,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem., </PDAT></ITALIC></HIL><PDAT>267(6):3718-3724 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Witzgall et al., &ldquo;The Kruppel-associated box-A (KRAB-A) domain of zinc finger proteins mediates transcriptional repression,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>91:4514-4518 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Wright et al., &ldquo;Expression of a Zinc Finger Gene in HTLV-I- and HTLV-II-transformed Cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>248:588-591 (1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Yang et al., &ldquo;Surface plasmon resonance based kinetic studies of zinc finger-DNA interactions,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Immunol. Methods, </PDAT></ITALIC></HIL><PDAT>183:175-182 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Yu et al., &ldquo;A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, </PDAT></ITALIC></HIL><PDAT>90:6340-6344 (1993).</PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
</B560>
<B570>
<B577><PDAT>14</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>530300</PDAT></B582>
<B582><PDAT>530324</PDAT></B582>
<B582><PDAT>530345</PDAT></B582>
<B582><PDAT>530350</PDAT></B582>
<B582><PDAT>435 697</PDAT></B582>
<B582><PDAT>514  2</PDAT></B582>
<B582><PDAT>514 12</PDAT></B582>
<B582><PDAT>514 21</PDAT></B582>
</B580>
<B590><B595><PDAT>4</PDAT></B595><B596><PDAT>10</PDAT></B596><B597US/>
</B590>
</B500>
<B600>
<B680US><DOC><DNUM><PDAT>60/076454</PDAT></DNUM><DATE><PDAT>19980302</PDAT></DATE><KIND><PDAT>00</PDAT></KIND></DOC></B680US>
</B600>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Jin-Soo</PDAT></FNM><SNM><STEXT><PDAT>Kim</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Inchon</PDAT></CITY>
<CTRY><PDAT>KR</PDAT></CTRY>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Carl O.</PDAT></FNM><SNM><STEXT><PDAT>Pabo</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Newton</PDAT></CITY>
<STATE><PDAT>MA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Massachusetts Institute of Technology</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>Cambridge</PDAT></CITY><STATE><PDAT>MA</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Robins &amp; Pasternak LLP</PDAT></STEXT></ONM></NAM>
</PARTY-US>
</B741>
<B741>
<PARTY-US>
<NAM><FNM><PDAT>Sean M.</PDAT></FNM><SNM><STEXT><PDAT>Brennan</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>Jeffrey E.</PDAT></FNM><SNM><STEXT><PDAT>Russel</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B748US><PDAT>1653</PDAT></B748US>
</B745>
</B700>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>Provided herein are chimeric zinc finger proteins comprising flexible linkers of at least 6 amino acids in length. Also provided are methods of making and using these chimeric zinc finger proteins.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<RELAPP>
<BTEXT>
<H LVL="1"><STEXT><PDAT>CROSS-REFERENCES TO RELATED APPLICATIONS</PDAT></STEXT></H>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>This application claims priority from U.S. Ser. No. 60/076,454, filed Mar. 2, 1998, herein incorporated by reference in its entirety.</PDAT></PTEXT></PARA>
</BTEXT>
</RELAPP>
<GOVINT>
<BTEXT>
<H LVL="1"><STEXT><PDAT>STATEMENT AS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT</PDAT></STEXT></H>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>Work described herein was supported by grants PO1-CA42063, CDR-8803014 and P30-CA14051 from the National Institutes of Health, National Science Foundation and National Cancer Institute, respectively. The U.S. Government has certain rights in the invention. Work described herein was also supported by the Howard Hughes Medical Institute.</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BACKGROUND OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>Zinc fingers belonging to the Cys</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>-His</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>family constitute one of the most common DNA-binding motifs found in eukaryotes, and these zinc fingers have provided a very attractive framework for the design and selection of DNA-binding proteins with novel sequence specificities. Numerous studies have used phage display methods or design ideas to explore and systematically alter the specificity of zinc finger-DNA interactions (Desjarlais &amp; Berg, </PDAT><HIL><ITALIC><PDAT>Proteins Struct. Funct. Genet. </PDAT></ITALIC></HIL><PDAT>12:101-104 (1992); Desjarlais &amp; Berg, </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>90:2256-2260 (1993); Rebar &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>263:671-673 (1994); Jamieson et al., </PDAT><HIL><ITALIC><PDAT>Biochemistry </PDAT></ITALIC></HIL><PDAT>33:5689-5695 (1994); Choo &amp; Klug, </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>91:11163-11167 (1994); Wu et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>92:344-348 (1995); and Greisman &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>275:657-661 (1997)).</PDAT></PTEXT></PARA>
<PARA ID="P-00005" LVL="0"><PTEXT><PDAT>Structure based computer design has been used to link Cys</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>-His</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>zinc fingers with other DNA-binding domains, including other zinc finger proteins, to generate hybrid proteins that recognize extended sites (Pomerantz et al., </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>267:93-96 (1995); Kim et al, </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>94:3616-3620 (1997)). For example, zinc finger proteins have been linked to a GAL4 dimerization domain to develop novel homo- and hetero-dimers (Pomerantz et al., </PDAT><HIL><ITALIC><PDAT>Biochemistry </PDAT></ITALIC></HIL><PDAT>4:965-970 (1997)), and to a nuclease domain to generate novel restriction enzymes (Kim et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>93:1156-1160 (1996)). Zinc finger/homeodomain fusion is being tested for potential applications in gene therapy (Rivera et al., </PDAT><HIL><ITALIC><PDAT>Nature Med. </PDAT></ITALIC></HIL><PDAT>2:1028-1032 (1996)).</PDAT></PTEXT></PARA>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>There also have been several attempts to increase affinity and specificity of zinc finger proteins by adding additional fingers to a three-finger protein (Rebar, (Ph.D. Thesis), </PDAT><HIL><ITALIC><PDAT>Selection Studies of Zinc Finger</PDAT></ITALIC></HIL><PDAT>-</PDAT><HIL><ITALIC><PDAT>NA Recognition, </PDAT></ITALIC></HIL><PDAT>Massachusetts Institute of Technology (1997); Shi, Y. (Ph.D. Thesis) </PDAT><HIL><ITALIC><PDAT>Molecular Mechanisms of Zinc Finger Protein</PDAT></ITALIC></HIL><PDAT>-</PDAT><HIL><ITALIC><PDAT>Nucleic Acid Interactions, </PDAT></ITALIC></HIL><PDAT>Johns Hopkins University (1995)) or by tandemly linking two three-finger proteins (Liu et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>94:5525-5530 (1997)). However, these previous design strategies for poly-finger proteins, which all used canonical &ldquo;TGEKP&rdquo; linkers (linkers having the amino acid sequence threonine-glycine-glutamate-lysine-proline; SEQ ID NO:13) to connect the additional fingers, resulted in relatively modest increases in affinity. There is thus a need to develop linkers that provide enhanced affinity and specificity to chimeric zinc finger proteins.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>The present invention therefore provides a method of using structure based design to select flexible linkers and make chimeric zinc finger proteins with enhanced affinity and specificity. The present invention also provides a method of making chimeric zinc finger proteins that have flexible linkers of 5 amino acids or more in length to make chimeric zinc finger proteins with enhanced affinity and specificity. Zinc finger proteins made using these methods have binding affinities in the femtomolar range and provide, e.g., high levels (more than about 70 fold) of transcriptional repression at a single target site. Such zinc finger proteins can be used for regulation of gene expression, e.g., as therapeutics, diagnostics, and for research applications such as functional genomics.</PDAT></PTEXT></PARA>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>In one aspect, the present invention provides a method of making a chimeric zinc finger protein that binds to adjacent target sites, the method comprising the steps of: (i) selecting a first and a second DNA-binding domain polypeptide of the chimeric zinc finger protein, wherein at least one of the domains comprises a zinc finger polypeptide, and wherein the first domain binds to a first target site and the second domain binds to a second target site, which target sites are adjacent; (ii) using structure-based design to determine the physical separation between the first and second domains when they are individually bound to the first and second target sites; (iii) selecting a flexible linker that is at least 1-2 &angst; longer than the physical separation between the first and second domains; and (iv) fusing the first and second domains with the flexible linker, thereby making a chimeric zinc finger protein that binds to adjacent target sites.</PDAT></PTEXT></PARA>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>In another aspect, the present invention provides a method of making a chimeric zinc finger protein that binds to adjacent target sites, the method comprising the steps of: (i) selecting a first and a second DNA-binding domain polypeptide of the chimeric zinc finger protein, wherein at least one of the domains comprises a zinc finger polypeptide, and wherein the first domain binds to a first target site and the second domain binds to a second target site, which target sites are adjacent; (ii) selecting a flexible linker that is five or more amino acids in length; and (iv) fusing the first and second domains with the flexible linker, thereby making a chimeric zinc finger protein that binds to adjacent target sites.</PDAT></PTEXT></PARA>
<PARA ID="P-00010" LVL="0"><PTEXT><PDAT>In another aspect, the present invention provides a chimeric zinc finger protein that binds to adjacent target sites, the chimeric zinc finger protein comprising: (i) a first and a second DNA-binding domain polypeptide of the chimeric zinc finger protein, wherein at least one of the domains comprises a zinc finger polypeptide, and wherein the first domain binds to a first target site and the second domain binds to a second target site, which target sites are adjacent; and (ii) a flexible linker that is at least 1-2 &angst; longer than the physical separation between the first and second domains when they are individually bound to the first and second target sites, as determined by structure-based modeling; wherein the first and second domains are fused with the flexible linker.</PDAT></PTEXT></PARA>
<PARA ID="P-00011" LVL="0"><PTEXT><PDAT>In another aspect, the present invention provides a chimeric zinc finger protein that binds to adjacent target sites, the chimeric zinc finger protein comprising: (i) a first and a second DNA-binding domain polypeptide of the chimeric zinc finger protein, wherein at least one of the domains comprises a zinc finger polypeptide, and wherein the first domain binds to a first target site and the second domain binds to a second target site, which target sites are adjacent; and (ii) a flexible linker that is five or more amino acids in length; wherein the first and second domains are fused with the flexible linker.</PDAT></PTEXT></PARA>
<PARA ID="P-00012" LVL="0"><PTEXT><PDAT>In one embodiment, the present invention provides nucleic acids encoding the chimeric zinc finger proteins.</PDAT></PTEXT></PARA>
<PARA ID="P-00013" LVL="0"><PTEXT><PDAT>In one embodiment, the first and the second domains are zinc finger polypeptides. In another embodiment, the zinc finger polypeptide is selected from the group consisting of Zif268 and NRE. In another embodiment, the zinc finger polypeptides are heterologous. In one embodiment, the first domain is a zinc finger polypeptide and the second domain comprises a heterologous DNA-binding domain polypeptide. In another embodiment, the chimeric zinc finger protein further comprises a regulatory domain polypeptide.</PDAT></PTEXT></PARA>
<PARA ID="P-00014" LVL="0"><PTEXT><PDAT>In one embodiment, the chimeric zinc finger protein has femtomolar affinity for the adjacent target sites. In another embodiment, the chimeric zinc finger protein has about 2-4 femtomolar affinity for the adjacent target sites.</PDAT></PTEXT></PARA>
<PARA ID="P-00015" LVL="0"><PTEXT><PDAT>In one embodiment, the flexible linker is 5, 8, or 11 amino acids in length. In another embodiment, the flexible linker has the sequence RQKDGERP (SEQ ID NO:14) or RQKDGGGSERP (SEQ ID NO:15).</PDAT></PTEXT></PARA>
<PARA ID="P-00016" LVL="0"><PTEXT><PDAT>In one embodiment, the target sites are separated by one or two nucleotides.</PDAT></PTEXT></PARA>
<PARA ID="P-00017" LVL="0"><PTEXT><PDAT>In one embodiment, the adjacent target sites are separated by zero nucleotides and the flexible linker is five or six amino acids in length. In another embodiment, the adjacent target sites are separated by one nucleotide and the flexible linker is seven, eight, or nine amino acids in length. In another embodiment, the adjacent target sites are separated by two nucleotides and the flexible linker is ten, eleven, or twelve amino acids in length. In another embodiment, the adjacent target sites are separated by three nucleotides and the flexible linker is twelve or more amino acids in length.</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DRWDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BRIEF DESCRIPTION OF THE DRAWINGS</PDAT></STEXT></H>
<PARA ID="P-00018" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT> depicts structure-based design of a six finger peptide, 268//NRE. The cocrystal structure of the Zif268-DNA complex and the template B-DNA (used at the junction) were aligned by superimposing phosphates (Pavletich &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>252:809-817 (1991); Elrod-Erickson et al., </PDAT><HIL><ITALIC><PDAT>Structure </PDAT></ITALIC></HIL><PDAT>4:1171-1180 (1996)). In this model, two three-finger peptides bind to corresponding 9-bp sites (bases shown in white) separated by a 2 bp gap (bases shown in gray). Note that the orientation of one three-finger peptide almost exactly matches that of the other three finger peptide because one helical turn of this underwound DNA contains 11 bp.</PDAT></PTEXT></PARA>
<PARA ID="P-00019" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> depicts schematic representations of zinc finger peptides and of reporter constructs used in transfection studies described herein. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2A</PDAT></FGREF><PDAT> shows zinc finger peptides. Each finger is represented with a circle. The amino acid sequence of a linker in the Zif268 peptide (which has a canonical &ldquo;TGEKP&rdquo; linker; SEQ ID NO:13) is shown (SEQ ID NO:16), and longer linkers used to connect the three-finger peptides are indicated below (SEQ ID NOS:17 and 18). In each case, the box on the left denotes the helical region and includes the second of the conserved His residues of the finger: the zigzag line denotes the first &bgr;-sheet of the next finger, which includes the first of the conserved Cys residues. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2B</PDAT></FGREF><PDAT> illustrates promoters of luciferase reporter genes. The nucleotide positions of the TATA box, the start codon, and zinc finger binding sites (N/Z&equals;SEQ ID NO:10; N//Z&equals;SEQ ID NO:11; N&equals;SEQ ID NO:9; NZ&equals;SEQ ID NO:8) are numbered with respect to the transcription start site (&plus;1).</PDAT></PTEXT></PARA>
<PARA ID="P-00020" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> depicts a gel shift assay. Various amounts (0, 0.01, 0.1, and 1 nM) of the NRE peptide were incubated for 1 hour with free binding sites (lanes 1-4) or binding sites preincubated with 0.1 nM of the Zif268 peptide for 0.5 hours (lanes 5-8). The positions of the free DNA and the protein-DNA complexes are indicated.</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT> depicts competition binding studies. In </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 4A</PDAT></FGREF><PDAT>, the 268//NRE peptide (5 pM) was preincubated with various amounts (0.05, 0.5, 5 and 50 nM) of cold competitor DNAs (lanes 3-14) for 1 hour, and then a slight molar excess (over the peptide concentration) of the labeled N/Z site (608 pM) was added to the reaction mixture. Aliquots were analyzed by gel electrophoresis at various time points, and this gel shows the results after 600 hours of incubation time at room temperature. In </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 4B</PDAT></FGREF><PDAT>, the 268//NRE (lanes 2-6) or Zif268 peptide (lanes 7-11) was mixed with the labeled N/Z site, a slight molar excess (over the peptide concentration) of unlabeled N/Z site was added (so that 70% of the labeled site would be shifted in the absence of salmon sperm DNA), and various amounts of salmon sperm DNA (0, 0.1, 1, 10, and 100 &mgr;g/ml) were included. Samples were analyzed by gel electrophoresis after 24 hours of incubation.</PDAT></PTEXT></PARA>
<PARA ID="P-00022" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT> depicts graphs (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 5A</PDAT></FGREF><PDAT>, </PDAT><HIL><BOLD><PDAT>5</PDAT></BOLD></HIL><PDAT>B, </PDAT><HIL><BOLD><PDAT>5</PDAT></BOLD></HIL><PDAT>C, and </PDAT><HIL><BOLD><PDAT>5</PDAT></BOLD></HIL><PDAT>D) illustrating transcriptional repression in vivo by zinc finger peptides. Human 293 cells were transfected as described (Cepek et al., </PDAT><HIL><ITALIC><PDAT>Genes Dev. </PDAT></ITALIC></HIL><PDAT>10:2079-2088 (1996)) using the calcium phosphate precipitation method. Luciferase and &bgr;-galactosidase activities were measured 48 hours later. The luciferase activities were divided by corresponding &bgr;-galactosidase activities to yield the relative luciferase activities. Repression levels (fold repression) were obtained by dividing 1) the relative luciferase activities from the cells transfected with the empty expression plasmid by 2) those from the cells transfected with zinc finger expression plasmids. Different scales are used in graphs for the different reporters. The 68/NR, 68/NRE, 68//NR, and 68//NRE peptides are variants of six-finger fusion proteins that are missing one or two of the terminal fingers. Thus the 68/NR peptide contains fingers 2 and 3 of the Zif268 peptide fused (via the shorter of the two linkers) to fingers 1 and 2 of the NRE peptide. The data represent an average of three independent experiments, and the standard error of the mean is shown.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>DETAILED DESCRIPTION OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00023" LVL="7"><PTEXT><PDAT>I. Introduction</PDAT></PTEXT></PARA>
<PARA ID="P-00024" LVL="0"><PTEXT><PDAT>The present invention provides a design strategy for linkers that fuse two DNA binding domains of a chimeric zinc finger protein. These linkers are flexible and longer than the canonical linkers previously used, allowing binding of the chimeric zinc finger protein to its target site without introducing any strain. The target site is typically a &ldquo;composite&rdquo; target site,&rdquo; composed of two adjacent target sites that are separated by zero to 5 or more nucleotides. Each of the adjacent target sites is recognized by one DNA-binding domain of the chimeric zinc finger protein. The linker design strategy involves structure-based design to determine a minimum length for a linker between two DNA-binding domains, and then adding additional amino acids to the linker to provide at least about 1-2 additional angstroms of flexibility to the linker. The present invention thus provides chimeric zinc finger proteins with femtomolar affinity for their target site, and which effectively repress gene expression, e.g., more than about 70 fold, when targeted to a single site.</PDAT></PTEXT></PARA>
<PARA ID="P-00025" LVL="0"><PTEXT><PDAT>Structural and biochemical analyses show that DNA often is slightly unwound when bound to zinc finger peptides (Pavletich &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>252:809-817 (1991); Shi &amp; Berg, </PDAT><HIL><ITALIC><PDAT>Biochemistry </PDAT></ITALIC></HIL><PDAT>35:3845-3848 (1996); Nekludova &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>91:6948-6952 (1994)). Modeling studies have shown that on ideal B DNA, the canonical linker is a bit too short to allow favorable docking of Zif268 (Elrod-Erickson et al., </PDAT><HIL><ITALIC><PDAT>Structure </PDAT></ITALIC></HIL><PDAT>4:1171-1180 (1996)); the DNA must be slightly unwound to interact with zinc fingers in the mode seen in the Zif268 complex. Essentially, it appears that the helical periodicity of the zinc fingers does not quite match the helical periodicity of B-DNA. Since the strain of unwinding may become a more serious problem when there are more fingers (the helical periodicities of the peptide and DNA may get progressively further out of phase), longer, more flexible linkers were tested in the design of poly-finger proteins (see Kim &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Proc. Nat&apos;l Acad. Sci. U.S.A. </PDAT></ITALIC></HIL><PDAT>95:2812-2817 (1998), herein incorporated by reference in its entirety).</PDAT></PTEXT></PARA>
<PARA ID="P-00026" LVL="0"><PTEXT><PDAT>The present invention demonstrates that linkers of 5 amino acids or more can be used to make chimeric zinc finger proteins with enhanced affinity. For example, a linker of 8 amino acids was used for a chimeric zinc finger protein that recognized adjacent target sites separated by one base pair. A linker of 11 amino acids was used for a chimeric zinc finger protein that recognized adjacent target sites separated by two base pairs. The linkers of the invention can also be designed using structure-based modeling. In structure-based modeling, a model is made that shows the binding of each DNA binding domain polypeptide to its DNA target site. The model is then used to determine the physical separation of the domains as they are bound to adjacent target sites. The physical separation between the domains is used to determine the minimum length of the linker used to connect the C-terminal amino acid of the first domain with the N-terminal amino acid of the second domain, without steric hindrance to the linker or the DNA binding domains. This length is then increased by 1-2 &angst;, to create a slightly longer, flexible linker that avoids introducing strain to the chimeric zinc finger protein.</PDAT></PTEXT></PARA>
<PARA ID="P-00027" LVL="0"><PTEXT><PDAT>Often computer programs are used for structure-based modeling, although the models can also be made physically. Examples of computer programs used for structure-based modeling include Insight II (Biosym Technologies, SanDiego) and Quanta 4.0 (Molecular Simulations (Burlington, Mass.). The programs often use information derived from x-ray crystallographic studies of DNA-binding proteins to provide the appropriate coordinates for proteins. This information can also be obtained from publicly available databases such as the Brookhaven Protein Data Bank. This information can also be used to extrapolate distances and coordinates for DNA binding proteins whose crystal structure is unknown. Models of B DNA are well known in the art. The relevant coordinates (e.g., distances and sizes) are used with computer modeling program of choice, using the manufacture&apos;s instructions and default parameters. Alternatively, customized parameters can be used. Structure-based modeling can be performed as described in, e.g., Kim &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Proc. Nat&apos;l. Acad. Sci. U.S.A. </PDAT></ITALIC></HIL><PDAT>95:2812-2817 (1998); Pavletich &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>252:809-817 (1991); Rebar, Ph.D. Thesis (Massachusetts Institute of Technology, Cambridge, Mass.) (1997); Liu et al., </PDAT><HIL><ITALIC><PDAT>Proc. Nat&apos;l. Acad. Sci. U.S.A. </PDAT></ITALIC></HIL><PDAT>94:5525-5530 (1997); Pomerantz et al., </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>267:93-96 (1995); Pomerantz et al., </PDAT><HIL><ITALIC><PDAT>Proc. Nat&apos;l. Acad. Sci. U.S.A. </PDAT></ITALIC></HIL><PDAT>92:9752-9756 (1995); Li et al., </PDAT><HIL><ITALIC><PDAT>Nature Biotechnology </PDAT></ITALIC></HIL><PDAT>16:190-195 (1998); Kim et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>94:3616-3620 (1997); and Pomerantz et al., </PDAT><HIL><ITALIC><PDAT>Biochemistry </PDAT></ITALIC></HIL><PDAT>4:965-970 (1997), herein incorporated by reference in their entirety). Two basic criteria suggest which alignments of DNA-binding domains have potential for combination in a chimeric protein which binds DNA: (1) lack of collision between domains, and (2) consistent positioning of the carboxyl- and amino-terminal regions of the domains, i.e., the domains are oriented such that the carboxyl-terminal region of one polypeptide can be joined to the amino-terminal region of the next polypeptide</PDAT></PTEXT></PARA>
<PARA ID="P-00028" LVL="0"><PTEXT><PDAT>The linker used to link the two DNA-binding domains can comprise any amino acid sequence that does not substantially hinder interaction of the DNA-binding domains with their respective target sites. Preferred amino acid residues for linkers of the present invention include, but are not limited to glycine, alanine, leucine, serine, valine and threonine. Once the length of the amino acid sequence has been selected, the sequence of the linker can be selected, e.g., by phage display library technology (see, e.g., U.S. Pat. No. 5,260,203), or using naturally occurring or synthetic linker sequences as a scaffold (e.g., GTGQKP (SEQ ID NO:19) and GEKP (SEQ ID NO:20), see Liu et al., </PDAT><HIL><ITALIC><PDAT>Proc. Nat&apos;l Acad. Sci. U.S.A. </PDAT></ITALIC></HIL><PDAT>94:5525-5530 (1997); see also Whitlow et al., </PDAT><HIL><ITALIC><PDAT>Methods: A Companion to Methods in Enzymology </PDAT></ITALIC></HIL><PDAT>2:97-105 (1991)). Typically, the linkers of the invention are made by making recombinant nucleic acids encoding the linker and the DNA-binding domains, which are fused via the linker amino acid sequence. Optionally, the linkers can also be made using peptide synthesis, and then linked to the polypeptide DNA-binding domains.</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="0"><PTEXT><PDAT>The chimeric zinc finger proteins of the invention are composed of two or more DNA-binding domains, where at least one of the DNA binding domains is a zinc finger polypeptide. The second DNA binding domain can be a zinc finger binding domain, either the same domain or a heterologous domain. Suitable zinc finger proteins include any protein from the Cys</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>-His</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>family, e.g., SP-1, SP-1C, ZIF268, NRE, Tramtrack, GLI, YY1, or TFIIIA (see, e.g., Jacobs, </PDAT><HIL><ITALIC><PDAT>EMBO J. </PDAT></ITALIC></HIL><PDAT>11:4507 (1992); Desjarlais &amp; Berg, </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>90:2256-2260 (1993); Christy et al., </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>85:7857-7861 (1988); Greisman &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>275:657-661 (1997); Fairall et al., </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>366:483 (1993); Paveltich et al., </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>261:1701 (1993)).</PDAT></PTEXT></PARA>
<PARA ID="P-00030" LVL="0"><PTEXT><PDAT>The second DNA binding domain can also be a heterologous DNA binding domain, e.g., from a restriction enzyme; a nuclear hormone receptor; a homeodomain protein or a helix turn helix motif protein such as MAT 1, MAT 2, MAT a1, Antennapedia, Ultrabithorax, Engrailed, Paired, Fushi tarazu, HOX, Unc86, Oct1, Oct2, Pit, lambda repressor and tet repressor; Gal 4; TATA binding protein; helix loop helix motif proteins such as myc, myo D, Daughterless, Achaete-scute (T3), E12, and E47; leucine zipper type proteins such as GCN4, C/EBP, c-Fos/c-Jun and JunB; and beta sheet motif proteins such as met, arc, and mnt repressors. In another embodiment, the zinc finger protein is linked to at least one or more regulatory domains, described below. Preferred regulatory domains include transcription factor repressor or activator domains such as KRAB and VP16, co-repressor and co-activator domains, DNA methyl transferases, histone acetyltransferases, histone deacetylases, and endonucleases such as Fok1. The amino acid sequences of the DNA-binding domains may be naturally-occurring or non-naturally-occurring (or modified).</PDAT></PTEXT></PARA>
<PARA ID="P-00031" LVL="0"><PTEXT><PDAT>The expression of chimeric zinc finger proteins can be also controlled by systems typified by the tet-regulated systems and the RU-486 system (see, e.g., Gossen &amp; Bujard, </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>89:5547 (1992); Oligino et al., </PDAT><HIL><ITALIC><PDAT>Gene Ther. </PDAT></ITALIC></HIL><PDAT>5:491-496 (1998); Wang et al., </PDAT><HIL><ITALIC><PDAT>Gene Ther. </PDAT></ITALIC></HIL><PDAT>4:432-441 (1997); Neering et al., </PDAT><HIL><ITALIC><PDAT>Blood </PDAT></ITALIC></HIL><PDAT>88:1147-1155 (1996); and Rendahl et al., </PDAT><HIL><ITALIC><PDAT>Nat. Biotechnol. </PDAT></ITALIC></HIL><PDAT>16:757-761 (1998)). These impart small molecule control on the expression of the chimeric zinc finger protein and thus impart small molecule control on the target gene(s) of interest. This beneficial feature could be used in cell culture models, in gene therapy, and in transgenic animals and plants.</PDAT></PTEXT></PARA>
<PARA ID="P-00032" LVL="0"><PTEXT><PDAT>The binding specificity of the chimeric DNA-binding proteins makes them particularly useful because they have DNA-binding properties distinct from those of known proteins. The chimeric proteins prefer to bind the adjacent target sites and, thus, can be used to modulate expression of genes having the adjacent target sites. These chimeric zinc finger proteins have an affinity for the adjacent target sites that is in the femtomolar range, e.g., 100 femtomoles, 10 femtomoles, or less, in some cases as low as 2-4 femtomoles, and in some cases 1 femtomolar or lower.</PDAT></PTEXT></PARA>
<PARA ID="P-00033" LVL="0"><PTEXT><PDAT>The zinc finger proteins made using the method of the invention have numerous applications, including therapeutic, diagnostic, and research applications such as in cell or animal models and functional genomics. For example, zinc finger proteins can be used to regulate gene expression, allowing for novel human and mammalian therapeutic applications, e.g., treatment of genetic diseases, cancer, fungal, protozoal, bacterial, and viral infection, ischemia, vascular disease, arthritis, immunological disorders, etc., as well as providing means for developing plants with altered phenotypes, including disease resistance, fruit ripening, sugar and oil composition, yield, and color. In addition, the zinc finger proteins of the present invention can be used for diagnostic assays and for functional genomics assays.</PDAT></PTEXT></PARA>
<PARA ID="P-00034" LVL="0"><PTEXT><PDAT>As described herein, zinc finger proteins can be designed to recognize any suitable target site for any of the uses described herein, e.g., eukaryotic and prokaryotic genes, cellular genes, viral genes, protozoal genes, fungal genes, and bacterial genes. In general, suitable genes to be regulated include cytokines, lymphokines, growth factors, mitogenic factors, chemotactic factors, onco-active factors, receptors, potassium channels, G-proteins, signal transduction molecules, and other disease-related genes.</PDAT></PTEXT></PARA>
<PARA ID="P-00035" LVL="0"><PTEXT><PDAT>A general theme in transcription factor function is that simple binding and sufficient proximity to the promoter are all that is generally needed. Exact positioning relative to the promoter, orientation, and within limits, distance do not matter greatly. This feature allows considerable flexibility in choosing sites for constructing zinc finger proteins. The target site recognized by the zinc finger protein therefore can be any suitable site in the target gene that will allow activation or repression of gene expression by a zinc finger protein, optionally linked to a regulatory domain.</PDAT></PTEXT></PARA>
<PARA ID="P-00036" LVL="0"><PTEXT><PDAT>Preferred target sites include regions adjacent to, downstream, or upstream of the transcription start site. In addition, target sites that are located in enhancer regions, repressor sites, RNA polymerase pause sites, and specific regulatory sites (e.g., SP-1 sites, hypoxia response elements, nuclear receptor recognition elements, p53 binding sites), sites in the cDNA encoding region or in an expressed sequence tag (EST) coding region. As described below, typically each finger recognizes 2-4 base pairs, with a two finger zinc finger protein binding to a 4 to 7 bp target site, a three finger zinc finger protein binding to a 6 to 10 base pair site, and a six finger zinc finger protein binding to two adjacent target sites, each target site having from 6-10 base pairs.</PDAT></PTEXT></PARA>
<PARA ID="P-00037" LVL="0"><PTEXT><PDAT>Chimeric zinc finger proteins of the invention can be tested for activity in vivo using a simple assay (</PDAT><HIL><ITALIC><PDAT>Current Protocols in Molecular Biology </PDAT></ITALIC></HIL><PDAT>(Ausubel et al., eds, 1994)). The in vivo assay uses a plasmid encoding the chimeric zinc finger protein, which is co-expressed with a reporter plasmid containing a test gene, e.g., the luciferase gene, the chloramphenicol acetyl transferase (CAT) gene or the human growth hormone (hGH) gene, with a target site for the chimeric zinc finger protein. The two plasmids are introduced together into host cells. A second group of cells serves as the control group and receives a plasmid encoding the transcription factor and a plasmid containing the reporter gene without the binding site for the transcription factor.</PDAT></PTEXT></PARA>
<PARA ID="P-00038" LVL="0"><PTEXT><PDAT>The production of reporter gene transcripts or the amount of activity of the relevant protein is measured; if mRNA synthesis from the reporter gene or the amount of activity of the relevant protein is greater than that of the control gene, the transcription factor is a positive regulator of transcription. If reporter gene mRNA synthesis or the amount of activity of the relevant protein is less than that of the control, the transcription factor is a negative regulator of transcription.</PDAT></PTEXT></PARA>
<PARA ID="P-00039" LVL="0"><PTEXT><PDAT>Optionally, the assay may include a transfection efficiency control plasmid. This plasmid expresses a gene product independent of the reporter gene, and the amount of this gene product indicates roughly how many cells are taking up the plasmids and how efficiently the DNA is being introduced into the cells. The chimeric zinc finger protein can also be tested for modulation of an endogenous gene in vivo, using methods known to those of skill in the art.</PDAT></PTEXT></PARA>
<PARA ID="P-00040" LVL="0"><PTEXT><PDAT>In one embodiment, the present invention provides a fusion in which the three-finger Zif268 peptide was linked to a designed three-finger peptide (designated &ldquo;NRE&rdquo;) that specifically recognizes a nuclear hormone response element (Greisman &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>275:657 (1997)). Gel shift assays indicate that this six-finger peptide, 268//NRE, binds to a composite 18 bp DNA site with a dissociation constant in the femtomolar range. The slightly longer linkers used in this fusion protein provide a dramatic improvement in DNA-binding affinity, working much better than the canonical &ldquo;TGEKP&rdquo; linkers (SEQ ID NO:13) that have been used in previous studies. Tissue culture transfection experiments also show that the 268//NRE peptide is an extremely effective repressor, giving 72-fold repression when targeted to a binding site close to the transcription start site. Using this strategy and linking peptides selected via phage display allows the design of novel DNA-binding proteins with extraordinary affinity and specificity for use in biological applications and gene therapy.</PDAT></PTEXT></PARA>
<PARA ID="P-00041" LVL="0"><PTEXT><PDAT>The new six-finger peptides bind far more tightly than previously reported poly-finger proteins which used a conventional &ldquo;TGEKP&rdquo; linker (SEQ ID NO:13) to connect two three-finger modules or to add additional fingers to a three-finger protein. Poly-finger proteins with canonical linkers had been tested by Rebar (Rebar, (Ph.D. Thesis), </PDAT><HIL><ITALIC><PDAT>Selection Studies of Zinc Finger</PDAT></ITALIC></HIL><PDAT>-</PDAT><HIL><ITALIC><PDAT>DNA Recognition, Massachusetts Institute of Technology </PDAT></ITALIC></HIL><PDAT>(1997)), by Shi (Shi, (Ph.D. Thesis), </PDAT><HIL><ITALIC><PDAT>Molecular Mechanisms of Zinc Finger Protein</PDAT></ITALIC></HIL><PDAT>-</PDAT><HIL><ITALIC><PDAT>Nucleic Acid Interactions, </PDAT></ITALIC></HIL><PDAT>Johns Hopkins University (1995)), and by Liu et al. (Liu et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>94:5525-5530 (1997)). Each study compared binding of the new poly-finger protein (at the appropriate extended site) with binding of the original three-finger peptide. Using canonical linkers, a four-finger peptide bound 6.3 times more tightly than the corresponding three-finger peptide (Rebar (Ph.D. Thesis), </PDAT><HIL><ITALIC><PDAT>Selection Studies of Zinc Finger</PDAT></ITALIC></HIL><PDAT>-</PDAT><HIL><ITALIC><PDAT>DNA Recognition, </PDAT></ITALIC></HIL><PDAT>Massachusetts Institute of Technology (1997)), a five-finger construct showed no improvement in K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>over the original three-finger peptide (Shi, (Ph.D. Thesis), </PDAT><HIL><ITALIC><PDAT>Molecular Mechanisms of Zinc Finger Protein</PDAT></ITALIC></HIL><PDAT>-</PDAT><HIL><ITALIC><PDAT>Nucleic Acid Interactions, </PDAT></ITALIC></HIL><PDAT>Johns Hopkins University (1995)), and six-finger peptides bound 58-74-fold more tightly than the corresponding three-finger peptides (Liu et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>94:5525-5530 (1997)).</PDAT></PTEXT></PARA>
<PARA ID="P-00042" LVL="0"><PTEXT><PDAT>In contrast, the peptides described herein (see Example section) bind 6,000-90,000-fold more tightly than the original three-finger peptides. It seems likely that the longer linkers used in the 268/NRE and 268//NRE constructs must relieve some strain that accumulates when a larger set of fingers all are connected with canonical linkers. Presumably this involves a slight mismatch in the helical periodicity of the DNA and the preferred helical periodicity of the zinc fingers, causing them to fall slightly out of register, particularly when 4 or more fingers are connected via canonical linkers.</PDAT></PTEXT></PARA>
<PARA ID="P-00043" LVL="7"><PTEXT><PDAT>II. Definitions</PDAT></PTEXT></PARA>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>As used herein, the following terms have the meanings ascribed to them unless specified otherwise.</PDAT></PTEXT></PARA>
<PARA ID="P-00045" LVL="0"><PTEXT><PDAT>The term &ldquo;zinc finger protein&rdquo; or &ldquo;ZFP&rdquo; or &ldquo;zinc finger polypeptide&rdquo; refers to a protein having DNA binding domains that are stabilized by zinc. The individual DNA binding domains are typically referred to as &ldquo;fingers.&rdquo; A zinc finger protein has at least one finger, typically two fingers, three fingers, or six fingers. Each finger binds from two to four base pairs of DNA, typically three or four base pairs of DNA (the &ldquo;subsite&rdquo;). A zinc finger protein binds to a nucleic acid sequence called a target site or target segment. Each finger typically comprises an approximately 30 amino acid, zinc-chelating, DNA-binding subdomain. An exemplary motif characterizing one class of these proteins (C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>class) is &mdash;Cys-(X)</PDAT><HIL><SB><PDAT>2-4</PDAT></SB></HIL><PDAT>-Cys-(X)</PDAT><HIL><SB><PDAT>12</PDAT></SB></HIL><PDAT>-His-(X)</PDAT><HIL><SB><PDAT>3-5</PDAT></SB></HIL><PDAT>-His (SEQ ID NO:21) (where X is any amino acid). Studies have demonstrated that a single zinc finger of this class consists of an alpha helix containing the two invariant histidine residues co-ordinated with zinc along with the two cysteine residues of a single beta turn (see, e.g., Berg &amp; Shi, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>271:1081-1085 (1996)).</PDAT></PTEXT></PARA>
<PARA ID="P-00046" LVL="0"><PTEXT><PDAT>A &ldquo;chimeric&rdquo; zinc finger protein refers to a protein that has at least two DNA-binding domains, one of which is a zinc finger polypeptide, linked to the other domain via a flexible linker. The two domains can be the same or heterologous. Both domains can be zinc finger proteins, either the same zinc finger protein or heterologous zinc finger proteins. Alternatively, one domain can be a heterologous DNA-binding protein.</PDAT></PTEXT></PARA>
<PARA ID="P-00047" LVL="0"><PTEXT><PDAT>A &ldquo;target site&rdquo; is the nucleic acid sequence recognized by a zinc finger protein or a heterologous DNA-binding polypeptide. For a zinc finger protein, a single target site typically has about four to about ten base pairs. Typically, a two-fingered zinc finger protein recognizes a four to seven base pair target site, a three-fingered zinc finger protein recognizes a six to ten base pair target site, and a six fingered zinc finger protein recognizes two adjacent nine to ten base pair target sites.</PDAT></PTEXT></PARA>
<PARA ID="P-00048" LVL="0"><PTEXT><PDAT>A &ldquo;subsite&rdquo; is a subsequence of the target site, and corresponds to a portion of the target site recognized by a single finger, e.g., a 2-4 base subsite, typically a 3 base subsite. A target site comprises at least two, typically three, four, five, six or more subsites, one for each finger of the protein.</PDAT></PTEXT></PARA>
<PARA ID="P-00049" LVL="0"><PTEXT><PDAT>The term &ldquo;adjacent target sites&rdquo; refers to non-overlapping target sites that are separated by zero to about 5 base pairs.</PDAT></PTEXT></PARA>
<PARA ID="P-00050" LVL="0"><PTEXT><PDAT>The &ldquo;physical separation&rdquo; between two DNA-binding domains refers to the distance between two domains when they are bound to their respective target sites. This distance is used to determine a minimum length of a linker. A minimum length of a linker is the length that would allow the two domains to be connected without providing steric hindrance to the domains or the linker (a minimum linker). A linker that provides more than the minimum length is a &ldquo;flexible linker.&rdquo;</PDAT></PTEXT></PARA>
<PARA ID="P-00051" LVL="0"><PTEXT><PDAT>&ldquo;Structure based design&rdquo; refers to methods of determining the length of minimum linkers and flexible linkers, using physical or computer models of DNA-binding proteins bound to their respective target sites.</PDAT></PTEXT></PARA>
<PARA ID="P-00052" LVL="0"><PTEXT><PDAT>&ldquo;K</PDAT><HIL><SB><PDAT>d</PDAT></SB></HIL><PDAT>&rdquo; refers to the dissociation constant for the compound, i.e., the concentration of a compound (e.g., a zinc finger protein) that gives half maximal binding of the compound to its target (i.e., half of the compound molecules are bound to the target) under given conditions (i.e., when &lsqb;target&rsqb;&lt;&lt;K</PDAT><HIL><SB><PDAT>d</PDAT></SB></HIL><PDAT>), as measured using a given assay system (see, e.g., U.S. Pat. No. 5,789,538). The assay system used to measure the K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>should be chosen so that it gives the most accurate measure of the actual K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>of the zinc finger protein. Any assay system can be used, as long is it gives an accurate measurement of the actual K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>of the zinc finger protein. In one embodiment, the K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>for the zinc finger proteins of the invention is measured using an electrophoretic mobility shift assay (&ldquo;EMSA&rdquo;), as described in herein. Unless an adjustment is made for zinc finger protein purity or activity, K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>calculations may result in an underestimate of the true K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>of a given zinc finger protein.</PDAT></PTEXT></PARA>
<PARA ID="P-00053" LVL="0"><PTEXT><PDAT>The phrase &ldquo;adjacent to a transcription initiation site&rdquo; refers to a target site that is within about 50 bases either upstream or downstream of a transcription initiation site. &ldquo;Upstream&rdquo; of a transcription initiation site refers to a target site that is more than about 50 bases 5&prime; of the transcription initiation site (i.e., in the non-transcribed region of the gene).</PDAT></PTEXT></PARA>
<PARA ID="P-00054" LVL="0"><PTEXT><PDAT>The phrase &ldquo;RNA polymerase pause site&rdquo; is described in Uptain et al., </PDAT><HIL><ITALIC><PDAT>Annu. Rev. Biochem. </PDAT></ITALIC></HIL><PDAT>66:117-172 (1997).</PDAT></PTEXT></PARA>
<PARA ID="P-00055" LVL="0"><PTEXT><PDAT>The term &ldquo;heterologous&rdquo; is a relative term, which when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, a nucleic acid that is recombinantly produced typically has two or more sequences from unrelated genes synthetically arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. The two nucleic acids are thus heterologous to each other in this context. When added to a cell, the recombinant nucleic acids would also be heterologous to the endogenous genes of the cell. Thus, in a chromosome, a heterologous nucleic acid would include an non-native (non-naturally occurring) nucleic acid that has integrated into the chromosome, or a non-native (non-naturally occurring) extrachromosomal nucleic acid. In contrast, a naturally translocated piece of chromosome would not be considered heterologous in the context of this patent application, as it comprises an endogenous nucleic acid sequence that is native to the mutated cell.</PDAT></PTEXT></PARA>
<PARA ID="P-00056" LVL="0"><PTEXT><PDAT>A &ldquo;regulatory domain&rdquo; refers to a protein or a protein domain that has an activity such as transcriptional modulation activity, DNA modifying activity, protein modifying activity and the like when tethered to a DNA binding domain, i.e., a zinc finger protein. Examples of regulatory domains include proteins or effector domains of proteins, e.g., transcription factors and co-factors (e.g., KRAB, MAD, ERD, SID, nuclear factor kappa B subunit p65, early growth response factor 1, and nuclear hormone receptors, VP16, VP64), endonucleases, integrases, recombinases, methyltransferases, histone acetyltransferases, histone deacetylases etc. Activators and repressors include co-activators and co-repressors (see, e.g., Utley et al., </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>394:498-502 (1998)).</PDAT></PTEXT></PARA>
<PARA ID="P-00057" LVL="0"><PTEXT><PDAT>A &ldquo;heterologous DNA-binding domain&rdquo; refers to a DNA binding domain from a protein that is not a zinc finger protein, such as a restriction enzyme, a nuclear hormone receptor, a homeodomain protein such as engrailed or antenopedia, a bacterial helix turn helix motif protein such as lambda repressor and tet repressor, Gal 4, TATA binding protein, helix loop helix motif proteins such as myc and myo D, leucine zipper type proteins such as fos and jun, and beta sheet motif proteins such as met, arc, and mnt repressors.</PDAT></PTEXT></PARA>
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>&ldquo;Humanized&rdquo; refers to a non-human polypeptide sequence that has been modified to minimize immunoreactivity in humans, typically by altering the amino acid sequence to mimic existing human sequences, without substantially altering the function of the polypeptide sequence (see, e.g., Jones et al., </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>321:522-525 (1986), and published UK patent application No. 8707252). Backbone sequences for the zinc finger proteins are preferably be selected from existing human C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>zinc finger proteins (e.g., SP-1). Functional domains are preferably selected from existing human genes, (e.g., the activation domain from the p65 subunit of NF-&kgr;B). Where possible, the recognition helix sequences will be selected from the thousands of existing zinc finger protein DNA recognition domains provided by sequencing the human genome. As much as possible, domains will be combined as units from the same existing proteins. All of these steps will minimize the introduction of new junctional epitopes in the chimeric zinc finger proteins and render the engineered zinc finger proteins less immunogenic.</PDAT></PTEXT></PARA>
<PARA ID="P-00059" LVL="0"><PTEXT><PDAT>&ldquo;Nucleic acid&rdquo; refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs). Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide. The nucleotide sequences are displayed herein in the conventional 5&prime;-3&prime; orientation.</PDAT></PTEXT></PARA>
<PARA ID="P-00060" LVL="0"><PTEXT><PDAT>The terms &ldquo;polypeptide,&rdquo; &ldquo;peptide&rdquo; and &ldquo;protein&rdquo; are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an analog or mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. Polypeptides can be modified, e.g., by the addition of carbohydrate residues to form glycoproteins. The terms &ldquo;polypeptide,&rdquo; &ldquo;peptide&rdquo; and &ldquo;protein&rdquo; include glycoproteins, as well as non-glycoproteins. The polypeptide sequences are displayed herein in the conventional N-terminal to C-terminal orientation.</PDAT></PTEXT></PARA>
<PARA ID="P-00061" LVL="0"><PTEXT><PDAT>The term &ldquo;amino acid&rdquo; refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an &agr; carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine, and methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00062" LVL="0"><PTEXT><PDAT>&ldquo;Conservatively modified variants&rdquo; applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., </PDAT><HIL><ITALIC><PDAT>Nucleic Acid Res. </PDAT></ITALIC></HIL><PDAT>19:5081(1991); Ohtsuka et al., </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>260:2605-2608 (1985); Rossolini et al., </PDAT><HIL><ITALIC><PDAT>Mol. Cell. Probes </PDAT></ITALIC></HIL><PDAT>8:91-98 (1994)). Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon in an amino acid herein, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are &ldquo;silent variations,&rdquo; which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.</PDAT></PTEXT></PARA>
<PARA ID="P-00063" LVL="0"><PTEXT><PDAT>As to amino acid and nucleic acid sequences, individual substitutions, deletions or additions that alter, add or delete a single amino acid or nucleotide or a small percentage of amino acids or nucleotides in the sequence create a &ldquo;conservatively modified variant,&rdquo; where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants and alleles of the invention.</PDAT></PTEXT></PARA>
<PARA ID="P-00064" LVL="0"><PTEXT><PDAT>The following groups each contain amino acids that are conservative substitutions for one another:</PDAT></PTEXT></PARA>
<PARA ID="P-00065" LVL="2"><PTEXT><PDAT>1) Alanine (A), Glycine (G);</PDAT></PTEXT></PARA>
<PARA ID="P-00066" LVL="2"><PTEXT><PDAT>2) Serine (S), Threonine (T);</PDAT></PTEXT></PARA>
<PARA ID="P-00067" LVL="2"><PTEXT><PDAT>3) Aspartic acid (D), Glutamic acid (E);</PDAT></PTEXT></PARA>
<PARA ID="P-00068" LVL="2"><PTEXT><PDAT>4) Asparagine (N), Glutamine (Q);</PDAT></PTEXT></PARA>
<PARA ID="P-00069" LVL="2"><PTEXT><PDAT>5) Cysteine (C), Methionine (M);</PDAT></PTEXT></PARA>
<PARA ID="P-00070" LVL="2"><PTEXT><PDAT>6) Arginine (R), Lysine (K), Histidine (H);</PDAT></PTEXT></PARA>
<PARA ID="P-00071" LVL="2"><PTEXT><PDAT>7) Isoleucine (I), Leucine (L), Valine (V); and</PDAT></PTEXT></PARA>
<PARA ID="P-00072" LVL="2"><PTEXT><PDAT>8) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).</PDAT></PTEXT></PARA>
<PARA ID="P-00073" LVL="7"><PTEXT><PDAT>(see, e.g., Creighton, </PDAT><HIL><ITALIC><PDAT>Proteins </PDAT></ITALIC></HIL><PDAT>(1984) for a discussion of amino acid properties).</PDAT></PTEXT></PARA>
<PARA ID="P-00074" LVL="7"><PTEXT><PDAT>III. Design of Zinc Finger Proteins</PDAT></PTEXT></PARA>
<PARA ID="P-00075" LVL="0"><PTEXT><PDAT>The chimeric zinc finger proteins of the invention comprise at least one zinc finger polypeptide linked via a flexible linker to at least a second DNA binding domain, which optionally is a second zinc finger polypeptide. The chimeric zinc finger protein may contain more than two DNA-binding domains, as well as one or more regulator domains. The zinc finger polypeptides of the invention can be engineered to recognize a selected target site in the gene of choice. Typically, a backbone from any suitable C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>ZFP, such as SP-1, SP-1C, or ZIF268, is used as the scaffold for the engineered zinc finger polypeptides (see, e.g., Jacobs, </PDAT><HIL><ITALIC><PDAT>EMBO J </PDAT></ITALIC></HIL><PDAT>11:4507 (1992); Desjarlais &amp; Berg, </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>90:2256-2260 (1993)). A number of methods can then be used to design and select a zinc finger polypeptide with high affinity for its target. A zinc finger polypeptide can be designed or selected to bind to any suitable target site in the target gene, with high affinity. WO 00/42219, herein incorporated by reference, comprehensively describes methods for design, construction, and expression of zinc finger polypeptides for selected target sites.</PDAT></PTEXT></PARA>
<PARA ID="P-00076" LVL="0"><PTEXT><PDAT>Any suitable method known in the art can be used to design and construct nucleic acids encoding zinc finger polypeptides, e.g., phage display, random mutagenesis, combinatorial libraries, computer/rational design, affinity selection, PCR, cloning from cDNA or genomic libraries, synthetic construction and the like. (see, e.g., U.S. Pat. No. 5,786,538; Wu et al., </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>92:344-348 (1995); Jamieson et al., </PDAT><HIL><ITALIC><PDAT>Biochemistry </PDAT></ITALIC></HIL><PDAT>33:5689-5695 (1994); Rebar &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>263:671-673 (1994); Choo &amp; Klug, </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>91:11163-11167 (1994); Choo &amp; Klug, </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>91: 11168-11172 (1994); Desjarlais &amp; Berg, </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>90:2256-2260 (1993); Desjarlais &amp; Berg, </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>89:7345-7349 (1992); Pomerantz et al., </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>267:93-96 (1995); Pomerantz et al., </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>92:9752-9756 (1995); and Liu et al., </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>94:5525-5530 (1997); Griesman &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>275:657-661(1997); Desjarlais &amp; Berg, </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>91:11-99-11103 (1994)).</PDAT></PTEXT></PARA>
<PARA ID="P-00077" LVL="0"><PTEXT><PDAT>In a preferred embodiment, WO 00/42219 provides methods that select a target gene, and identify a target site within the gene containing one to six (or more) D-able sites (see definition below). Using these methods, a zinc finger polypeptide can then be synthesized that binds to the preselected site. These methods of target site selection are premised, in part, on the recognition that the presence of one or more D-able sites in a target segment confers the potential for higher binding affinity in a zinc finger polypeptide selected or designed to bind to that site relative to zinc finger polypeptides that bind to target segments lacking D-able sites.</PDAT></PTEXT></PARA>
<PARA ID="P-00078" LVL="0"><PTEXT><PDAT>A D-able site or subsite is a region of a target site that allows an appropriately designed single zinc finger to bind to four bases rather than three of the target site. Such a zinc finger binds to a triplet of bases on one strand of a double-stranded target segment (target strand) and a fourth base on the other strand (see </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> of WO 00/42219). Binding of a single zinc finger to a four base target segment imposes constraints both on the sequence of the target strand and on the amino acid sequence of the zinc finger. The target site within the target strand should include the &ldquo;D-able&rdquo; site motif 5&prime; NNGK 3&prime;, in which N and K are conventional IUPAC-IUB ambiguity codes. A zinc finger for binding to such a site should include an arginine residue at position &minus;1 and an aspartic acid (or less preferably a glutamic acid) at position &plus;2. The arginine residues at position &minus;1 interacts with the G residue in the D-able site. The aspartic acid (or glutamic acid) residue at position &plus;2 of the zinc finger interacts with the opposite strand base complementary to the K base in the D-able site. It is the interaction between aspartic acid (symbol D) and the opposite strand base (fourth base) that confers the name D-able site. As is apparent from the D-able site formula, there are two subtypes of D-able sites: 5&prime; NNGG 3&prime; and 5&prime; NNGT 3&prime;. For the former site, the aspartic acid or glutamic acid at position &plus;2 of a zinc finger interacts with a C in the opposite strand to the D-able site. In the latter site, the aspartic acid or glutamic acid at position &plus;2 of a zinc finger interacts with an A in the opposite strand to the D-able site. In general, NNGG is preferred over NNGT.</PDAT></PTEXT></PARA>
<PARA ID="P-00079" LVL="0"><PTEXT><PDAT>In the design of a zinc finger polypeptide with three fingers, a target site should be selected in which at least one finger of the protein, and optionally, two or all three fingers have the potential to bind a D-able site. Such can be achieved by selecting a target site from within a larger target gene having the formula 5&prime;-NNx aNy bNzc-3&prime;, wherein</PDAT></PTEXT></PARA>
<PARA ID="P-00080" LVL="2"><PTEXT><PDAT>each of the sets (x, a), (y, b) and (z, c) is either (N, N) or (G, K);</PDAT></PTEXT></PARA>
<PARA ID="P-00081" LVL="2"><PTEXT><PDAT>at least one of (x, a), (y, b) and (z, c) is (G, K). and</PDAT></PTEXT></PARA>
<PARA ID="P-00082" LVL="2"><PTEXT><PDAT>N and K are IUPAC-IUB ambiguity codes</PDAT></PTEXT></PARA>
<PARA ID="P-00083" LVL="0"><PTEXT><PDAT>In other words, at least one of the three sets (x, a), (y, b) and (z, c) is the set (G, K), meaning that the first position of the set is G and the second position is G or T. Those of the three sets (if any) which are not (G, K) are (N, N), meaning that the first position of the set can be occupied by any nucleotide and the second position of the set can be occupied by any nucleotide. As an example, the set (x, a) can be (G, K) and the sets (y, b) and (z, c) can both be (N, N).</PDAT></PTEXT></PARA>
<PARA ID="P-00084" LVL="0"><PTEXT><PDAT>In the formula 5&prime;-NNx aNy bNzc-3&prime;, the triplets of NNx aNy and bNzc represent the triplets of bases on the target strand bound by the three fingers in a zinc finger polypeptide. If only one of x, y and z is a G, and this G is followed by a K, the target site includes a single D-able subsite. For example, if only x is G, and a is K, the site reads 5&prime;-NNG KNy bNzc-3&prime; with the D-able subsite highlighted. If both x and y but not z are G, and a and b are K, then the target site has two overlapping D-able subsites as follows: 5&prime;-NNG KNG KNz c-3&prime; (SEQ ID NO:22), with one such site being represented in bold and the other in italics. If all three of x, y and z are G and a, b, and c are K, then the target segment includes three D-able subsites, as follows 5&prime;NNG KNG </PDAT><HIL><ULINE><PDAT>KNG K</PDAT></ULINE></HIL><PDAT>3&prime; (SEQ ID NO:23), the D-able subsites being represented by bold, italics and underline.</PDAT></PTEXT></PARA>
<PARA ID="P-00085" LVL="0"><PTEXT><PDAT>These methods thus work by selecting a target gene, and systematically searching within the possible subsequences of the gene for target sites conforming to the formula 5&prime;-NNx aNy bNzc-3&prime;, as described above. In some such methods, every possible subsequence of 10 contiguous bases on either strand of a potential target gene is evaluated to determine whether it conforms to the above formula, and, if so, how many D-able sites are present. Typically, such a comparison is performed by computer, and a list of target sites conforming to the formula are output. Optionally, such target sites can be output in different subsets according to how many D-able sites are present.</PDAT></PTEXT></PARA>
<PARA ID="P-00086" LVL="0"><PTEXT><PDAT>In a variation, the methods of the invention identify first and second target segments, each independently conforming to the above formula. The two target segments in such methods are constrained to be adjacent or proximate (i.e., within about 0-5 bases) of each other in the target gene. The strategy underlying selection of proximate target segments is to allow the design of a zinc finger polypeptide formed by linkage of two component zinc finger polypeptides specific for the first and second target segments respectively. These principles can be extended to select target sites to be bound by zinc finger polypeptides with any number of component fingers. For example, a suitable target site for a nine finger protein would have three component segments, each conforming to the above formula.</PDAT></PTEXT></PARA>
<PARA ID="P-00087" LVL="0"><PTEXT><PDAT>The target sites identified by the above methods can be subject to further evaluation by other criteria or can be used directly for design or selection (if needed) and production of a zinc finger polypeptide specific for such a site. A further criteria for evaluating potential target sites is their proximity to particular regions within a gene. If a zinc finger polypeptide is to be used to repress a cellular gene on its own (i.e., without linking the zinc finger polypeptide to a repressing moiety), then the optimal location appears to be at, or within 50 bp upstream or downstream of the site of transcription initiation, to interfere with the formation of the transcription complex (Kim &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>272:29795-296800 (1997)) or compete for an essential enhancer binding protein. If, however, a zinc finger polypeptide is fused to a functional domain such as the KRAB repressor domain or the VP16 activator domain, the location of the binding site is considerably more flexible and can be outside known regulatory regions. For example, a KRAB domain can repress transcription at a promoter up to at least 3 kbp from where KRAB is bound (Margolin et al., </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>91:4509-4513 (1994)). Thus, target sites can be selected that do not necessarily include or overlap segments of demonstrable biological significance with target genes, such as regulatory sequences. Other criteria for further evaluating target segments include the prior availability of zinc finger polypeptide s binding to such segments or related segments, and/or ease of designing new zinc finger polypeptides to bind a given target segment.</PDAT></PTEXT></PARA>
<PARA ID="P-00088" LVL="0"><PTEXT><PDAT>After a target segment has been selected, a zinc finger polypeptide that binds to the segment can be provided by a variety of approaches. The simplest of approaches is to provide a precharacterized zinc finger polypeptide from an existing collection that is already known to bind to the target site. However, in many instances, such zinc finger polypeptides do not exist. An alternative approach can also be used to design new zinc finger polypeptides, which uses the information in a database of existing zinc finger polypeptides and their respective binding affinities. A further approach is to design a zinc finger polypeptide based on substitution rules as discussed above. A still further alternative is to select a zinc finger polypeptide with specificity for a given target by an empirical process such as phage display. In some such methods, each component finger of a zinc finger polypeptide is designed or selected independently of other component fingers. For example, each finger can be obtained from a different preexisting zinc finger polypeptide or each finger can be subject to separate randomization and selection.</PDAT></PTEXT></PARA>
<PARA ID="P-00089" LVL="0"><PTEXT><PDAT>Once a zinc finger polypeptide has been selected, designed, or otherwise provided to a given target segment, the zinc finger polypeptide or the DNA encoding it are synthesized. Exemplary methods for synthesizing and expressing DNA encoding zinc finger proteins are described below. The zinc finger polypeptide or a polynucleotide encoding it can then be used for modulation of expression, or analysis of the target gene containing the target site to which the zinc finger polypeptide binds.</PDAT></PTEXT></PARA>
<PARA ID="P-00090" LVL="7"><PTEXT><PDAT>IV. Expression and purification of zinc finger proteins made using the methods of the invention</PDAT></PTEXT></PARA>
<PARA ID="P-00091" LVL="0"><PTEXT><PDAT>Chimeric zinc finger proteins comprising a flexible linker and nucleic acids encoding such chimeric zinc finger proteins can be made using routine techniques in the field of recombinant genetics. Basic texts disclosing the general methods of use in this invention include Sambrook et al., </PDAT><HIL><ITALIC><PDAT>Molecular Cloning, A Laboratory Manual </PDAT></ITALIC></HIL><PDAT>(2nd ed. 1989); Kriegler, </PDAT><HIL><ITALIC><PDAT>Gene Transfer and Expression: A Laboratory Manual </PDAT></ITALIC></HIL><PDAT>(1990); and </PDAT><HIL><ITALIC><PDAT>Current Protocols in Molecular Biology </PDAT></ITALIC></HIL><PDAT>(Ausubel et al., eds., 1994)). In addition, essentially any nucleic acid can be custom ordered from any of a variety of commercial sources. Similarly, peptides and antibodies can be custom ordered from any of a variety of commercial sources.</PDAT></PTEXT></PARA>
<PARA ID="P-00092" LVL="0"><PTEXT><PDAT>Two alternative methods are typically used to create the coding sequences required to express newly designed DNA-binding polypeptides and the flexible linker. One protocol is a PCR-based assembly procedure that utilizes six overlapping oligonucleotides (to make one three finger zinc finger polypeptide). Three oligonucleotides correspond to &ldquo;universal&rdquo; sequences that encode portions of the DNA-binding domain between the recognition helices. These oligonucleotides remain constant for all zinc finger constructs. The other three &ldquo;specific&rdquo; oligonucleotides are designed to encode the recognition helices. These oligonucleotides contain substitutions primarily at positions &minus;1, 2, 3 and 6 on the recognition helices making them specific for each of the different zinc fingers.</PDAT></PTEXT></PARA>
<PARA ID="P-00093" LVL="0"><PTEXT><PDAT>To make a three finger zinc finger polypeptide, the PCR synthesis is carried out in two steps. First, a double stranded DNA template is created by combining the six oligonucleotides (three universal, three specific) in a four cycle PCR reaction with a low temperature annealing step, thereby annealing the oligonucleotides to form a DNA &ldquo;scaffold.&rdquo; The gaps in the scaffold are filled in by high-fidelity thermostable polymerase, the combination of Taq and Pfu polymerases also suffices. In the second phase of construction, the zinc finger template is amplified by external primers designed to incorporate restriction sites at either end for cloning into a shuttle vector or directly into an expression vector.</PDAT></PTEXT></PARA>
<PARA ID="P-00094" LVL="0"><PTEXT><PDAT>An alternative method of cloning the newly designed DNA-binding proteins relies on annealing complementary oligonucleotides encoding the specific regions of the desired chimeric zinc finger protein. This particular application requires that the oligonucleotides be phosphorylated prior to the final ligation step. This is usually performed before setting up the annealing reactions, but kinasing can also occur post-annealing. In brief, the &ldquo;universal&rdquo; oligonucleotides encoding the constant regions of the proteins (oligos 1, 2 and 3 of above) are annealed with their complementary oligonucleotides. Additionally, the &ldquo;specific&rdquo; oligonucleotides encoding the finger recognition helices are annealed with their respective complementary oligonucleotides. These complementary oligos are designed to fill in the region which was previously filled in by polymerase in the protocol described above. The complementary oligos to the common oligos 1 and finger 3 are engineered to leave overhanging sequences specific for the restriction sites used in cloning into the vector of choice. The second assembly protocol differs from the initial protocol in the following aspects: the &ldquo;scaffold&rdquo; encoding the newly designed ZFP is composed entirely of synthetic DNA thereby eliminating the polymerase fill-in step, additionally the fragment to be cloned into the vector does not require amplification. Lastly, the design of leaving sequence-specific overhangs eliminates the need for restriction enzyme digests of the inserting fragment.</PDAT></PTEXT></PARA>
<PARA ID="P-00095" LVL="0"><PTEXT><PDAT>The resulting fragment encoding the newly designed zinc finger polypeptide is ligated into an expression vector. The sequences encoding the flexible linker and the second DNA-binding domain (optionally a zinc finger polypeptide) are also ligated into the vector to create a chimeric zinc finger proteins. Typically, the flexible linker is encoded by a oligonucleotide that is ligated into the expression vector between the two DNA binding domains. The second DNA binding domain can be made as described above, or can be cloned or obtained from an alternative source using methods well known in the art, e.g., PCR and the like. Expression vectors that are commonly utilized include, but are not limited to, a modified pMAL-c2 bacterial expression vector (New England BioLabs, &ldquo;NEB&rdquo;) or a eukaryotic expression vector, pcDNA (Promega).</PDAT></PTEXT></PARA>
<PARA ID="P-00096" LVL="0"><PTEXT><PDAT>The nucleic acid encoding the chimeric zinc finger protein of choice is typically cloned into intermediate vectors for transformation into prokaryotic or eukaryotic cells for replication and/or expression, e.g., for determination of K</PDAT><HIL><SB><PDAT>d</PDAT></SB></HIL><PDAT>. Intermediate vectors are typically prokaryote vectors, e.g., plasmids, or shuttle vectors, or insect vectors, for storage or manipulation of the nucleic acid encoding zinc finger protein or production of protein. The nucleic acid encoding a zinc finger protein is also typically cloned into an expression vector, for administration to a plant cell, animal cell, preferably a mammalian cell or a human cell, fungal cell, bacterial cell, or protozoal cell.</PDAT></PTEXT></PARA>
<PARA ID="P-00097" LVL="0"><PTEXT><PDAT>To obtain expression of a cloned gene or nucleic acid, a chimeric zinc finger protein is typically subcloned into an expression vector that contains a promoter to direct transcription. Suitable bacterial and eukaryotic promoters are well known in the art and described, e.g., in Sambrook et al., </PDAT><HIL><ITALIC><PDAT>Molecular Cloning, A Laboratory Manual </PDAT></ITALIC></HIL><PDAT>(2nd ed. 1989); Kriegler, </PDAT><HIL><ITALIC><PDAT>Gene Transfer and Expression: A Laboratory Manual </PDAT></ITALIC></HIL><PDAT>(1990); and </PDAT><HIL><ITALIC><PDAT>Current Protocols in Molecular Biology </PDAT></ITALIC></HIL><PDAT>(Ausubel et al., eds., 1994). Bacterial expression systems for expressing the zinc finger protein are available in, e.g., </PDAT><HIL><ITALIC><PDAT>E. coli, </PDAT></ITALIC></HIL><PDAT>Bacillus sp., and Salmonella (Palva et al., </PDAT><HIL><ITALIC><PDAT>Gene </PDAT></ITALIC></HIL><PDAT>22:229-235 (1983)). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available.</PDAT></PTEXT></PARA>
<PARA ID="P-00098" LVL="0"><PTEXT><PDAT>The promoter used to direct expression of a chimeric zinc finger protein nucleic acid depends on the particular application. For example, a strong constitutive promoter is typically used for expression and purification of zinc finger protein. In contrast, when a zinc finger protein is administered in vivo for gene regulation, either a constitutive or an inducible promoter is used, depending on the particular use of the zinc finger protein. The promoter typically can also include elements that are responsive to transactivation, e.g., hypoxia response elements, Gal4 response elements, lac repressor response element, and small molecule control systems such as tet-regulated systems and the RU-486 system (see, e.g., Gossen &amp; Bujard, </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. U.S.A. </PDAT></ITALIC></HIL><PDAT>89:5547 (1992); Oligino et al., </PDAT><HIL><ITALIC><PDAT>Gene Ther. </PDAT></ITALIC></HIL><PDAT>5:491-496 (1998); Wang et al., </PDAT><HIL><ITALIC><PDAT>Gene Ther. </PDAT></ITALIC></HIL><PDAT>4:432-441 (1997); Neering et al., </PDAT><HIL><ITALIC><PDAT>Blood </PDAT></ITALIC></HIL><PDAT>88:1147-1155 (1996); and Rendahl et al., </PDAT><HIL><ITALIC><PDAT>Nat. Biotechnol. </PDAT></ITALIC></HIL><PDAT>16:757-761 (1998)).</PDAT></PTEXT></PARA>
<PARA ID="P-00099" LVL="0"><PTEXT><PDAT>In addition to the promoter, the expression vector typically contains a transcription unit or expression cassette that contains all the additional elements required for the expression of the nucleic acid in host cells, either prokaryotic or eukaryotic. A typical expression cassette thus contains a promoter operably linked, e.g., to the nucleic acid sequence encoding the zinc finger protein, and signals required, e.g., for efficient polyadenylation of the transcript, transcriptional termination, ribosome binding sites, or translation termination. Additional elements of the cassette may include, e.g., enhancers, and heterologous spliced intronic signals.</PDAT></PTEXT></PARA>
<PARA ID="P-00100" LVL="0"><PTEXT><PDAT>The particular expression vector used to transport the genetic information into the cell is selected with regard to the intended use of the zinc finger protein, e.g., expression in plants, animals, bacteria, fungus, protozoa, etc. Standard bacterial expression vectors include plasmids such as pBR322 based plasmids, pSKF, pET23D, and commercially available fusion expression systems such as GST and LacZ. A preferred fusion protein is the maltose binding protein, &ldquo;MBP.&rdquo; Such fusion proteins are used for purification of the zinc finger protein. Epitope tags can also be added to recombinant proteins to provide convenient methods of isolation, for monitoring expression, and for monitoring cellular and subcellular localization, e.g., c-myc or FLAG.</PDAT></PTEXT></PARA>
<PARA ID="P-00101" LVL="0"><PTEXT><PDAT>Expression vectors containing regulatory elements from eukaryotic viruses are often used in eukaryotic expression vectors, e.g., SV40 vectors, papilloma virus vectors, and vectors derived from Epstein-Barr virus. Other exemplary eukaryotic vectors include pMSG, pAV009/A&plus;, pMTO10/A&plus;, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the SV40 early promoter, SV40 late promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.</PDAT></PTEXT></PARA>
<PARA ID="P-00102" LVL="0"><PTEXT><PDAT>Some expression systems have markers for selection of stably transfected cell lines such as thymidine kinase, hygromycin B phosphotransferase, and dihydrofolate reductase. High yield expression systems are also suitable, such as using a baculovirus vector in insect cells, with a zinc finger protein encoding sequence under the direction of the polyhedrin promoter or other strong baculovirus promoters.</PDAT></PTEXT></PARA>
<PARA ID="P-00103" LVL="0"><PTEXT><PDAT>The elements that are typically included in expression vectors also include a replicon that functions in </PDAT><HIL><ITALIC><PDAT>E. coli, </PDAT></ITALIC></HIL><PDAT>a gene encoding antibiotic resistance to permit selection of bacteria that harbor recombinant plasmids, and unique restriction sites in nonessential regions of the plasmid to allow insertion of recombinant sequences.</PDAT></PTEXT></PARA>
<PARA ID="P-00104" LVL="0"><PTEXT><PDAT>Standard transfection methods are used to produce bacterial, mammalian, yeast or insect cell lines that express large quantities of protein, which are then purified using standard techniques (see, e.g., Colley et al., </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>264:17619-17622 (1989); </PDAT><HIL><ITALIC><PDAT>Guide to Protein Purification, in Methods in Enzymology, </PDAT></ITALIC></HIL><PDAT>vol. 182 (Deutscher, ed., 1990)). Transformation of eukaryotic and prokaryotic cells are performed according to standard techniques (see, e.g., Morrison, </PDAT><HIL><ITALIC><PDAT>J. Bact. </PDAT></ITALIC></HIL><PDAT>132:349-351 (1977); Clark-Curtiss &amp; Curtiss, </PDAT><HIL><ITALIC><PDAT>Methods in Enzymology </PDAT></ITALIC></HIL><PDAT>101:347-362 (Wu et al., eds, 1983).</PDAT></PTEXT></PARA>
<PARA ID="P-00105" LVL="0"><PTEXT><PDAT>Any of the well known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, liposomes, microinjection, naked DNA, plasmid vectors, viral vectors, both episomal and integrative, and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Sambrook et al., supra). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing the protein of choice.</PDAT></PTEXT></PARA>
<PARA ID="P-00106" LVL="0"><PTEXT><PDAT>Any suitable method of protein purification known to those of skill in the art can be used to purify the chimeric zinc finger proteins of the invention (see Ausubel, supra, Sambrook, supra). In addition, any suitable host can be used, e.g., bacterial cells, insect cells, yeast cells, mammalian cells, and the like.</PDAT></PTEXT></PARA>
<PARA ID="P-00107" LVL="0"><PTEXT><PDAT>In one embodiment, expression of the zinc finger protein fused to a maltose binding protein (MBP-zinc finger protein) in bacterial strain JM109 allows for straightforward purification through an amylose column (NEB). High expression levels of the chimeric zinc finger protein can be obtained by induction with IPTG since the MBP-zinc finger protein fusion in the pMa1-c2 expression plasmid is under the control of the IPTG inducible tac promoter (NEB). Bacteria containing the MBP-zinc finger protein fusion plasmids are inoculated in to 2xYT medium containing 10 &mgr;M ZnCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, 0.02% glucose, plus 50 &mgr;g/ml ampicillin and shaken at 37&deg; C. At mid-exponential growth IPTG is added to 0.3 mM and the cultures are allowed to shake. After 3 hours the bacteria are harvested by centrifugation, disrupted by sonication, and then insoluble material is removed by centrifugation. The MBP-zinc finger protein proteins are captured on an amylose-bound resin, washed extensively with buffer containing 20 mM Tris-HCl (pH 7.5), 200 mM NaCl, 5 mM DTT and 50 &mgr;M ZnCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, then eluted with maltose in essentially the same buffer (purification is based on a standard protocol from NEB). Purified proteins are quantitated and stored for biochemical analysis.</PDAT></PTEXT></PARA>
<PARA ID="P-00108" LVL="0"><PTEXT><PDAT>The biochemical properties of the purified proteins, e.g., K</PDAT><HIL><SB><PDAT>d</PDAT></SB></HIL><PDAT>, can be characterized by any suitable assay. In one embodiment, K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>is characterized via electrophoretic mobility shift assays (&ldquo;EMSA&rdquo;) (Buratowski &amp; Chodosh, in </PDAT><HIL><ITALIC><PDAT>Current Protocols in Molecular Biology </PDAT></ITALIC></HIL><PDAT>pp. 12.2.1-12.2.7 (Ausubel ed., 1996)).</PDAT></PTEXT></PARA>
<PARA ID="P-00109" LVL="7"><PTEXT><PDAT>V. Regulatory domains</PDAT></PTEXT></PARA>
<PARA ID="P-00110" LVL="0"><PTEXT><PDAT>The chimeric zinc finger proteins made using the methods of the invention can optionally be associated with regulatory domains for modulation of gene expression. The chimeric zinc finger protein can be covalently or non-covalently associated with one or more regulatory domains, alternatively two or more regulatory domains, with the two or more domains being two copies of the same domain, or two different domains. The regulatory domains can be covalently linked to the chimeric zinc finger protein, e.g., via an amino acid linker, as part of a fusion protein. The zinc finger proteins can also be associated with a regulatory domain via a non-covalent dimerization domain, e.g., a leucine zipper, a STAT protein N terminal domain, or an FK506 binding protein (see, e.g., O&apos;Shea, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>254: 539 (1991), Barahmand-Pour et al., </PDAT><HIL><ITALIC><PDAT>Curr. Top. Microbiol. Immunol. </PDAT></ITALIC></HIL><PDAT>211:121-128 (1996); Klemm et al., </PDAT><HIL><ITALIC><PDAT>Annu. Rev. Immunol. </PDAT></ITALIC></HIL><PDAT>16:569-592 (1998); Klemm et al., </PDAT><HIL><ITALIC><PDAT>Annu. Rev. Immunol. </PDAT></ITALIC></HIL><PDAT>16:569-592 (1998); Ho et al., </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>382:822-826 (1996); and Pomeranz et al., </PDAT><HIL><ITALIC><PDAT>Biochem. </PDAT></ITALIC></HIL><PDAT>37:965 (1998)). The regulatory domain can be associated with the chimeric zinc finger protein at any suitable position, including the C- or N-terminus of the chimeric zinc finger protein.</PDAT></PTEXT></PARA>
<PARA ID="P-00111" LVL="0"><PTEXT><PDAT>Common regulatory domains for addition to the chimeric zinc finger protein made using the methods of the invention include, e.g., heterologous DNA binding domains from transcription factors, effector domains from transcription factors (activators, repressors, co-activators, co-repressors), silencers, nuclear hormone receptors, oncogene transcription factors (e.g., myc, jun, fos, myb, max, mad, rel, ets, bcl, myb, mos family members etc.); and chromatin associated proteins and their modifiers (e.g., kinases, acetylases and deacetylases).</PDAT></PTEXT></PARA>
<PARA ID="P-00112" LVL="0"><PTEXT><PDAT>Transcription factor polypeptides from which one can obtain a regulatory domain include those that are involved in regulated and basal transcription. Such polypeptides include transcription factors, their effector domains, coactivators, silencers, nuclear hormone receptors (see, e.g., Goodrich et al., </PDAT><HIL><ITALIC><PDAT>Cell </PDAT></ITALIC></HIL><PDAT>84:825-30 (1996) for a review of proteins and nucleic acid elements involved in transcription; transcription factors in general are reviewed in Barnes &amp; Adcock, </PDAT><HIL><ITALIC><PDAT>Clin. Exp. Allergy </PDAT></ITALIC></HIL><PDAT>25 Suppl. 2:46-9 (1995) and Roeder, </PDAT><HIL><ITALIC><PDAT>Methods Enzymol. </PDAT></ITALIC></HIL><PDAT>273:165-71 (1996)). Databases dedicated to transcription factors are also known (see, e.g., </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>269:630 (1995)). Nuclear hormone receptor transcription factors are described in, for example, Rosen et al., </PDAT><HIL><ITALIC><PDAT>J. Med. Chem. </PDAT></ITALIC></HIL><PDAT>38:4855-74 (1995). The C/EBP family of transcription factors are reviewed in Wedel et al., </PDAT><HIL><ITALIC><PDAT>Immunobiology </PDAT></ITALIC></HIL><PDAT>193:171-85 (1995). Coactivators and co-repressors that mediate transcription regulation by nuclear hormone receptors are reviewed in, for example, Meier, </PDAT><HIL><ITALIC><PDAT>Eur. J. Endocrinol. </PDAT></ITALIC></HIL><PDAT>134(2):158-9 (1996); Kaiser et al., </PDAT><HIL><ITALIC><PDAT>Trends Biochem. Sci. </PDAT></ITALIC></HIL><PDAT>21:342-5 (1996); and Utley et al., </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>394:498-502 (1998)). GATA transcription factors, which are involved in regulation of hematopoiesis, are described in, for example, Simon, </PDAT><HIL><ITALIC><PDAT>Nat. Genet. </PDAT></ITALIC></HIL><PDAT>11:9-11 (1995); Weiss et al., </PDAT><HIL><ITALIC><PDAT>Exp. Hematol. </PDAT></ITALIC></HIL><PDAT>23:99-107. TATA box binding protein (TBP) and its associated TAF polypeptides (which include TAF30, TAF55, TAF80, TAF110, TAF150, and TAF250) are described in Goodrich &amp; Tjian, </PDAT><HIL><ITALIC><PDAT>Curr. Opin. Cell Biol. </PDAT></ITALIC></HIL><PDAT>6:403-9 (1994) and Hurley, </PDAT><HIL><ITALIC><PDAT>Curr. Opin. Struct. Biol. </PDAT></ITALIC></HIL><PDAT>6:69-75 (1996). The STAT family of transcription factors are reviewed in, for example, Barahmand-Pour et al., </PDAT><HIL><ITALIC><PDAT>Curr. Top. Microbiol. Immunol. </PDAT></ITALIC></HIL><PDAT>211:121-8 (1996). Transcription factors involved in disease are reviewed in Aso et al., </PDAT><HIL><ITALIC><PDAT>J. Clin. Invest. </PDAT></ITALIC></HIL><PDAT>97:1561-9 (1996).</PDAT></PTEXT></PARA>
<PARA ID="P-00113" LVL="0"><PTEXT><PDAT>In one embodiment, the KRAB repression domain from the human KOX-1 protein is used as a transcriptional repressor (Thiesen et al., </PDAT><HIL><ITALIC><PDAT>New Biologist </PDAT></ITALIC></HIL><PDAT>2:363-374 (1990); Margolin et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. U.S.A. </PDAT></ITALIC></HIL><PDAT>91:4509-4513 (1994); Pengue et al., </PDAT><HIL><ITALIC><PDAT>Nucl. Acids Res. </PDAT></ITALIC></HIL><PDAT>22:2908-2914 (1994); Witzgall et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. U.S.A. </PDAT></ITALIC></HIL><PDAT>91:4514-4518 (1994)). In another embodiment, KAP-1, a KRAB co-repressor, is used with KRAB (Friedman et al., </PDAT><HIL><ITALIC><PDAT>Genes Dev. </PDAT></ITALIC></HIL><PDAT>10:2067-2078 (1996)). Alternatively, KAP-1 can be used alone with a zinc finger protein. Other preferred transcription factors and transcription factor domains that act as transcriptional repressors include MAD (see, e.g., Sommer et al., </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>273:6632-6642 (1998); Gupta et al., </PDAT><HIL><ITALIC><PDAT>Oncogene </PDAT></ITALIC></HIL><PDAT>16:1149-1159 (1998); Queva et al., </PDAT><HIL><ITALIC><PDAT>Oncogene </PDAT></ITALIC></HIL><PDAT>16:967-977 (1998); Larsson et al., </PDAT><HIL><ITALIC><PDAT>Oncogene </PDAT></ITALIC></HIL><PDAT>15:737-748 (1997); Laherty et al., </PDAT><HIL><ITALIC><PDAT>Cell </PDAT></ITALIC></HIL><PDAT>89:349-356 (1997); and Cultraro et al., </PDAT><HIL><ITALIC><PDAT>Mol Cell. Biol. </PDAT></ITALIC></HIL><PDAT>17:2353-2359 (19977)); FKHR (forkhead in rhapdosarcoma gene; Ginsberg et al., </PDAT><HIL><ITALIC><PDAT>Cancer Res. </PDAT></ITALIC></HIL><PDAT>15:3542-3546 (1998); Epstein et al., </PDAT><HIL><ITALIC><PDAT>Mol. Cell. Biol. </PDAT></ITALIC></HIL><PDAT>18:4118-4130 (1998)); EGR-1 (early growth response gene product-1; Yan et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. U.S.A. </PDAT></ITALIC></HIL><PDAT>95:8298-8303 (1998); and Liu et al., </PDAT><HIL><ITALIC><PDAT>Cancer Gene Ther. </PDAT></ITALIC></HIL><PDAT>5:3-28 (1998)); the ets2 repressor factor repressor domain (ERD; Sgouras et al., </PDAT><HIL><ITALIC><PDAT>EMBO J. </PDAT></ITALIC></HIL><PDAT>14:4781-4793 ((19095)); and the MAD smSIN3 interaction domain (SID; Ayer et al., </PDAT><HIL><ITALIC><PDAT>Mol. Cell. Biol. </PDAT></ITALIC></HIL><PDAT>16:5772-5781 (1996)).</PDAT></PTEXT></PARA>
<PARA ID="P-00114" LVL="0"><PTEXT><PDAT>In one embodiment, the HSV VP16 activation domain is used as a transcriptional activator (see, e.g., Hagmann et al., </PDAT><HIL><ITALIC><PDAT>J. Virol. </PDAT></ITALIC></HIL><PDAT>71:5952-5962 (1997)). Other preferred transcription factors that could supply activation domains include the VP64 activation domain (Seipel et al., </PDAT><HIL><ITALIC><PDAT>EMBO J. </PDAT></ITALIC></HIL><PDAT>11:4961-4968 (1996)); nuclear hormone receptors (see, e.g., Torchia et al., </PDAT><HIL><ITALIC><PDAT>Curr. Opin. Cell. Biol. </PDAT></ITALIC></HIL><PDAT>10:373-383 (1998)); the p65 subunit of nuclear factor kappa B (Bitko &amp; Barik, </PDAT><HIL><ITALIC><PDAT>J. Virol. </PDAT></ITALIC></HIL><PDAT>72:5610-5618 (1998) and Doyle &amp; Hunt, </PDAT><HIL><ITALIC><PDAT>Neuroreport </PDAT></ITALIC></HIL><PDAT>8:2937-2942 (1997)); and EGR-1 (early growth response gene product-1; Yan et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. U.S.A. </PDAT></ITALIC></HIL><PDAT>95:8298-8303 (1998); and Liu et al., </PDAT><HIL><ITALIC><PDAT>Cancer Gene Ther. </PDAT></ITALIC></HIL><PDAT>5:3-28 (1998)).</PDAT></PTEXT></PARA>
<PARA ID="P-00115" LVL="0"><PTEXT><PDAT>Kinases, phosphatases, and other proteins that modify polypeptides involved in gene regulation are also useful as regulatory domains for chimeric zinc finger proteins. Such modifiers are often involved in switching on or off transcription mediated by, for example, hormones. Kinases involved in transcription regulation are reviewed in Davis, </PDAT><HIL><ITALIC><PDAT>Mol. Reprod. Dev. </PDAT></ITALIC></HIL><PDAT>42:459-67 (1995), Jackson et al., </PDAT><HIL><ITALIC><PDAT>Adv. Second Messenger Phosphoprotein Res. </PDAT></ITALIC></HIL><PDAT>28:279-86 (1993), and Boulikas, </PDAT><HIL><ITALIC><PDAT>Crit. Rev. Eukaryot. Gene Expr. </PDAT></ITALIC></HIL><PDAT>5:1-77 (1995), while phosphatases are reviewed in, for example, Schonthal &amp; Semin, </PDAT><HIL><ITALIC><PDAT>Cancer Biol. </PDAT></ITALIC></HIL><PDAT>6:239-48 (1995). Nuclear tyrosine kinases are described in Wang, </PDAT><HIL><ITALIC><PDAT>Trends Biochem. Sci. </PDAT></ITALIC></HIL><PDAT>19:373-6 (1994).</PDAT></PTEXT></PARA>
<PARA ID="P-00116" LVL="0"><PTEXT><PDAT>As described, useful domains can also be obtained from the gene products of oncogenes (e.g., myc, jun, fos, myb, max, mad, rel, ets, bcl, myb, mos family members) and their associated factors and modifiers. Oncogenes are described in, for example, Cooper, </PDAT><HIL><ITALIC><PDAT>Oncogenes, </PDAT></ITALIC></HIL><PDAT>2nd ed., The Jones and Bartlett Series in Biology, Boston, Mass., Jones and Bartlett Publishers, 1995. The ets transcription factors are reviewed in Waslylk et al., </PDAT><HIL><ITALIC><PDAT>Eur. J. Biochem. </PDAT></ITALIC></HIL><PDAT>211:7-18 (1993) and Crepieux et al., </PDAT><HIL><ITALIC><PDAT>Crit. Rev. Oncog. </PDAT></ITALIC></HIL><PDAT>5:615-38 (1994). Myc oncogenes are reviewed in, for example, Ryan et al., </PDAT><HIL><ITALIC><PDAT>Biochem. J. </PDAT></ITALIC></HIL><PDAT>314:713-21 (1996). The jun and fos transcription factors are described in, for example, </PDAT><HIL><ITALIC><PDAT>The Fos and Jun Families of Transcription Factors, </PDAT></ITALIC></HIL><PDAT>Angel &amp; Herrlich, eds. (1994). The max oncogene is reviewed in Hurlin et al., </PDAT><HIL><ITALIC><PDAT>Cold Spring Harb. Symp. Quant. Biol. </PDAT></ITALIC></HIL><PDAT>59:109-16. The myb gene family is reviewed in Kanei-Ishii et al., </PDAT><HIL><ITALIC><PDAT>Curr. Top. Microbiol. Immunol. </PDAT></ITALIC></HIL><PDAT>211:89-98 (1996). The mos family is reviewed in Yew et al., </PDAT><HIL><ITALIC><PDAT>Curr. Opin. Genet. Dev. </PDAT></ITALIC></HIL><PDAT>3:19-25 (1993).</PDAT></PTEXT></PARA>
<PARA ID="P-00117" LVL="0"><PTEXT><PDAT>In another embodiment, histone acetyltransferase is used as a transcriptional activator (see, e.g., Jin &amp; Scotto, </PDAT><HIL><ITALIC><PDAT>Mol. Cell. Biol. </PDAT></ITALIC></HIL><PDAT>18:4377-4384 (1998); Wolffe, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>272:371-372 (1996); Taunton et al., </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>272:408-411 (1996); and Hassig et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. U.S.A. </PDAT></ITALIC></HIL><PDAT>95:3519-3524 (1998)). In another embodiment, histone deacetylase is used as a transcriptional repressor (see, e.g., Jin &amp; Scotto, </PDAT><HIL><ITALIC><PDAT>Mol. Cell. Biol. </PDAT></ITALIC></HIL><PDAT>18:4377-4384 (1998); Syntichaki &amp; Thireos, </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>273:24414-24419 (1998); Sakaguchi et al., </PDAT><HIL><ITALIC><PDAT>Genes Dev. </PDAT></ITALIC></HIL><PDAT>12:2831-2841 (1998); and Martinez et al., </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>273:23781-23785 (1998)).</PDAT></PTEXT></PARA>
<PARA ID="P-00118" LVL="0"><PTEXT><PDAT>In addition to regulatory domains, often the chimeric zinc finger protein is expressed as a fusion protein such as maltose binding protein (&ldquo;MBP&rdquo;), glutathione S transferase (GST), hexahistidine, c-myc, and the FLAG epitope, for ease of purification, monitoring expression, or monitoring cellular and subcellular localization.</PDAT></PTEXT></PARA>
<PARA ID="P-00119" LVL="0"><PTEXT><PDAT>All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.</PDAT></PTEXT></PARA>
<PARA ID="P-00120" LVL="0"><PTEXT><PDAT>Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.</PDAT></PTEXT></PARA>
</BTEXT>
</DRWDESC>
<DETDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>EXAMPLES</PDAT></STEXT></H>
<PARA ID="P-00121" LVL="0"><PTEXT><PDAT>The following examples are provided by way of illustration only and not by way of limitation. Those of skill in the art will readily recognize a variety of noncritical parameters that could be changed or modified to yield essentially similar results.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>METHODS</PDAT></STEXT></H>
<PARA ID="P-00122" LVL="0"><PTEXT><PDAT>Plasmid construction. Zinc finger expression plasmids used in transfection studies were constructed by PCR amplification of DNA segments encoding the desired fingers of the Zif268 peptide and/or the NRE peptide. These DNA segments were inserted into the HindIII and BamHI sites of pCS, which had been constructed by subcloning an oligonucleotide duplex 5&prime;-AGCTACCATGGCCAAGGAAACCGCAGCTGCCAAAT TCGAAAGACAGCATATGGATTCTAAGCTTCGCGGATCCT-3&prime; (SEQ ID NO: 1) 5&prime;-CTAGAGGATCCGCGAAGCTTAGAATCCATATGCTGTCT TTCGAATTTGGCAGCTGCGGTTTCCTTGGCCATGGT-3&prime;) (SEQ ID NO: 2) into the HindIII and XbaI sites of pcDNA3 (Invitrogen). These expression plasmids were designed to produce zinc finger peptides with both an S-peptide tag (Kim &amp; Raines, </PDAT><HIL><ITALIC><PDAT>Protein Sci. </PDAT></ITALIC></HIL><PDAT>2:348-356(1993); Kim &amp; Raines, i. 219:165-166 (1995)) and a nuclear localization signal from SV40 large T-antigen (Kalderon et al., </PDAT><HIL><ITALIC><PDAT>Cell </PDAT></ITALIC></HIL><PDAT>39:499-509 (1984)) at their N-terminus. Reporter plasmid were constructed by site-directed mutagenesis using the QuikChangeTM kit (Stratagene). Construction of the template plasmid (pGL3-TATA/Inr) for the mutagenesis was described previously (Kim &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>272:29795-29800 (1997)). The DNA sequences of all constructs were confirmed by dideoxy sequencing.</PDAT></PTEXT></PARA>
<PARA ID="P-00123" LVL="0"><PTEXT><PDAT>Protein production and purification. The DNA segments encoding the Zif268, NRE, and 268//NRE peptides were amplified by PCR and subcloned into pGEX-6P-3 (Pharmacia). The zinc finger proteins were expressed in </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>as fusions with glutathione S-transferase (GST) and were purified using affinity chromatography according to the manufacturer&apos;s protocol. These constructs did not have an S-peptide tag or an SV40 nuclear localization signal. GST was subsequently removed by digestion with PreScission TM Protease (Pharmacia). Protein concentrations were estimated by using SDS-polyacrylamide gel electrophoresis with bovine serum albumin as a standard (Pomerantz et al., </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>267:93-96 (1995)). Concentrations of active zinc finger proteins were determined essentially as described (Rebar &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>263:671-673 (1994)). These two methods gave comparable results, indicating that almost all of the protein was active.</PDAT></PTEXT></PARA>
<PARA ID="P-00124" LVL="0"><PTEXT><PDAT>Gel shift assay. DNA binding reactions contained the appropriate zinc finger peptide and binding site(s) in a solution of 20 mM bis-Tris propane pH 7.0, 100 mM NaCl, 5 mM MgCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, 20 mM ZnSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>, 10% glycerol, 0.1% Nonidet P40, 5 mM DTT, and 0.10 mg/mL bovine serum albumin in a total volume of 10 mL. All binding experiments were performed at room temperature. The DNA sequences of the binding sites follow: N site, 5&prime;-TCTGC </PDAT><HIL><ULINE><PDAT>AAGGGTTCA</PDAT></ULINE></HIL><PDAT> GGCGACACCAACCAA-3&prime; (SEQ ID NO:3); Z site, 5&prime;-GTGTGTGTGTGATCT </PDAT><HIL><ULINE><PDAT>GCGTGGGCG</PDAT></ULINE></HIL><PDAT> GTAAG-3&prime; (SEQ ID NO:4); NZ site, 5&prime;-TCTGC </PDAT><HIL><ULINE><PDAT>AAGGGTTCA</PDAT></ULINE></HIL><HIL><ULINE><PDAT>GCGTGGGCG</PDAT></ULINE></HIL><PDAT> GTAAG-3&prime; (SEQ ID NO:5); N/Z site, 5&prime;-TCTGC </PDAT><HIL><ULINE><PDAT>AAGGGTTCA</PDAT></ULINE></HIL><PDAT> G </PDAT><HIL><ULINE><PDAT>GCGTGGGCG</PDAT></ULINE></HIL><PDAT> GTAAG-3&prime; (SEQ ID NO:6); and N//Z site, 5&prime;-TCTGC </PDAT><HIL><ULINE><PDAT>AAGGGTTCA</PDAT></ULINE></HIL><PDAT> GT </PDAT><HIL><ULINE><PDAT>GCGTGGGCG</PDAT></ULINE></HIL><PDAT> GTAAG-3&prime; (SEQ ID NO:7). In each case, the 9-bp recognition sequences are underlined. Labeled DNAs used in gel shift assays were prepared by Klenow extension or kinase reaction.</PDAT></PTEXT></PARA>
<PARA ID="P-00125" LVL="0"><PTEXT><PDAT>To determine dissociation constants, 3-fold serial dilutions of the Zif268 or NRE peptide were incubated with a labeled probe DNA (0.4-1.4 pM) at room temperature for 1 h, and then the reaction mixtures were subjected to gel electrophoresis. The radioactive signals were quantitated by phosphorimager analysis; apparent dissociation constants were determined as described (Rebar &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>263:671-673 (1994)).</PDAT></PTEXT></PARA>
<PARA ID="P-00126" LVL="0"><PTEXT><PDAT>On-rates and off-rates were also determined by gel shift assay. To initiate the binding reaction when determining on-rate constants, a labeled probe DNA (final concentration, &tilde;0.4 pM) was added to the zinc finger peptide (final concentration, 5-10 pM) at room temperature, and aliquots were analyzed by gel electrophoresis at various time points (0-20 min). The fraction bound at time t was determined by phosphorimager analysis of the gels. The data were then fit (KaleidaGraph&trade; program (Synergy Software)) to the equation:</PDAT></PTEXT></PARA>
<PARA ID="P-00127" LVL="0"><PTEXT><F><PTEXT><HIL><ITALIC><PDAT>F&equals;F</PDAT></ITALIC></HIL><HIL><SB><PDAT>final</PDAT></SB></HIL><PDAT>&lsqb;1&minus;</PDAT><HIL><ITALIC><PDAT>exp</PDAT></ITALIC></HIL><PDAT>(&minus;</PDAT><HIL><ITALIC><PDAT>k</PDAT></ITALIC></HIL><HIL><SB><PDAT>obs</PDAT></SB></HIL><HIL><ITALIC><PDAT>&times;t</PDAT></ITALIC></HIL><PDAT>)&rsqb;</PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00128" LVL="7"><PTEXT><PDAT>where F is the fraction bound at time t; F</PDAT><HIL><SB><PDAT>final </PDAT></SB></HIL><PDAT>is the calculated fraction bound at the completion of the reaction; and k</PDAT><HIL><SB><PDAT>obs </PDAT></SB></HIL><PDAT>is the rate constant (Hoopes et al., </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>267:11539-11547 (1992)). The on-rate constant was calculated from the equation:</PDAT></PTEXT></PARA>
<PARA ID="P-00129" LVL="0"><PTEXT><F><PTEXT><HIL><ITALIC><PDAT>k</PDAT></ITALIC></HIL><HIL><SB><PDAT>on</PDAT></SB></HIL><PDAT>&equals;(</PDAT><HIL><ITALIC><PDAT>F</PDAT></ITALIC></HIL><HIL><SB><PDAT>final</PDAT></SB></HIL><HIL><ITALIC><PDAT>&times;k</PDAT></ITALIC></HIL><HIL><SB><PDAT>obs</PDAT></SB></HIL><PDAT>)/&lsqb;</PDAT><HIL><ITALIC><PDAT>P&rsqb;</PDAT></ITALIC></HIL></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00130" LVL="7"><PTEXT><PDAT>where &lsqb;P&rsqb; is the concentration of the zinc finger protein. Off-rate constants were determined essentially as described (Kim et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>94:3616-3620 (1997)). Proteins (final concentration, 100 pM) were preincubated with a labeled probe DNA for 1 hour and then a large excess of unlabeled probe DNA (final concentration, 20 nM) was added. Aliquots were removed at various time points and analyzed by gel electrophoresis. The fraction of labeled site was normalized to the fraction found at the end of the 1 hour preincubation period. The natural log of the normalized fraction bound was plotted against time, and the off-rate was determined from the slope. All data points for fast on-rate and off-rate measurements were corrected for the electrophoresis dead time.</PDAT></PTEXT></PARA>
<PARA ID="P-00131" LVL="0"><PTEXT><PDAT>Competition binding studies. The 268//NRE peptide (final concentration, 5 pM) was first incubated for 1 hour with various amounts of a cold competitor DNA (0, 0.05, 0.5, 5, and 50 nM), and then the labeled N/Z site (6-8 pM) was added. Samples were analyzed by gel electrophoresis after 2, 24, 48, 96, 190, and 600 hours. Specificity ratios (Kdc/Kd) were calculated from the equation:</PDAT></PTEXT></PARA>
<PARA ID="P-00132" LVL="0"><PTEXT><F><PTEXT><HIL><ITALIC><PDAT>K</PDAT></ITALIC></HIL><HIL><SB><PDAT>dc</PDAT></SB></HIL><HIL><ITALIC><PDAT>/K</PDAT></ITALIC></HIL><HIL><SB><PDAT>d</PDAT></SB></HIL><HIL><ITALIC><PDAT>&equals;&lcub;&lsqb;C&rsqb;/&lsqb;P&rsqb;</PDAT></ITALIC></HIL><HIL><SB><PDAT>t</PDAT></SB></HIL><PDAT>&rcub;&times;(</PDAT><HIL><ITALIC><PDAT>F</PDAT></ITALIC></HIL><HIL><SB><PDAT>o</PDAT></SB></HIL><HIL><ITALIC><PDAT>&times;F</PDAT></ITALIC></HIL><PDAT>)/(</PDAT><HIL><ITALIC><PDAT>F</PDAT></ITALIC></HIL><HIL><SB><PDAT>o</PDAT></SB></HIL><HIL><ITALIC><PDAT>&minus;F</PDAT></ITALIC></HIL><PDAT>)(1</PDAT><HIL><ITALIC><PDAT>&minus;F</PDAT></ITALIC></HIL><PDAT>)</PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00133" LVL="7"><PTEXT><PDAT>where K</PDAT><HIL><SB><PDAT>dc </PDAT></SB></HIL><PDAT>is the dissociation constant for binding to the competitor DNA; K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>is the dissociation constant for binding to the intact chimeric site; &lsqb;C&rsqb; is the concentration of competitor DNA; &lsqb;P&rsqb;</PDAT><HIL><SB><PDAT>t </PDAT></SB></HIL><PDAT>is the total concentration of the protein; F</PDAT><HIL><SB><PDAT>o </PDAT></SB></HIL><PDAT>is the fraction bound in the absence of the competitor DNA; and F is the fraction bound in the presence of the competitor DNA. This equation assumes that the concentration of free protein is significantly smaller than that of protein bound to DNA. This criterion should readily be satisfied since the Kd of the 268//NRE peptide at the N/Z site is 3.8 fM, and 5 pM of the fusion peptide was used in these competition experiments.</PDAT></PTEXT></PARA>
<PARA ID="P-00134" LVL="0"><PTEXT><PDAT>Competition experiments with salmon sperm DNA contained the 268//NRE or Zif268 peptide (200 pM), the labeled N/Z site, and a slight molar excess of unlabeled N/Z site. Various amounts of salmon sperm DNA were added, and samples were analyzed by gel electrophoresis after 2, 24, and 48 hours incubation. When calculating specificity ratios, it was assumed that each base in the salmon sperm DNA represents the beginning of a potential (nonspecific) binding site.</PDAT></PTEXT></PARA>
<PARA ID="P-00135" LVL="0"><PTEXT><PDAT>Transient cotransfection assay. The 293 cells were transfected by calcium phosphate precipitation with a glycerol shock as described (Cepek et al., </PDAT><HIL><ITALIC><PDAT>Genes Dev. </PDAT></ITALIC></HIL><PDAT>10:2079-2088 (1996)). Transfection experiments typically used cells at 10-30% confluency in monolayer cultures (6-well plates), and the following plasmids were added: 0.2 mg of the empty expression plasmid (pCS) or of expression plasmids encoding zinc finger peptides; 0.2 mg of a reporter plasmid; 1 mg of activator plasmid (GAL4-VP16); 0.1 mg of &bgr;-galactosidase expression plasmid (pCMVb; Clontech); and 2.5 mg of carrier plasmid (pUC19). The luciferase and &bgr;-galactosidase activities in the transfected cells were measured as described (Kim et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>94:3616-3620 (1997); Kim &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>272:29795-29800 (1997)). All the zinc finger peptides expressed in 293 cells were quantitated by using the S.Tag&trade; Rapid Assay kit (Novagen) (Kim &amp; Raines, </PDAT><HIL><ITALIC><PDAT>Protein Sci. </PDAT></ITALIC></HIL><PDAT>2:348-356(1993); Kim &amp; Raines, </PDAT><HIL><ITALIC><PDAT>Anal. Biochem. </PDAT></ITALIC></HIL><PDAT>219:165-166 (1995)).</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>RESULTS</PDAT></STEXT></H>
<PARA ID="P-00136" LVL="0"><PTEXT><PDAT>Structure-based design of poly-zinc finger peptides. The design strategy involved linking two three-finger peptides, using longer (noncanonical) linkers at the junction to avoid introducing any strain. To further reduce any risk of interference or collision between the fingers, the linkers were designed so they could accommodate composite binding sites with one or two additional base pairs inserted between the individual 9-bp binding sites. Studies reported in this paper used the three-finger Zif268 peptide (which recognizes the site 5&prime;-GCG TGG GCG-3&prime;; SEQ ID NO:8) and a three-finger &ldquo;NRE&rdquo; peptide (a Zif268 variant previously selected via phage display) that binds tightly and specifically to part of a nuclear hormone response element (5&prime;-AAG GGT TCA-3&prime;; SEQ ID NO:9) (Greisman &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>275:657-661 (1997)). The composite target site with one additional base pair at the center has the sequence 5&prime;-AAG GGT TCA G GCG TGG GCG-3&prime;; SEQ ID NO:10) and is called the N/Z site (N denotes the binding site for the NRE peptide and Z the binding site for Zif268). The site with two additional base pairs at the center has the sequence 5&prime;-AAG GGT TCA GT GCG TGG GCG-3&prime;; SEQ ID NO:11) and is called the N//Z site.</PDAT></PTEXT></PARA>
<PARA ID="P-00137" LVL="0"><PTEXT><PDAT>Structure-based design, with the Zif268 complex (Pavletich &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>252:809-817 (1991); Elrod-Erickson et al., </PDAT><HIL><ITALIC><PDAT>Structure </PDAT></ITALIC></HIL><PDAT>4:1171-1180 (1996)) as a model, was used to determine the appropriate length of linkers for making poly-finger proteins that could recognize each binding site (see FIGS. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT> and </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>). At the N/Z site, it appeared that having 8 residues between the Leu at the a-helical end of the first peptide and the Tyr residue at the first b-sheet of the next peptide would allow sufficient flexibility. A canonical &ldquo;TGEKP&rdquo; linker (SEQ ID NO:13) has 4 residues (i.e., Gly-Glu-Lys-Pro; SEQ ID NO:20) in this region. At the N//Z site, it seemed reasonable to use 11 residues between the Leu and the Tyr (FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>A). Each linker (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2A</PDAT></FGREF><PDAT>) contained sequences that naturally flank the N-terminus and C-terminus of the three-finger Zif268 peptide. To allow additional flexibility, a glycine was included in the shorter linker (which still is 4 residues longer than a canonical linker), and a Gly-Gly-Gly-Ser (SEQ ID NO:24) sequence was included in the longer linker (which is 7 residues longer than a canonical linker). Using a notation analogous to that for the binding sites, the fusion protein with the shorter linker is denoted as 268/NRE and the fusion protein with the longer linker is denoted as 268//NRE.</PDAT></PTEXT></PARA>
<PARA ID="P-00138" LVL="0"><PTEXT><PDAT>Gel shift assays to determine dissociation constants and half-lives of protein-DNA complexes. The Zif268, NRE, and 268//NRE zinc finger peptides were expressed and purified from </PDAT><HIL><ITALIC><PDAT>E. coli, </PDAT></ITALIC></HIL><PDAT>and used in several sets of gel shift experiments. A preliminary set of experiments was simply designed to determine whether two three-finger proteins could bind at adjacent 9-bp sites (any interference in binding of the unlinked peptides could reduce the affinity of a poly-finger protein for the composite sites). The first experiments used a DNA fragment (referred to as the NZ site) with the NRE- and Zif268-binding sites directly juxtaposed (5&prime;-AAG GGT TCA GCG TGG GCG-3&prime;; SEQ ID NO:12). Various amounts of the NRE peptide were incubated with labeled NZ site in the presence or absence of Zif268 (FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>). It was determined that the three-finger NRE peptide actually binds slightly more tightly to the NZ site with prebound Zif268 than to the free site. The apparent dissociation constant (K</PDAT><HIL><SB><PDAT>d</PDAT></SB></HIL><PDAT>) of the NRE peptide is 180 pM when it binds alone but 60 pM when Zif268 is prebound to the neighboring site. Similar results were obtained at the N/Z site. These experiments prove that there is no collision between peptides bound at adjacent sites and suggest that there may even be some modest cooperative effect. It appears that previous limits in the affinity of poly-finger proteins (Rebar (Ph.D. Thesis), </PDAT><HIL><ITALIC><PDAT>Selection Studies of Zinc Finger</PDAT></ITALIC></HIL><PDAT>-</PDAT><HIL><ITALIC><PDAT>DNA Recognition, </PDAT></ITALIC></HIL><PDAT>Massachusetts Institute of Technology (1997); Shi, (Ph.D. Thesis), </PDAT><HIL><ITALIC><PDAT>Molecular Mechanisms of Zinc Finger Protein</PDAT></ITALIC></HIL><PDAT>-</PDAT><HIL><ITALIC><PDAT>Nucleic Acid Interactions, </PDAT></ITALIC></HIL><PDAT>Johns Hopkins University (1995); Liu et al., Proc. Natl. Acad. Sci. USA 94:5525-5530 (1997)) were due to problems with linker design.</PDAT></PTEXT></PARA>
<PARA ID="P-00139" LVL="0"><PTEXT><PDAT>A second set of binding studies confirms the efficacy of the new linker design. Equilibrium titrations show that the 268//NRE peptide has significantly higher affinity for the composite sites than for the individual 9-bp sites (Table 1). The fusion protein binds to the isolated 9-bp sites with K</PDAT><HIL><SB><PDAT>d</PDAT></SB></HIL><PDAT>s similar to those of the NRE peptide (180 pM) and the Zif268 peptide (14 pM) for their binding sites. In contrast, the 268//NRE fusion protein binds composite sites so tightly that dissociation constants are too small to readily be determined by protein titration. At least 0.4 pM of labeled probe DNA was needed in these gel shift experiments, making it difficult to accurately determine K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>values of &lt;1 pM. Given these technical difficulties, it was decided to measure the on-rate and off-rate for binding of the 268//NRE peptide and to use these rates to estimate the equilibrium binding constant (Table 1). Parallel studies with the three-finger peptides provided useful controls. On rates for the 268//NRE, NRE, and Zif268 peptides were fast and were close to the diffusion-controlled limit (108 to 109 M-1s-1) (von Hippel &amp; Berg, I. 264:675-678 (1989)). The off rates showed amazing differences: The three-finger peptides have half-lives of &lt;39 seconds, whereas the 268//NRE peptide has a half-life of 370 hours at the NZ site. Control studies show that the 268//NRE peptide forms a much less stable complex with a single 9-bp site (thus the half-life&equals;150 seconds at the N site). Both the NRE fingers and the Zif268 fingers must bind their respective 9-bp subsites to form the extraordinarily stable complex observed with the 268//NRE peptide at the NZ site.</PDAT></PTEXT></PARA>
<PARA ID="P-00140" LVL="0"><PTEXT><PDAT>In all cases where parallel measurements could be performed, K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>values calculated from the ratio of kinetic constants (k</PDAT><HIL><SB><PDAT>off</PDAT></SB></HIL><PDAT>/k</PDAT><HIL><SB><PDAT>on</PDAT></SB></HIL><PDAT>) were in good agreement with those determined from equilibrium studies (Table 1). This gave confidence in using the kinetic data to determine K</PDAT><HIL><SB><PDAT>d</PDAT></SB></HIL><PDAT>s in cases where direct titration was impracticable. Calculations show that the 268//NRE peptide has femtomolar affinity for the composite binding sites, with a K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>of 2.1&times;10-15 M (2.1 fM) at the NZ site, 3.7 fM at the N/Z site, and 3.0 fM at the N//Z site (the consistency of these three K</PDAT><HIL><SB><PDAT>d</PDAT></SB></HIL><PDAT>s also is encouraging since it would be expected that the longer, flexible linker should readily accommodate any of these spacings). The data show that the new linker design is quite effective: the 268//NRE fusion peptide binds far more tightly (5,000-95,000 fold) to the composite site than to the individual 9-bp sites, and it binds far more tightly (6,000-90,000 fold) than either of the original three-finger peptides.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00001">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 1</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Dissociation Constants and Rate Data</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="5">
<colspec colname="1" colwidth="42pt" align="center"/>
<colspec colname="2" colwidth="28pt" align="center"/>
<colspec colname="3" colwidth="35pt" align="center"/>
<colspec colname="4" colwidth="49pt" align="center"/>
<colspec colname="5" colwidth="63pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>Binding</PDAT></PTEXT></entry>
<entry></entry>
<entry></entry>
<entry></entry>
</row>
<row>
<entry><PTEXT><PDAT>Protein</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>site</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>K</PDAT><HIL><SB><PDAT>d</PDAT></SB></HIL><PDAT>, pM</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>k</PDAT><HIL><SB><PDAT>on</PDAT></SB></HIL><PDAT>,M</PDAT><HIL><SP><PDAT>&minus;1</PDAT></SP></HIL><PDAT>s</PDAT><HIL><SP><PDAT>&minus;1</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>k</PDAT><HIL><SB><PDAT>off</PDAT></SB></HIL><PDAT>,s</PDAT><HIL><SP><PDAT>&minus;1</PDAT></SP></HIL></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>268//NRE</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>190 &plusmn; 50</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2.5 &plusmn; 0.4 &times; 10</PDAT><HIL><SP><PDAT>7</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>4.7 &plusmn; 2.9 &times; 10</PDAT><HIL><SP><PDAT>&minus;3</PDAT></SP></HIL></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>268//NRE</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Z</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10*</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>268//NRE</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>NZ</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&lt;1.0&dagger;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2.5 &plusmn; 0.2 &times; 10</PDAT><HIL><SP><PDAT>8</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>5.2 &plusmn; 0.9 &times; 10</PDAT><HIL><SP><PDAT>&minus;7</PDAT></SP></HIL></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>268//NRE</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N/Z</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&lt;1.0&dagger;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2.5 &plusmn; 0.2 &times; 10</PDAT><HIL><SP><PDAT>8</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>9.2 &plusmn; 0.7 &times; 10</PDAT><HIL><SP><PDAT>&minus;7</PDAT></SP></HIL></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>268//NRE</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N//Z</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&lt;1.0&dagger;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2.6 &plusmn; 0.6 &times; 10</PDAT><HIL><SP><PDAT>8</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>7.7 &plusmn; 1.3 &times; 10</PDAT><HIL><SP><PDAT>&minus;7</PDAT></SP></HIL></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>NRE</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N/Z</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>180 &plusmn; 43</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&gt;7.3 &times; 10</PDAT><HIL><SP><PDAT>7</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>&gt;5.9 &times; 10</PDAT><HIL><SP><PDAT>&minus;2</PDAT></SP></HIL></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Zif268</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>NZ</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;12 &plusmn; 3&ensp;</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Zif268</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N/Z</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;14 &plusmn; 4&ensp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&gt;7.0 &times; 10</PDAT><HIL><SP><PDAT>8</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>1.4 &plusmn; 0.4 &times; 10</PDAT><HIL><SP><PDAT>&minus;2</PDAT></SP></HIL></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Zif268</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N//Z</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;14 &plusmn; 1&ensp;</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
<row>
<entry namest="1" nameend="5" align="left"><PTEXT><FOO ID="FOO-00001"><PTEXT><PDAT>All the constants were determined in at least two separate experiments, and the SEM is indicated. </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="5" align="left"><PTEXT><FOO ID="FOO-00002"><PTEXT><PDAT>*An exact K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>value could not be determined because this complex gave a smeared band on the gels. </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="5" align="left"><PTEXT><FOO ID="FOO-00003"><PTEXT><PDAT>&dagger;As explained in the text, these K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>values could not be measured directly. Estimating K</PDAT><HIL><SB><PDAT>d </PDAT></SB></HIL><PDAT>from the ratio k</PDAT><HIL><SB><PDAT>off</PDAT></SB></HIL><PDAT>/k</PDAT><HIL><SB><PDAT>on </PDAT></SB></HIL><PDAT>gives values of 2.1 fM at the NZ site, 3.7 fM at the N/Z site and 3.0 fM at the N//Z site. </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00141" LVL="0"><PTEXT><PDAT>Competition experiments were also used to further study the affinity and specificity of the six-finger 268//NRE peptide (FIG. </PDAT><HIL><BOLD><PDAT>4</PDAT></BOLD></HIL><PDAT>A). One set of experiments directly tested how well the 9-bp N and Z sites could compete with the composite N/Z site for binding to the fusion peptide. In these experiments, various amounts of cold N or Z site were mixed with a limiting amount of the 268//NRE peptide. After 1 hour of incubation, a slightly molar excess (relative to the total amount of fusion protein) of labeled N/Z site was added. Under these conditions, about 70% of the labeled DNA is shifted in the absence of competitor DNA. Samples taken at various time points were analyzed by gel electrophoresis. Since the 268//NRE peptide concentration in this experiment (5 pM) is a few orders of magnitude higher than the peptide&apos;s dissociation constant for the N/Z site, almost all the peptide binds to the N/Z site when no competitor DNA is added. Any decrease in the amount of shifted N/Z site in the presence of competitor DNA reflects binding of the 268//NRE peptide to the competing site.</PDAT></PTEXT></PARA>
<PARA ID="P-00142" LVL="0"><PTEXT><PDAT>Equilibration in these experiments requires hundreds of hours, and the stability of the purified protein actually becomes a significant concern (the composite site is added last, and equilibration takes a long time since the fusion protein may encounter cold Z sites hundreds or thousands of times before it first encounters a labeled N/Z site). After pre-equilibration with high concentrations of cold N or Z site, it was determined that the fraction of N/Z label shifted increases steadily with increasing incubation times of up to about 600 hours. After 600 hour of incubation, a significant fraction of the labeled N/Z site is shifted even in the presence of a 10,000-fold molar excess of cold N or Z site. Specificity ratios (calculated as described above) indicate that the 268//NRE peptide prefers the composite site over the N site by a factor of at least 3,800&plus;1,600 and that the fusion peptide prefers the composite site over the Z site by a factor of at least 320&plus;44. These experiments directly confirm the remarkable specificity of the six-finger peptide, but these values are only lower bounds on the specificity ratios. The protein sample loses some activity during the long incubation time required by these experiments (the activity of the free protein has a half-life of about 2 days under these conditions), and denatured protein will never have a chance to shift the labeled N/Z site.</PDAT></PTEXT></PARA>
<PARA ID="P-00143" LVL="0"><PTEXT><PDAT>Competition experiments with salmon sperm DNA were used to estimate the ratio of specific/nonspecific binding constants for the 268//NRE peptide (FIG. </PDAT><HIL><BOLD><PDAT>4</PDAT></BOLD></HIL><PDAT>B). These experiments showed that the 268//NRE peptide discriminates very effectively against nonspecific DNA and indicate a specificity ratio (K</PDAT><HIL><SB><PDAT>dns</PDAT></SB></HIL><PDAT>/K</PDAT><HIL><SB><PDAT>d</PDAT></SB></HIL><PDAT>) of 8.8&plus;1.5&times;10</PDAT><HIL><SP><PDAT>6</PDAT></SP></HIL><PDAT>. Parallel experiments with the three-finger Zif268 peptide give a specificity ratio of 1.2&plus;0.1&times;10</PDAT><HIL><SP><PDAT>5</PDAT></SP></HIL><PDAT>. Previous studies, using calf thymus DNA as a competitor and slightly different conditions, had given a specificity ratio of 0.31&times;10</PDAT><HIL><SP><PDAT>5 </PDAT></SP></HIL><PDAT>for the Zif268 peptide (Greisman &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>275:657-661 (1997)). Taken together, data on the affinity and specificity of the six-finger 268//NRE fusion peptide suggested that it might serve as a very effective repressor and certainly indicated that it would be an excellent candidate for further analysis in vivo.</PDAT></PTEXT></PARA>
<PARA ID="P-00144" LVL="0"><PTEXT><PDAT>Transient cotransfection studies in the 293 human cell line were used to see whether the new poly-finger peptides could effectively repress transcription from reporter genes. In a previous study, it had been shown that the Zif268 peptide could efficiently repress both basal and VP16-activated transcription when the Zif268 peptide bound to a site near the TATA box or the initiator element (Kim &amp; Pabo, </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>272:29795-29800 (1997)). In this current study, a luciferase reporter and similar promoter constructs were used in which appropriate binding sites (Z, N, N/Z, and N//Z) were incorporated at comparable positions near the initiator element (FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>B).</PDAT></PTEXT></PARA>
<PARA ID="P-00145" LVL="0"><PTEXT><PDAT>It was determined that the 268//NRE peptide gives 72-fold repression of VP16-activated transcription at a promoter containing the N/Z site and 47-fold repression at a promoter containing the N//Z site (FIGS. </PDAT><HIL><BOLD><PDAT>5</PDAT></BOLD></HIL><PDAT>A-</PDAT><HIL><BOLD><PDAT>5</PDAT></BOLD></HIL><PDAT>D). The 268/NRE peptide gives 68-fold repression at the N/Z site. Clearly, these fusion peptides are very effective repressors at sites with the appropriate spacings. Parallel experiments with the three-finger peptides show repression but indicate that they are considerably less effective than the fusion peptides. Thus the NRE peptide gives 1.9-fold repression with an N site in the promoter; 1.8-fold repression with an N/Z site; 2.7-fold repression with an N//Z site; and no repression with an isolated Z site. The Zif268 peptide gives 13-fold repression from the Z promoter; 8.9-fold repression from the N/Z promoter; 15-fold repression from the N//Z promoter; and no repression with an isolated N site. Further experiments prove that covalent coupling is needed to achieve the much higher repression levels obtained with the fusion proteins at the N/Z site.</PDAT></PTEXT></PARA>
<PARA ID="P-00146" LVL="0"><PTEXT><PDAT>Thus co-expressing the Zif268 and NRE peptides as separate polypeptide chains (by including both expression plasmids in the cotransfection assays) gives only 8.5-fold repression at the N/Z site, a level comparable (within experimental error) to the 8.9-fold repression obtained at this site with the isolated Zif268 peptide. This is far less than the 68-fold and 72-fold repression that the 268/NRE and 268//NRE fusion proteins give at the N/Z site, and it is clear that these &ldquo;synergistic&rdquo; effects require covalent linkage.</PDAT></PTEXT></PARA>
<PARA ID="P-00147" LVL="0"><PTEXT><PDAT>It is noted that the additional fingers in the fusion peptides may have some modest repressive effects even in cases where only three of the fingers can bind specifically. Thus the six-finger peptides (268/NRE and 268//NRE) give 21 to 23-fold repression from the Z promoter. A similar (22-fold) repression level is obtained with the 268/NRE peptide at the N//Z site. Modeling suggests that the linker is too short to allow specific binding of all six fingers at this site. These repression levels are consistently somewhat higher than the level observed with the isolated Zif268 peptide at the Z site (13-fold repression). It seems possible (when the 268//NRE peptide binds to the Z site) that 1) the NRE fingers are free and yet sterically interfere with assembly of the transcription complex or that 2) the NRE fingers make weak nonspecific contacts with the DNA and thus slightly enhance the stability of the complex. Further studies indicate that all peptides are expressed at comparable levels.</PDAT></PTEXT></PARA>
<PARA ID="P-00148" LVL="0"><PTEXT><PDAT>The zinc finger peptides expressed in 293 cells had an S-peptide tag, and the amount of peptide was quantitated by using a ribonuclease assay after activating with S-protein (Kim &amp; Raines, </PDAT><HIL><ITALIC><PDAT>Protein Sci. </PDAT></ITALIC></HIL><PDAT>2:348-356(1993); Kim &amp; Raines, </PDAT><HIL><ITALIC><PDAT>Anal. Biochem. </PDAT></ITALIC></HIL><PDAT>219:165-166 (1995)). A conservative estimate indicates that the expression levels of the peptides in cells are significantly higher (at least 100 fold) than the dissociation constants of the three-finger peptides. Plasmids that would encode four- and five-finger variants of the 268/NRE and 268//NRE peptides were also constructed. These were tested in tissue culture transfection studies, and they typically gave repression levels intermediate between those obtained with the three-finger peptides and those obtained with the six-finger peptides (FIGS. </PDAT><HIL><BOLD><PDAT>5</PDAT></BOLD></HIL><PDAT>A-</PDAT><HIL><BOLD><PDAT>5</PDAT></BOLD></HIL><PDAT>D).</PDAT></PTEXT></PARA>
<CWU>
<SEQLST-US ID="SEQLST-1">
<SEQ-LST-NEW>
<S100>
<S160>
<PDAT>24</PDAT>
</S160>
</S100>
<S200>
<S210>
<PDAT>1</PDAT>
</S210>
<S211>
<PDAT>74</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequence
      oligonucleotide duplex</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 1
agctaccatg gccaaggaaa ccgcagctgc caaattcgaa agacagcata tggattctaa     60
gcttcgcgga tcct                                                       74
</PDAT>
</S400>
<S200>
<S210>
<PDAT>2</PDAT>
</S210>
<S211>
<PDAT>74</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequence
      oligonucleotide duplex</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 2
ctagaggatc cgcgaagctt agaatccata tgctgtcttt cgaatttggc agctgcggtt     60
tccttggcca tggt                                                       74
</PDAT>
</S400>
<S200>
<S210>
<PDAT>3</PDAT>
</S210>
<S211>
<PDAT>29</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial SequenceN site zinc
      finger binding site</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 3
tctgcaaggg ttcaggcgac accaaccaa                                       29
</PDAT>
</S400>
<S200>
<S210>
<PDAT>4</PDAT>
</S210>
<S211>
<PDAT>29</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial SequenceZ site zinc
      finger binding site</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 4
gtgtgtgtgt gatctgcgtg ggcggtaag                                       29
</PDAT>
</S400>
<S200>
<S210>
<PDAT>5</PDAT>
</S210>
<S211>
<PDAT>28</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial SequenceNZ site zinc
      finger binding site</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 5
tctgcaaggg ttcagcgtgg gcggtaag                                        28
</PDAT>
</S400>
<S200>
<S210>
<PDAT>6</PDAT>
</S210>
<S211>
<PDAT>29</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial SequenceN/Z site
      zinc finger binding site</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 6
tctgcaaggg ttcaggcgtg ggcggtaag                                       29
</PDAT>
</S400>
<S200>
<S210>
<PDAT>7</PDAT>
</S210>
<S211>
<PDAT>30</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial SequenceN//Z site
      zinc finger binding site</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 7
tctgcaaggg ttcagtgcgt gggcggtaag                                      30
</PDAT>
</S400>
<S200>
<S210>
<PDAT>8</PDAT>
</S210>
<S211>
<PDAT>9</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequencethree-finger
      Zif268 peptide recognition site</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 8
gcgtgggcg                                                              9
</PDAT>
</S400>
<S200>
<S210>
<PDAT>9</PDAT>
</S210>
<S211>
<PDAT>9</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequencethree-finger
      NRE (nuclear hormone response element) peptide
      binding site</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 9
aagggttca                                                              9
</PDAT>
</S400>
<S200>
<S210>
<PDAT>10</PDAT>
</S210>
<S211>
<PDAT>19</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial SequenceN/Z site
      composite target site with one additional base
      pair at the center</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 10
aagggttcag gcgtgggcg                                                  19
</PDAT>
</S400>
<S200>
<S210>
<PDAT>11</PDAT>
</S210>
<S211>
<PDAT>20</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial SequenceN//Z site
      composite terget site with two additional base
      pairs at the center</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 11
aagggttcag tgcgtgggcg                                                 20
</PDAT>
</S400>
<S200>
<S210>
<PDAT>12</PDAT>
</S210>
<S211>
<PDAT>18</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial SequenceNZ site with
      NRE- and Zif268-binding sites directly juxtaposed</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 12
aagggttcag cgtgggcg                                                   18
</PDAT>
</S400>
<S200>
<S210>
<PDAT>13</PDAT>
</S210>
<S211>
<PDAT>5</PDAT>
</S211>
<S212>
<PDAT>PRT</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequencecanonical
      &ldquo;TGEKP&rdquo; linker</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 13
Thr Gly Glu Lys Pro
  1               5
</PDAT>
</S400>
<S200>
<S210>
<PDAT>14</PDAT>
</S210>
<S211>
<PDAT>8</PDAT>
</S211>
<S212>
<PDAT>PRT</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequenceshorter
      flexible linker for fusion protein 268/NRE
      containing a glycine</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 14
Arg Gln Lys Asp Gly Glu Arg Pro
  1               5
</PDAT>
</S400>
<S200>
<S210>
<PDAT>15</PDAT>
</S210>
<S211>
<PDAT>11</PDAT>
</S211>
<S212>
<PDAT>PRT</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequencelonger
      flexible linker for fusion protein 268//NRE containing a
      Gly-Gly-Gly-Ser sequence</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 15
Arg Gln Lys Asp Gly Gly Gly Ser Glu Arg Pro
  1               5                  10
</PDAT>
</S400>
<S200>
<S210>
<PDAT>16</PDAT>
</S210>
<S211>
<PDAT>9</PDAT>
</S211>
<S212>
<PDAT>PRT</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequencelinker
      region in Zif268</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 16
His Thr Gly Glu Lys Pro Phe Ala Cys
  1               5
</PDAT>
</S400>
<S200>
<S210>
<PDAT>17</PDAT>
</S210>
<S211>
<PDAT>13</PDAT>
</S211>
<S212>
<PDAT>PRT</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequencelinker
      region on 268/NRE</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 17
His Leu Arg Gln Lys Asp Gly Glu Arg Pro Tyr Ala Cys
  1               5                  10
</PDAT>
</S400>
<S200>
<S210>
<PDAT>18</PDAT>
</S210>
<S211>
<PDAT>16</PDAT>
</S211>
<S212>
<PDAT>PRT</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequencelinker
      region in 268//NRE</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 18
His Leu Arg Gln Lys Asp Gly Gly Gly Ser Glu Arg Pro Tyr Ala Cys
  1               5                  10                  15
</PDAT>
</S400>
<S200>
<S210>
<PDAT>19</PDAT>
</S210>
<S211>
<PDAT>6</PDAT>
</S211>
<S212>
<PDAT>PRT</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequencesynthetic
      linker sequence</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 19
Gly Thr Gly Gln Lys Pro
  1               5
</PDAT>
</S400>
<S200>
<S210>
<PDAT>20</PDAT>
</S210>
<S211>
<PDAT>4</PDAT>
</S211>
<S212>
<PDAT>PRT</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequencesynthetic
      linker sequence</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 20
Gly Glu Lys Pro
  1
</PDAT>
</S400>
<S200>
<S210>
<PDAT>21</PDAT>
</S210>
<S211>
<PDAT>25</PDAT>
</S211>
<S212>
<PDAT>PRT</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequenceexemplary
      motif for C2H2 zinc finger protein</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 21
Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
  1               5                  10                  15
Xaa Xaa His Xaa Xaa Xaa Xaa Xaa His
             20                  25
</PDAT>
</S400>
<S200>
<S210>
<PDAT>22</PDAT>
</S210>
<S211>
<PDAT>10</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequencezinc finger
      target site with two overlapping D-able subsites</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 22
nngkngknnn                                                            10
</PDAT>
</S400>
<S200>
<S210>
<PDAT>23</PDAT>
</S210>
<S211>
<PDAT>10</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequencezinc finger
      target site with three overlapping D-able subsites</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 23
nngkngkngk                                                            10
</PDAT>
</S400>
<S200>
<S210>
<PDAT>24</PDAT>
</S210>
<S211>
<PDAT>4</PDAT>
</S211>
<S212>
<PDAT>PRT</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequencesequence
      included in longer linker to allow additional
      flexibility</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 24
Gly Gly Gly Ser
  1
</PDAT>
</S400>
</SEQ-LST-NEW>
</SEQLST-US>
</CWU>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>What is claimed is: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00149" LVL="0"><PTEXT><PDAT>1. A chimeric zinc finger protein that binds to adjacent target sites, the chimeric zinc finger protein comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>(i) a first and a second DNA-binding domain polypeptide of the chimeric zinc finger protein, wherein at least one of the domains comprises an engineered zinc finger polypeptide, and wherein the first domain binds to a first target site and the second domain binds to a second target site, which target sites are adjacent; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(ii) a flexible linker that is six or more amino acids in length; </PDAT></PTEXT></CLMSTEP>
<PARA ID="P-00150" LVL="7"><PTEXT><PDAT>wherein the first and second domains are fused with the flexible linker.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00151" LVL="0"><PTEXT><PDAT>2. The chimeric zinc finger protein of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the adjacent target sites are separated by one nucleotide and the flexible linker is seven, eight, or nine amino acids in length.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00152" LVL="0"><PTEXT><PDAT>3. The chimeric zinc finger protein of </PDAT><CLREF ID="CLM-00002"><PDAT>claim 2</PDAT></CLREF><PDAT>, wherein the flexible linker has the amino acid sequence RQKDGERP (SEQ ID NO:14).</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00153" LVL="0"><PTEXT><PDAT>4. The chimeric zinc finger protein of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the adjacent target sites are separated by two nucleotides and the flexible linker is ten, eleven, or twelve amino acids in length.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00005">
<PARA ID="P-00154" LVL="0"><PTEXT><PDAT>5. The chimeric zinc finger protein of </PDAT><CLREF ID="CLM-00004"><PDAT>claim 4</PDAT></CLREF><PDAT>, wherein the flexible linker has the amino acid sequence RQKDGGGSERP (SEQ ID NO:15).</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00006">
<PARA ID="P-00155" LVL="0"><PTEXT><PDAT>6. The chimeric zinc finger protein of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the adjacent target sites are separated by three nucleotides and the flexible linker is twelve or more amino acids in length.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00007">
<PARA ID="P-00156" LVL="0"><PTEXT><PDAT>7. The chimeric zinc finger protein of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the first and the second domains are zinc finger polypeptides.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00008">
<PARA ID="P-00157" LVL="0"><PTEXT><PDAT>8. The chimeric zinc finger protein of </PDAT><CLREF ID="CLM-00007"><PDAT>claim 7</PDAT></CLREF><PDAT>, wherein the zinc finger polypeptide is selected from the group consisting of Zif268 and NRE.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00009">
<PARA ID="P-00158" LVL="0"><PTEXT><PDAT>9. The chimeric zinc finger protein of </PDAT><CLREF ID="CLM-00007"><PDAT>claim 7</PDAT></CLREF><PDAT>, wherein the zinc finger polypeptides are heterologous.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00010">
<PARA ID="P-00159" LVL="0"><PTEXT><PDAT>10. The chimeric zinc finger protein of </PDAT><CLREF ID="CLM-00007"><PDAT>claim 7</PDAT></CLREF><PDAT>, wherein the chimeric zinc finger protein has femtomolar affinity for the adjacent target sites.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00011">
<PARA ID="P-00160" LVL="0"><PTEXT><PDAT>11. The chimeric zinc finger protein of </PDAT><CLREF ID="CLM-00010"><PDAT>claim 10</PDAT></CLREF><PDAT>, wherein the chimeric zinc finger protein has about 2-4 femtomolar affinity for the adjacent target sites.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00012">
<PARA ID="P-00161" LVL="0"><PTEXT><PDAT>12. The chimeric zinc finger protein of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the chimeric zinc finger protein further comprises a regulatory domain polypeptide.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00013">
<PARA ID="P-00162" LVL="0"><PTEXT><PDAT>13. The chimeric zinc finger protein of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the first domain comprises a poly-finger zinc finger protein.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00014">
<PARA ID="P-00163" LVL="0"><PTEXT><PDAT>14. The chimeric zinc finger protein of </PDAT><CLREF ID="CLM-00013"><PDAT>claim 13</PDAT></CLREF><PDAT>, wherein the second domain comprises a poly-finger zinc finger protein.</PDAT></PTEXT></PARA>
</CLM>
</CL>
</SDOCL>
<SDODR ID="DRAWINGS">
<EMI ID="EMI-D00000" ALT="embedded image" FILE="US06479626-20021112-D00000.TIF"/>
<EMI ID="EMI-D00001" ALT="embedded image" FILE="US06479626-20021112-D00001.TIF" TYPE="HALFTONE"/>
<EMI ID="EMI-D00002" ALT="embedded image" FILE="US06479626-20021112-D00002.TIF"/>
<EMI ID="EMI-D00003" ALT="embedded image" FILE="US06479626-20021112-D00003.TIF" TYPE="HALFTONE"/>
<EMI ID="EMI-D00004" ALT="embedded image" FILE="US06479626-20021112-D00004.TIF"/>
</SDODR>
</PATDOC>

